isoniazid has been researched along with Latent Tuberculosis in 412 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
Latent Tuberculosis: The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Rifapentine clearance is higher among women with HIV, but all women achieved exposures of rifapentine and isoniazid associated with successful tuberculosis prevention." | 9.51 | Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. ( Bradford, S; Britto, P; Chakhtoura, N; Chalermchockcharoentkit, A; Chipato, T; Dooley, KE; Gupta, A; Jayachandran, P; Kamthunzi, P; Langat, D; Mathad, JS; Montepiedra, G; Norman, J; Patil, S; Popson, S; Rouzier, V; Savic, R; Townley, E; Wiesner, L; Zhang, N, 2022) |
| "3 months of weekly rifapentine plus isoniazid (3HP) and 4 months of daily rifampicin (4R) are recommended for tuberculosis preventive treatment." | 9.41 | Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. ( Belknap, R; Benedetti, A; Borisov, A; Campbell, JR; Chaisson, RE; Chan, PC; Martinson, N; Menzies, D; Nahid, P; Scott, NA; Sizemore, E; Sterling, TR; Villarino, ME; Wang, JY; Winters, N, 2023) |
| "Four months of rifampin treatment for latent tuberculosis infection is safer, has superior treatment completion rates, and is as effective as 9 months of isoniazid." | 9.34 | Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings. ( Adjobimey, M; Al-Jahdali, H; Apriani, L; Baah, JO; Bastos, ML; Benedetti, A; Campbell, JR; Elwood, K; Hoeppner, V; Kim, HJ; Long, R; Menzies, D; Oxlade, O; Ruslami, R; Schwartzman, K; Toelle, BG; Trajman, A, 2020) |
| "We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9-month group) in HIV-infected patients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection." | 9.30 | One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. ( Andersen, J; Banda, P; Benson, CA; Chaisson, RE; da Silva Escada, RO; Fletcher, CV; Gupta, A; Hakim, J; Jean Juste, MA; Kanyama, C; Lama, JR; Langat, D; Leon-Cruz, J; Masheto, G; Mawlana, S; Mohapi, L; Moran, L; Mwelase, N; Nuermberger, E; Omoz-Oarhe, A; Ramchandani, R; Severe, P; Supparatpinyo, K; Swindells, S; Valencia, J, 2019) |
| "A 9-month regimen of isoniazid can prevent active tuberculosis in persons with latent tuberculosis infection." | 9.27 | Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. ( Adjobimey, M; Al-Jahdali, H; Apriani, L; Bah, B; Benedetti, A; Boakye, I; Camara, A; Cook, VJ; Dion, MJ; Elwood, K; Gninafon, M; Goldberg, H; Hill, PC; Hoeppner, V; Hornby, K; Kim, H; Koesoemadinata, RC; Kritski, A; Li, PZ; Long, R; Marks, GB; Menzies, D; Obeng Baah, J; Rolla, V; Ruslami, R; Schwartzman, K; Sow, O; Trajman, A; Valiquette, C, 2018) |
| "These results support using self-administered, once-weekly isoniazid and rifapentine to treat latent tuberculosis infection in the United States, and such treatment could be considered in similar settings when direct observation is not feasible." | 9.24 | Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. ( Arevalo, B; Belknap, R; Borisov, AS; Caylà, JA; Chen, MP; Feng, PJ; Holland, D; Martinson, NA; Millet, JP; Miró, JM; Moro, RN; Scott, NA; Villarino, ME; Weiner, M; Wright, A, 2017) |
| "Currently, treatment of latent tuberculosis infection (LTBI) in Australia consists most commonly of a 9-month course of isoniazid (9H)." | 9.24 | SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication. ( Biggs, B; Chen, C; Denholm, JT; Eisen, D; Leder, K; Matchett, E; McBryde, ES; Shultz, TR; Street, A, 2017) |
| "We conducted a systematic review examining the cost effectiveness of a 3-month course of isoniazid and rifapentine, known as 3HP, given by directly observed treatment, compared to 9 months of isoniazid that is directly observed or self-administered, for latent tuberculosis infection." | 9.22 | Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review. ( Brethour, K; Chaisson, RE; D'Silva, O; Lai, WA; Zwerling, AA, 2022) |
| "Weekly rifapentine plus isoniazid for 3 months (3HP) is as effective as daily isoniazid for 9 months (9H) for latent tuberculosis infection in high-risk persons, but there have been reports of possible flu-like syndrome." | 9.20 | Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. ( Adkinson, NF; Borisov, AS; Ho, C; Moro, RN; Phillips, E; Shepherd, G; Sterling, TR; Villarino, ME; Weis, S, 2015) |
| "The recommended treatment for latent tuberculosis (TB) infection in adults is a daily dose of isoniazid (INH) 300 mg for six months." | 9.20 | Using a single tablet daily to treat latent tuberculosis infection in Brazil: bioequivalence of two different isoniazid formulations (300 mg and 100 mg) demonstrated by a sensitive and rapid high-performance liquid chromatography-tandem mass spectrometry ( Barreira, D; Daher, A; Pinto, D; Pitta, L; Santos, T, 2015) |
| "This open-label randomized trial compared isoniazid (9 months) to rifampin (4 months) on toxicity and completion in a jailed population with latent tuberculosis infection." | 9.16 | Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. ( Chen, L; Goldenson, J; Kawamura, LM; Lee, JR; Spetz, J; Tulsky, JP; White, MC, 2012) |
| "Standard treatment for latent tuberculosis infection (LTBI) is 9 months daily isoniazid (9INH)." | 9.15 | Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials. ( Aspler, A; Esfahani, K; Menzies, D; Schwartzman, K, 2011) |
| "The mainstay therapy for latent tuberculosis infection is a 9-month regimen of daily isoniazid (9H) and a 3-month regimen of 12 once-weekly doses of isoniazid and rifapentine (3HP)." | 9.12 | Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis. ( Chang, TE; Huang, YH; Huang, YS; Perng, CL; Tseng, SY, 2021) |
| "A 76-year-old man complicated with end-stage renal disease had latent tuberculosis infection (LTBI), and isoniazid (INH) 300 mg daily was started to prevent reactivation of LTBI before using biologic agents for rheumatoid arthritis." | 8.98 | Rhabdomyolysis Induced by Isoniazid in a Patient with Rheumatoid Arthritis and End-stage Renal Disease: A Case Report and Review of the Literature. ( Fujio, K; Komai, T; Sumitomo, S; Teruya, S, 2018) |
| " Three-month isoniazid-rifapentine was determined to be equal to other latent tuberculosis infection regimens in effectiveness (OR=0." | 8.98 | Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. ( Borisov, AS; Moro, RN; Morris, SB; Njie, GJ; Vernon, AA; Woodruff, RY, 2018) |
| "This systematic review was carried out to determine the effectiveness of continuous isoniazid (given for at least 36 months) for the treatment of latent tuberculosis infection (LTBI) in people living with HIV (PLHIV)." | 8.93 | Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. ( Den Boon, S; Ford, N; Getahun, H; Matteelli, A, 2016) |
| "To examine chronic viral hepatitis (CVH) as a risk factor for hepatotoxicity during isoniazid (INH) treatment for latent tuberculosis infection (LTBI)." | 8.85 | The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. ( Bliven, EE; Podewils, LJ, 2009) |
| "Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI)." | 8.31 | High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. ( Chaisson, RE; Chihota, V; Churchyard, GJ; Dooley, KE; Jarrett, RT; Marzinke, MA; Shotwell, MS; van der Heijden, Y, 2023) |
| "Three months of weekly rifapentine plus isoniazid (3HP) therapy for latent tuberculosis infection (LTBI) is recommended worldwide." | 8.31 | Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. ( Belknap, R; Borisov, A; Caylà, JA; Chen, MP; Gandhi, NR; Holland, DP; Millet, JP; Moro, RN; Sadowski, C; Scott, NA; Wright, A, 2023) |
| "Scaling up a shorter preventive regimen such as weekly isoniazid and rifapentine (3HP) for 3 months is a priority for tuberculosis (TB) preventive treatment (TPT)." | 8.31 | Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment. ( Amanullah, F; Becerra, MC; Dahri, AA; Farooq, S; Hussain, H; Islam, Z; Jaswal, M; Keshavjee, S; Khan, AJ; Khowaja, S; Madhani, F; Malik, AA; Manzar, S; Noorani, S; Safdar, N; Salahuddin, N; Shah, JA; Shahbaz, SS; Shahzad, M, 2023) |
| "A once-weekly oral dose of isoniazid and rifapentine for 3 months (3HP) is recommended by the CDC for treatment of latent tuberculosis infection (LTBI)." | 8.12 | Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs. ( Cole, J; Day, CL; Dick, EJ; Foreman, TW; Ganatra, SR; Gandhi, NR; Gonzalez, O; Hall-Ursone, S; Kaushal, D; Mehra, S; Peloquin, CA; Rengarajan, J; Schlesinger, LS; Sharan, R; Shivanna, V; Singh, DK; Thippeshappa, R, 2022) |
| "To investigate associations between isoniazid for latent tuberculosis and risk of severe hepatitis, affecting patients with rheumatoid arthritis or ankylosing spondylitis whose treatment includes tumor necrosis factor inhibitors." | 8.02 | Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors. ( Chao, PH; Chen, WW; Huang, WI; Huang, YC; Lai, EC; Liang, HY; Weng, MY, 2021) |
| "Short-course preventive therapy with 1-month course of daily administration of isoniazid (300-mg) plus rifapentine (600-mg) (1HP) and 3-month course of weekly administration of isoniazid (900-mg) plus rifapentine (900-mg) (3HP) has higher completion rates than 9-month course of daily isoniazid (9H) for individuals with latent tuberculosis infection (LTBI)." | 8.02 | Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. ( Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY, 2021) |
| "Weekly rifapentine and isoniazid (3HP) is gaining popularity for latent tuberculosis infection treatment because of its short course and high completion rate." | 8.02 | Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection. ( Chen, TC; Cheng, MH; Chong, IW; Huang, CK; Huang, HL; Lai, PC; Lee, MR; Lu, PL; Sheu, CC; Wang, JY, 2021) |
| " We compared the cost per completed course of preventive treatment with either 6 months of daily isoniazid (6H) or 3 months of weekly isoniazid and rifapentine (3HP), delivered by the Indus Health Network tuberculosis program in Karachi, Pakistan, between October 2016 and February 2018." | 8.02 | Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting. ( Becerra, MC; Hussain, H; Jaswal, M; Keshavjee, S; Khan, AJ; Lu, C; Majidulla, A; Malik, AA; Safdar, N; Yuen, CM, 2021) |
| "Three months of weekly rifapentine plus isoniazid (3HP) is a short course regimen for latent tuberculosis infection treatment with satisfied safety and efficacy." | 8.02 | High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study. ( Hu, ZD; Li, T; Liu, XH; Lu, SH; Ma, JY; Xia, L; Yang, H; Yang, Y; Yu, X, 2021) |
| "We aimed to determine overall incidence of severe and mild isoniazid (INH) hepatotoxicity and outcome of hepatotoxicity in children who were receiving INH for latent tuberculosis." | 8.02 | Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection. ( Aksay, A; Aktürk, H; Apa, H; Bayram, N; Can, D; Devrim, F; Devrim, İ, 2021) |
| "An important problem limiting treatment of latent tuberculosis infection is the occurrence of adverse events with isoniazid." | 7.96 | Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. ( Adjobimey, M; Benedetti, A; Campbell, JR; Cook, VJ; Eisenbeis, L; Fregonese, F; Johnston, JC; Menzies, D; Ruslami, R; Trajman, A; Valiquette, C, 2020) |
| "Isoniazid preventative therapy is widely used for latent tuberculosis infection." | 7.91 | Mania induced by isoniazid preventive therapy during steroid treatment for rheumatoid arthritis and organising pneumonia. ( Miura, T; Nagano, H; Ueda, T, 2019) |
| "Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI)." | 7.91 | Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis. ( Chen, WW; Chiou, HL; Huang, WC; Huang, YW; Lin, CH; Tsao, SM; Yang, SF; Yang, WT; Yu, YY, 2019) |
| "The consequences of once-weekly rifapentine plus isoniazid for 3 months (3HP) against latent tuberculosis infections in hemodialysis patients have not been studied before." | 7.91 | Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events. ( Chen, TC; Chen, YH; Chiu, YW; Hsieh, MH; Hwang, SJ; Lin, SY; Lu, PL, 2019) |
| " Isoniazid is an antibiotic with high bactericidal effect on replicating mycobacteria and constitutes the most commonly prescribed treatment for latent tuberculosis infection." | 7.91 | Severe psoriasis entering remission after treatment for latent tuberculosis with isoniazid: Report of two cases. ( Giácaman-von der Weth, M; Hernández-Bel, P; Partarrieu-Mejías, F; Pérez-Ferriols, A, 2019) |
| "To evaluate the impact of isoniazid (INH) treatment for latent tuberculosis infection (LTBI) on the development of liver function test (LFT) abnormality and the persistence of tumor necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients." | 7.88 | Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy. ( Bae, SC; Cho, SK; Choi, CB; Jun, JB; Kim, D; Kim, TH; Sung, YK; Won, S; Yoo, DH, 2018) |
| "One of the reasons why Isoniazid preventive therapy (IPT) for Tuberculosis (TB) is not widely used in low income countries is concerns on cost of excluding active TB." | 7.85 | Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study. ( Aboud, S; Bakari, M; Chitama, D; Moshiro, C; Mugusi, F; Shayo, GA, 2017) |
| "A 41-year-old woman treated with isoniazid (INH) for latent tuberculosis infection and an oral corticosteroid for sarcoidosis developed severe anemia two months after initiating INH." | 7.85 | Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature. ( Hachisu, Y; Hisada, T; Kaira, K; Koga, Y; Koiso, H; Ono, A; Osaki, T; Oyama, T; Saito, Y; Sakurai, R; Sato, K; Sawada, Y; Sunaga, N; Tsukagoshi, Y; Yamada, M, 2017) |
| "The current recommendation for the treatment of latent tuberculosis infection (LTBI) in solid organ transplant candidates is isoniazid for 9 months, but this treatment has the main problem of frequently reaching the posttransplant period." | 7.85 | Efficacy and safety of short-term treatment with isoniazid and rifampicin for latent tuberculosis infection in lung transplant candidates. ( Guirao-Arrabal, E; Redel, J; Santos, F; Torre-Cisneros, J; Vaquero, JM, 2017) |
| " Centers for Disease Control and Prevention (CDC) recommended a new regimen for treatment of latent tuberculosis (three months of weekly isoniazid and rifapentine) in late 2011." | 7.85 | Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine. ( Dhanireddy, S; Eastment, M; McClintock, AH; McKinney, CM; Molnar, A; Narita, M; Park, DR; Pitney, CL, 2017) |
| "Isoniazid daily for 9 months is the recommended regimen for latent tuberculosis infection (LTBI) in solid organ transplant (SOT) candidates, but its use is controversial, due to reports of hepatotoxicity and low treatment completion rates." | 7.85 | Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates. ( Dhand, A; Knoll, BM; Nog, R; Wu, Y, 2017) |
| "[Purpose] To conduct a literature review on clin- ical studies and national guidelines in various countries, for the purposes of facilitating discussion regarding whether latent tuberculosis infection (LTBI) treatment regimens com- posed of isoniazid and rifampicin should be introduced in Japan." | 7.83 | [TREATMENT OF LATENT TUBERCULOSIS INFECTION WITH A COMBINATION OF ISONIAZID AND RIFAMPICIN]. ( Ito, K, 2016) |
| "[Purpose] To investigate the frequency and risk factors of severe liver dysfunction in patients receiving isoniazid (INH) mono-therapy for latent tuberculosis infection (LTBI)." | 7.83 | [FREQUENCY AND RISK FACTORS OF SEVERE LIVER DYSFUNCTION IN ISONIAZID MONO-THERAPY FOR LATENT TUBERCULOSIS INFECTION]. ( Ito, K, 2016) |
| " Objective The aim of this study was to present the follow-up results for Isoniazid (INH) chemoprophylaxis in patients with psoriasis receiving different biological therapies." | 7.83 | Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia. ( Cataño, J; Morales, M, 2016) |
| "Treating latent tuberculosis infection is a strategy for eliminating tuberculosis, and isoniazid is recommended as preventive therapy." | 7.81 | Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection. ( Hamana, S; Matsuoka, S; Miyazawa, S; Moriyama, M; Nagai, S; Nakamura, H; Nirei, K, 2015) |
| "Short-course directly observed isoniazid plus rifapentine (INH/RPT) combination could have potential advantages over a standard 9-month INH regimen for the treatment of latent tuberculosis infection in solid-organ transplant (SOT) candidates." | 7.80 | Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates. ( de Castilla, DL; Jain, R; Limaye, AP; Narita, M; Rakita, RM; Spitters, CE, 2014) |
| "We report a 37-year-old patient with latent tuberculosis infection who received isoniazid (INH) antituberculosis chemoprophylaxis." | 7.80 | [Development of eosinophilic pneumonia in a patient with latent tuberculosis infection resulting from isoniazid]. ( Inada, Y; Mamoto, T; Umeda, N, 2014) |
| " The main barriers as reported by 144 HCWs working in hospitals without IPT programme, were: (1) unclear direction of national policy (60%), (2) fear of emerging Isoniazid resistant tuberculosis (52%), and (3) fear of poor adherence (30%)." | 7.79 | Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. ( Kaewkungwal, J; Lawpoolsri, S; Moolphate, S; Pungrassami, P; Sanguanwongse, N; Yamada, N, 2013) |
| "To determine the rate of and risk factors for discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis infection in a large, multi-site study." | 7.79 | Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. ( Bethel, J; Colson, PW; Hirsch-Moverman, Y; Pettit, AC; Sterling, TR, 2013) |
| "Patient adherence to isoniazid (INH) monotherapy for latent tuberculosis infection (LTBI) has been suboptimal despite its proven efficacy." | 7.79 | House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study. ( Bhatia, G; Chang, AH; Polesky, A, 2013) |
| "The purpose of this study was to evaluate the cost-effectiveness of the strategy of controlling the contacts of tuberculosis patients with latent tuberculosis infection by means of treatment with rifampin for 4 months or isoniazid for 9 months." | 7.79 | Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection. ( Clotet, L; Domínguez, A; Ferrer, A; Garrido, P; Pina, JM; Sala, MR; Salleras, L, 2013) |
| "A 66-year-old woman with seropositive rheumatoid arthritis (RA) and latent tuberculosis infection developed minimal-change nephrotic syndrome following the initiation of anti-tuberculosis chemoprophylaxis with isoniazid." | 7.77 | Minimal-change nephrotic syndrome associated with isoniazid in anti-tuberculosis chemoprophylaxis for a patient with rheumatoid arthritis. ( Arizono, K; Matsushita, Y; Mori, S, 2011) |
| "Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability." | 7.77 | Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. ( Hamilton, CD; Holland, DP; Sanders, GD; Stout, JE, 2011) |
| "To compare rates of treatment interruption because of side effects and completion rates between subjects treated for latent tuberculosis infection (LTBI) by isoniazid (INH) for 6 months and subjects treated with rifampicin (RIF) for 4 months." | 7.77 | Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. ( Bridevaux, PO; Fresard, I; Janssens, JP; Rochat, T, 2011) |
| "A 75-year-female with a history of Isoniazid (INH) therapy for latent tuberculosis, was admitted with a 4-week duration of dyspnea, cough, and pleuritic chest pain." | 7.77 | Isoniazid (INH)-induced eosinophilic exudative pleural effusion and lupus erythematosus. A clinical reminder of drug side effects. ( Dahal, K; Khattri, S; Kushawaha, A; Lee, M; Mobarakai, N, 2011) |
| "Since the 1960s, 6 to 9 months of isoniazid (INH) has been the mainstay of treatment for latent tuberculosis infection (LTBI), but its application has been limited by concerns about the toxicity of INH and the long duration of treatment." | 7.76 | Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. ( , 2010) |
| "BACKGROUND/SETTING: Treatment for 3 months with rifampicin (R) and isoniazid (H) (3RH) for latent tuberculosis infection (LTBI), defined as an inappropriately positive tuberculin skin test with no clinical or x-ray evidence of disease, has been used locally since 1989." | 7.76 | Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. ( Bright-Thomas, R; Morris, JA; Nandwani, S; Ormerod, LP; Smith, J, 2010) |
| "The successful scale-up of a latent tuberculosis (TB) infection testing and treatment programme is essential to achieve TB elimination." | 7.11 | Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for ( Abubakar, I; Bern, H; Booth, HL; Calvert, J; Clarke, AL; Crook, A; Duong, T; Francis, M; Ghanouni, A; Griffiths, C; Hack, V; Hamada, Y; Horne, R; Kunst, H; Layton, C; Lipman, M; Mandelbaum, M; Owen-Powell, E; Rangaka, MX; Sanders, K; Surey, J; White, PJ; Zenner, D, 2022) |
| "Pregnancy is accompanied by immune suppression." | 7.01 | Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. ( Aaron, L; Bradford, S; Browning, R; Costello, D; Denti, P; Gausi, K; Gupta, A; Haas, DW; Kabugho, E; LaCourse, SM; Masheto, G; Mathad, JS; McCarthy, K; Mmbaga, B; Montepiedra, G; Naik, S; Pahwa, S; Pierre, MF; Sterling, TR; Theron, G; Vhembo, T; Weinberg, A; Zimmer, B, 2021) |
| "Treatment of latent tuberculosis (TB) infection (LTBI) effectively prevents its progression to active TB." | 6.87 | Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. ( Chan, PC; Chang, LY; Chuang, YC; Huang, WC; Huang, YW; Ruan, SY; Sun, HY; Wang, JT; Wang, JY, 2018) |
| "The main aim of this study is to determine the demographics, compliance, completion rates and adverse events of patients on preventive therapy (PT) for LTBI at our institution." | 6.82 | Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection. ( Goldberg, HF; Gray, EL, 2016) |
| "Treatment of persons with latent tuberculosis (TB) infection at greatest risk of reactivation is an important component of TB control and elimination strategies." | 6.80 | Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis. ( Canizales, S; Carranza, C; Cruz-Hervert, P; Delgado-Sánchez, G; Ferreira-Guerrero, E; Ferreyra-Reyes, L; García-García, L; Guio, H; Molina, S; Mongua-Rodriguez, N; Montero-Campos, R; Ponce-de Leon, A; Sada, E; Sifuentes-Osornio, J; Téllez, N; Torres, M; Wilkinson, RJ; Young, DB, 2015) |
| "Effective yet safe treatment of latent tuberculosis is important for preventing the spread of tuberculosis and the progression to active disease in pediatric patients." | 6.72 | Adverse events associated with weekly short course isoniazid and rifapentine therapy in pediatric patients with latent tuberculosis: A chart and literature review. ( Boyce, C; Huang, FS; Khalil, N; Kohlrieser, CM; Peck, GM; Schlaudecker, EP; Staat, MA, 2021) |
| " We aimed to determine whether the INH/RPT-3 regimen had similar or lesser rates of adverse events compared to other LTBI regimens, namely INH for 9 months, INH for 6 months, rifampin for 3 to 4 months, and rifampin plus INH for 3 to 4 months." | 6.58 | A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. ( Alvarez, GG; Barbeau, P; Hamel, C; Hutton, B; Pease, C; Skidmore, B; Wolfe, D; Yazdi, F, 2018) |
| " We provide suggested dolutegravir dosing considerations with concomitant rifapentine use, not currently addressed in recommended guidelines." | 5.91 | Alternative dolutegravir dosing strategies with concurrent rifapentine utilized for latent tuberculosis treatment. ( Pecora Fulco, P; Taylor, A; Winthrop, E, 2023) |
| "Treatment of latent tuberculosis (LTBI) is important for tuberculosis (TB) prevention, and short course rifamycin-based therapies are preferred." | 5.62 | Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis. ( Aiona, K; Belknap, RW; Erlandson, KM; Haas, MK, 2021) |
| "Objective Treating latent tuberculosis infection (LTBI) is essential for eliminating the serious endemicity of tuberculosis." | 5.56 | Use of Rifampin Compared with Isoniazid for the Treatment of Latent Tuberculosis Infection in Japan: A Bayesian Inference with Markov Chain Monte Carlo Method. ( Iwata, K; Miyakoshi, C; Morishita, N; Nishiwaki, M, 2020) |
| "We report pregnancy outcomes among South African women with HIV enrolled in a randomized trial of 4 TPT regimens (two 3-month regimens, rifapentine/isoniazid [3HP] or rifampin/isoniazid [3HR], isoniazid for 6 months, or isoniazid continuously)." | 5.51 | Pregnancy in Women With HIV in a Tuberculosis Preventive Therapy Trial. ( Barnes, GL; Chaisson, RE; Gupta, A; Martinson, NA; Moulton, LH; Msandiwa, R; Singh, P, 2022) |
| "The treatment of latent tuberculosis infection (LTBI) in individuals at risk of reactivation is essential for tuberculosis control." | 5.51 | Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid. ( Carranza, C; de Oyarzabal, E; Ferreyra-Reyes, L; García-García, L; Herrera, MT; Juárez, E; Orozco, L; Ponce-de-León, A; Rangel-Escareño, C; Sada, E; Sifuentes-Osornio, J; Torres, M; Wilkinson, RJ, 2019) |
| " Rifapentine clearance is higher among women with HIV, but all women achieved exposures of rifapentine and isoniazid associated with successful tuberculosis prevention." | 5.51 | Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. ( Bradford, S; Britto, P; Chakhtoura, N; Chalermchockcharoentkit, A; Chipato, T; Dooley, KE; Gupta, A; Jayachandran, P; Kamthunzi, P; Langat, D; Mathad, JS; Montepiedra, G; Norman, J; Patil, S; Popson, S; Rouzier, V; Savic, R; Townley, E; Wiesner, L; Zhang, N, 2022) |
| "Renal transplant candidates (RTC) with latent tuberculosis infection (LTBI) are at significant risk for tuberculosis reactivation." | 5.46 | Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates. ( Abbo, LM; Camargo, JF; Morris, MI; Rosa, R; Simkins, J, 2017) |
| "3 months of weekly rifapentine plus isoniazid (3HP) and 4 months of daily rifampicin (4R) are recommended for tuberculosis preventive treatment." | 5.41 | Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. ( Belknap, R; Benedetti, A; Borisov, A; Campbell, JR; Chaisson, RE; Chan, PC; Martinson, N; Menzies, D; Nahid, P; Scott, NA; Sizemore, E; Sterling, TR; Villarino, ME; Wang, JY; Winters, N, 2023) |
| "Isoniazid is a therapeutic agent for the treatment of latent tuberculosis infection." | 5.41 | A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators. ( Cho, JY; Chun Ji, S; Goo Lee, M; Jang, IJ; Kim, SH; Oh, J; Yoo, H; Yoon, JG; Yu, KS, 2021) |
| "This article examines costs to treat latent tuberculosis infection (LTBI) in an urban clinic population and highlights the potential effectiveness of an alternative transitional treatment regimen." | 5.40 | Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin. ( Fluegge, KR, 2014) |
| "Further, a murine model of latent tuberculosis was used and the standard 9-month isoniazid and 4-month rifampicin regimen along with thioridazine as an adjunct drug were evaluated." | 5.40 | Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis. ( Sharma, S; Singh, A, 2014) |
| " The average values of alanine aminotransferase pre- and posttreatment were similar (69 and 72 U/l respectively), demonstrating that tuberculosis prophylaxis with INH was safe for liver transplant candidates." | 5.38 | Is isoniazid safe for liver transplant candidates with latent tuberculosis? ( Angerami, RN; Ataide, EC; Boin, IF; Stucchi, RS; Udo, EY; Zanaga, L, 2012) |
| "Although treatment for latent tuberculosis infection lowers the risk of reactivation of tuberculosis due to tumor necrosis factor alpha-blockers, it cannot completely inactivate tuberculosis." | 5.37 | [Development of cervical tuberculous lymphadenitis in a patient with Crohn's disease receiving infliximab despite of chemoprophylaxis with isoniazid]. ( Furuta, K; Ikeue, T; Morita, K; Nakagawa, A; Nishiyama, H; Sugita, T, 2011) |
| "We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9-month group) in HIV-infected patients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection." | 5.30 | One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. ( Andersen, J; Banda, P; Benson, CA; Chaisson, RE; da Silva Escada, RO; Fletcher, CV; Gupta, A; Hakim, J; Jean Juste, MA; Kanyama, C; Lama, JR; Langat, D; Leon-Cruz, J; Masheto, G; Mawlana, S; Mohapi, L; Moran, L; Mwelase, N; Nuermberger, E; Omoz-Oarhe, A; Ramchandani, R; Severe, P; Supparatpinyo, K; Swindells, S; Valencia, J, 2019) |
| "To assess safety and pregnancy outcomes among pregnant women who were inadvertently exposed to study medications in two latent tuberculosis infection trials (PREVENT TB or iAdhere) evaluating 3HP and 9 months of daily isoniazid (H, 300 mg) (9H)." | 5.27 | Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials. ( Belknap, RW; Chaisson, RE; Goldberg, SV; Leung, CC; Lopez, M; Machado, ES; Moro, RN; Narita, M; Sanchez, J; Schluger, NW; Schwartzman, K; Scott, NA; Sterling, TR; Tepper, NK; Vernon, A; Villarino, ME, 2018) |
| "Once-weekly isoniazid and rifapentine for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection." | 5.27 | Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine. ( Alfaro, RM; Brooks, KM; De, P; Dobos, KM; George, JM; Hadigan, C; Kellogg, A; Kovacs, JA; Kumar, P; McLaughlin, M; McManus, M; Mehaffy, C; Pau, AK; Rupert, A, 2018) |
| "These results support using self-administered, once-weekly isoniazid and rifapentine to treat latent tuberculosis infection in the United States, and such treatment could be considered in similar settings when direct observation is not feasible." | 5.24 | Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. ( Arevalo, B; Belknap, R; Borisov, AS; Caylà, JA; Chen, MP; Feng, PJ; Holland, D; Martinson, NA; Millet, JP; Miró, JM; Moro, RN; Scott, NA; Villarino, ME; Weiner, M; Wright, A, 2017) |
| "Currently, treatment of latent tuberculosis infection (LTBI) in Australia consists most commonly of a 9-month course of isoniazid (9H)." | 5.24 | SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication. ( Biggs, B; Chen, C; Denholm, JT; Eisen, D; Leder, K; Matchett, E; McBryde, ES; Shultz, TR; Street, A, 2017) |
| "We conducted a systematic review examining the cost effectiveness of a 3-month course of isoniazid and rifapentine, known as 3HP, given by directly observed treatment, compared to 9 months of isoniazid that is directly observed or self-administered, for latent tuberculosis infection." | 5.22 | Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review. ( Brethour, K; Chaisson, RE; D'Silva, O; Lai, WA; Zwerling, AA, 2022) |
| "Three months of a once-weekly combination of rifapentine and isoniazid for treatment of latent tuberculosis infection is safe and effective for persons 12 years or older." | 5.20 | Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. ( Conde, MB; Goldberg, SV; Jones, B; Moro, RN; Nachman, S; Oliveira, R; Scott, NA; Shang, N; Sterling, TR; Villarino, ME; Weiner, M; Weis, SE, 2015) |
| "Weekly rifapentine plus isoniazid for 3 months (3HP) is as effective as daily isoniazid for 9 months (9H) for latent tuberculosis infection in high-risk persons, but there have been reports of possible flu-like syndrome." | 5.20 | Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. ( Adkinson, NF; Borisov, AS; Ho, C; Moro, RN; Phillips, E; Shepherd, G; Sterling, TR; Villarino, ME; Weis, S, 2015) |
| "With the renewed emphasis to implement isoniazid preventive therapy (IPT) in Sub-Saharan Africa, we investigated the effect of IPT on immunological profiles among household contacts with latent tuberculosis." | 5.20 | Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study. ( Biraro, IA; Cose, S; Dockrell, HM; Egesa, M; Elliott, AM; Joloba, M; Katamba, A; Kimuda, S; Levin, J; Smith, SG; Toulza, F, 2015) |
| "To compare the tolerance, adherence and effectiveness of two approaches for the treatment of latent tuberculosis infection (LTBI): 6 months of isoniazid (6H) vs." | 5.17 | Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. ( Altet-Gómez, MN; de Souza-Galvao, ML; Jiménez-Fuentes, MA; Mila Augé, C; Solsona Peiró, J, 2013) |
| "The roles of the NAT2 genotype and enzyme maturation on isoniazid pharmacokinetics were investigated in South African infants with perinatal HIV exposure enrolled in a randomized, double-blind, controlled trial of isoniazid for prevention of tuberculosis disease and latent infection." | 5.16 | The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. ( D'Argenio, DZ; Fletcher, CV; Kiser, JJ; Mitchell, CD; Seifart, HI; Werely, CJ; Zhu, R, 2012) |
| " the standard 6-month daily isoniazid regimen (6H) for latent tuberculosis infection (LTBI) in prison inmates." | 5.16 | Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. ( Chan, PC; Chang, LY; Fang, CT; Hsueh, PR; Huang, LM; Lu, BY; Lu, CY; Shao, PL; Wang, KF; Yang, CH, 2012) |
| "To evaluate the safety of isoniazid (INH) prophylaxis for newly identified latent tuberculosis infection (LTBI) in ustekinumab-treated patients with psoriasis." | 5.16 | The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. ( Ho, V; Kato, T; Leonardi, C; Li, S; Shen, YK; Song, M; Szapary, P; Tsai, TF; Wasfi, Y, 2012) |
| "Treatment for latent tuberculosis infection with isoniazid for 9 months (9INH) has poor completion and serious adverse events, while treatment for 4 months with daily rifampin (4RIF) has significantly higher completion and fewer adverse events." | 5.14 | Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. ( Aspler, A; Dion, MJ; Khan, K; Long, R; Menzies, D; Schwartzman, K; Trajman, A, 2010) |
| "The mainstay therapy for latent tuberculosis infection is a 9-month regimen of daily isoniazid (9H) and a 3-month regimen of 12 once-weekly doses of isoniazid and rifapentine (3HP)." | 5.12 | Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis. ( Chang, TE; Huang, YH; Huang, YS; Perng, CL; Tseng, SY, 2021) |
| "A 76-year-old man complicated with end-stage renal disease had latent tuberculosis infection (LTBI), and isoniazid (INH) 300 mg daily was started to prevent reactivation of LTBI before using biologic agents for rheumatoid arthritis." | 4.98 | Rhabdomyolysis Induced by Isoniazid in a Patient with Rheumatoid Arthritis and End-stage Renal Disease: A Case Report and Review of the Literature. ( Fujio, K; Komai, T; Sumitomo, S; Teruya, S, 2018) |
| " Three-month isoniazid-rifapentine was determined to be equal to other latent tuberculosis infection regimens in effectiveness (OR=0." | 4.98 | Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. ( Borisov, AS; Moro, RN; Morris, SB; Njie, GJ; Vernon, AA; Woodruff, RY, 2018) |
| "This systematic review was carried out to determine the effectiveness of continuous isoniazid (given for at least 36 months) for the treatment of latent tuberculosis infection (LTBI) in people living with HIV (PLHIV)." | 4.93 | Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. ( Den Boon, S; Ford, N; Getahun, H; Matteelli, A, 2016) |
| "Isoniazid (INH) has been the mainstay of treatment of latent tuberculosis infection for almost 50 years." | 4.86 | Treatment of latent tuberculosis infection: An update. ( Lobue, P; Menzies, D, 2010) |
| "In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding pyrazinamide in chemotherapy regimens lasting up to 6 months; adding rifampicin to isoniazid regimens; benefits of different regimens; chemotherapy for less than 6 months; daily chemotherapy; direct observation treatment; intermittent chemotherapy for 6 months or longer; isoniazid; low-level laser therapy for pulmonary tuberculosis; regimens containing quinolones; rifampicin plus isoniazid; substituting rifampicin with ethambutol in the continuous phase; and support mechanisms for directly observed treatment." | 4.85 | Tuberculosis (HIV-negative people). ( Garner, P; Ziganshina, LE, 2009) |
| "To examine chronic viral hepatitis (CVH) as a risk factor for hepatotoxicity during isoniazid (INH) treatment for latent tuberculosis infection (LTBI)." | 4.85 | The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. ( Bliven, EE; Podewils, LJ, 2009) |
| "A population pharmacokinetic (PPK) study of the correlation of adverse drug reactions (ADRs) with the 3HP regimen (weekly high-dose rifapentine plus isoniazid for 12 doses) for latent tuberculosis infection (LTBI) remains lacking." | 4.31 | Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: A population pharmacokinetic analysis. ( Fujita, Y; Huang, HL; Ieiri, I; Lee, CH; Lee, MC; Muraki, S; Wang, JY, 2023) |
| "Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI)." | 4.31 | High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. ( Chaisson, RE; Chihota, V; Churchyard, GJ; Dooley, KE; Jarrett, RT; Marzinke, MA; Shotwell, MS; van der Heijden, Y, 2023) |
| "Three months of weekly rifapentine plus isoniazid (3HP) therapy for latent tuberculosis infection (LTBI) is recommended worldwide." | 4.31 | Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. ( Belknap, R; Borisov, A; Caylà, JA; Chen, MP; Gandhi, NR; Holland, DP; Millet, JP; Moro, RN; Sadowski, C; Scott, NA; Wright, A, 2023) |
| "Scaling up a shorter preventive regimen such as weekly isoniazid and rifapentine (3HP) for 3 months is a priority for tuberculosis (TB) preventive treatment (TPT)." | 4.31 | Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment. ( Amanullah, F; Becerra, MC; Dahri, AA; Farooq, S; Hussain, H; Islam, Z; Jaswal, M; Keshavjee, S; Khan, AJ; Khowaja, S; Madhani, F; Malik, AA; Manzar, S; Noorani, S; Safdar, N; Salahuddin, N; Shah, JA; Shahbaz, SS; Shahzad, M, 2023) |
| "The development of age-appropriate dosage forms is essential for effective pharmacotherapy, especially when long-term drug treatment is required, as in the case of latent tuberculosis infection treatment with up to 9 months of daily isoniazid (ISO)." | 4.12 | Semi-solid extrusion 3D printing of starch-based soft dosage forms for the treatment of paediatric latent tuberculosis infection. ( Bouropoulos, N; Chatzitaki, AT; Fatouros, DG; Karavasili, C; Mystiridou, E; Ritzoulis, C, 2022) |
| "Systemic drug reaction (SDR) is a major safety concern with weekly rifapentine plus isoniazid for 12 doses (3HP) for latent tuberculosis infection (LTBI)." | 4.12 | Whole-Blood 3-Gene Signature as a Decision Aid for Rifapentine-based Tuberculosis Preventive Therapy. ( Cheng, MH; Chong, IW; Huang, HL; Huang, SH; Huang, YW; Lee, CH; Lee, JY; Lee, MR; Liu, IH; Lo, YS; Lu, PL; Wang, JY; Yang, JM, 2022) |
| "A once-weekly oral dose of isoniazid and rifapentine for 3 months (3HP) is recommended by the CDC for treatment of latent tuberculosis infection (LTBI)." | 4.12 | Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs. ( Cole, J; Day, CL; Dick, EJ; Foreman, TW; Ganatra, SR; Gandhi, NR; Gonzalez, O; Hall-Ursone, S; Kaushal, D; Mehra, S; Peloquin, CA; Rengarajan, J; Schlesinger, LS; Sharan, R; Shivanna, V; Singh, DK; Thippeshappa, R, 2022) |
| "We estimated costs of managing different forms of tuberculosis (TB) across Canada by conducting a retrospective chart review and cost assessment of patients treated for TB infection, drug-susceptible TB (DS TB), isoniazid-resistant TB, or multidrug-resistant TB (MDR TB) at 3 treatment centers." | 4.12 | Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010-2016. ( Brode, SK; Campbell, JR; Chiang, LY; Jamieson, F; Johnston, JC; Khadawardi, H; Mah, HK; Nsengiyumva, P; Oxlade, O; Rasberry, H; Rea, E; Romanowski, K; Sabur, NF; Sander, B; Schwartzman, K; Uppal, A, 2022) |
| "To investigate associations between isoniazid for latent tuberculosis and risk of severe hepatitis, affecting patients with rheumatoid arthritis or ankylosing spondylitis whose treatment includes tumor necrosis factor inhibitors." | 4.02 | Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors. ( Chao, PH; Chen, WW; Huang, WI; Huang, YC; Lai, EC; Liang, HY; Weng, MY, 2021) |
| "Short-course preventive therapy with 1-month course of daily administration of isoniazid (300-mg) plus rifapentine (600-mg) (1HP) and 3-month course of weekly administration of isoniazid (900-mg) plus rifapentine (900-mg) (3HP) has higher completion rates than 9-month course of daily isoniazid (9H) for individuals with latent tuberculosis infection (LTBI)." | 4.02 | Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. ( Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY, 2021) |
| " Treatment with isoniazid within 12 months of starting a biologic was summarized to evaluate the duration of treatment for latent tuberculosis infection and the time between start of isoniazid and initiation of a biologic." | 4.02 | Treatment of latent tuberculosis infection in patients receiving biologic agents. ( Iba, A; Jo, T; Ono, S; Tomio, J; Yamana, H; Yasunaga, H, 2021) |
| "Weekly rifapentine and isoniazid (3HP) is gaining popularity for latent tuberculosis infection treatment because of its short course and high completion rate." | 4.02 | Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection. ( Chen, TC; Cheng, MH; Chong, IW; Huang, CK; Huang, HL; Lai, PC; Lee, MR; Lu, PL; Sheu, CC; Wang, JY, 2021) |
| " We compared the cost per completed course of preventive treatment with either 6 months of daily isoniazid (6H) or 3 months of weekly isoniazid and rifapentine (3HP), delivered by the Indus Health Network tuberculosis program in Karachi, Pakistan, between October 2016 and February 2018." | 4.02 | Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting. ( Becerra, MC; Hussain, H; Jaswal, M; Keshavjee, S; Khan, AJ; Lu, C; Majidulla, A; Malik, AA; Safdar, N; Yuen, CM, 2021) |
| "Objective This study aimed to evaluate the treatment outcome of latent tuberculosis infection (LTBI) in persons with fibrotic pulmonary lesions, treated with isoniazid (INH) or rifampicin (RFP) in Nishinari Ward, Osaka City." | 4.02 | [Treatment outcome of latent tuberculosis infection in persons with fibrotic pulmonary lesions]. ( Komukai, J; Kudoh, S; Matsumoto, K; Okado, A; Shimouchi, A; Yoshida, H; Yoshiyama, T, 2021) |
| "To assess the cost effectiveness of once weekly rifapentine and isoniazid for 12 weeks (3HP) to the current standard care for latent tuberculosis (TB) infection (LTBI) in Iqaluit, Nunavut." | 4.02 | Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting. ( Alvarez, G; Finn, S; Habis, Y; Kilabuk, E; Mallick, R; Mulpuru, S; Patterson, M; Pease, C; Schwartzman, K; Zwerling, A, 2021) |
| "Three months of weekly rifapentine plus isoniazid (3HP) is a short course regimen for latent tuberculosis infection treatment with satisfied safety and efficacy." | 4.02 | High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study. ( Hu, ZD; Li, T; Liu, XH; Lu, SH; Ma, JY; Xia, L; Yang, H; Yang, Y; Yu, X, 2021) |
| "We aimed to determine overall incidence of severe and mild isoniazid (INH) hepatotoxicity and outcome of hepatotoxicity in children who were receiving INH for latent tuberculosis." | 4.02 | Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection. ( Aksay, A; Aktürk, H; Apa, H; Bayram, N; Can, D; Devrim, F; Devrim, İ, 2021) |
| "During 2001-2009, the Tuberculosis Trials Consortium conducted Study 26 (PREVENT TB), a randomized clinical trial at 26 sites in four countries, among persons with latent tuberculosis infection at high risk for tuberculosis disease progression, comparing 3 months of directly observed once-weekly rifapentine plus isoniazid with 9 months of self-administered daily isoniazid." | 3.96 | Nonparticipation reasons in a randomized international trial of a new latent tuberculosis infection regimen. ( Arevalo, B; Bessler, P; Borisov, AS; Bozeman, L; Dukes Hamilton, C; Goldberg, SV; Hecker, EJ; Hedges, KNC; Kerrigan, A; Moreno-Martinez, A; Saukkonen, JJ; Scott, NA, 2020) |
| "An important problem limiting treatment of latent tuberculosis infection is the occurrence of adverse events with isoniazid." | 3.96 | Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. ( Adjobimey, M; Benedetti, A; Campbell, JR; Cook, VJ; Eisenbeis, L; Fregonese, F; Johnston, JC; Menzies, D; Ruslami, R; Trajman, A; Valiquette, C, 2020) |
| "The objective of this study was to evaluate a novel collaborative care model using community pharmacies as additional access points for latent tuberculosis infection (LTBI) treatment for patients using combination weekly therapy with isoniazid and rifapentine (3HP) plus directly observed therapy for 12 weeks." | 3.96 | Addressing Latent Tuberculosis Infection Treatment Through a Collaborative Care Model With Community Pharmacies and a Health Department. ( Bachyrycz, A; Borrego, ME; Burgos, M; Ferreira, J; Fortune, D; Jakeman, B; Logothetis, SJ; Roberts, MH, 2020) |
| "Isoniazid preventative therapy is widely used for latent tuberculosis infection." | 3.91 | Mania induced by isoniazid preventive therapy during steroid treatment for rheumatoid arthritis and organising pneumonia. ( Miura, T; Nagano, H; Ueda, T, 2019) |
| "Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI)." | 3.91 | Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis. ( Chen, WW; Chiou, HL; Huang, WC; Huang, YW; Lin, CH; Tsao, SM; Yang, SF; Yang, WT; Yu, YY, 2019) |
| "The consequences of once-weekly rifapentine plus isoniazid for 3 months (3HP) against latent tuberculosis infections in hemodialysis patients have not been studied before." | 3.91 | Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events. ( Chen, TC; Chen, YH; Chiu, YW; Hsieh, MH; Hwang, SJ; Lin, SY; Lu, PL, 2019) |
| "Isoniazid (INH) prophylaxis is recommended for the prevention of tuberculosis (TB) reactivation before or/and during initiation of treatment with tumour necrosis factor antagonists (anti-TNF agents)." | 3.91 | Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy? ( Akyuz, F; Besisik, F; Cagatay, T; Cavus, B; Demir, K; Evirgen, S; Gulluoglu, M; Iliaz, R; Karaca, C; Kaymakoglu, S; Keskin, M; Koksalan, K; Onder, S; Ormeci, A; Soyer, OM, 2019) |
| " Isoniazid is an antibiotic with high bactericidal effect on replicating mycobacteria and constitutes the most commonly prescribed treatment for latent tuberculosis infection." | 3.91 | Severe psoriasis entering remission after treatment for latent tuberculosis with isoniazid: Report of two cases. ( Giácaman-von der Weth, M; Hernández-Bel, P; Partarrieu-Mejías, F; Pérez-Ferriols, A, 2019) |
| "Isoniazid monotherapy for six or nine months and the combination of isoniazid and rifampicin for three or four months are the most used regimens for treating latent tuberculosis." | 3.88 | Latent tuberculosis in childhood: tolerability of two different therapeutic approaches. ( Bianchi, L; Chiappini, E; Cordola, C; de Martino, M; Galli, L; Montagnani, C; Piccini, P; Sollai, S; Tersigni, C; Venturini, E, 2018) |
| "Here, we report a 51-year-old woman with latent tuberculosis infection who developed nephrotic syndrome during treatment with rifampicin and isoniazid for 25 days." | 3.88 | Minimal change disease related to rifampicin presenting with acute renal failure during treatment for latent tuberculosis infection: A case report. ( Choi, EY; Kim, JS; Kim, KJ, 2018) |
| "To evaluate the impact of isoniazid (INH) treatment for latent tuberculosis infection (LTBI) on the development of liver function test (LFT) abnormality and the persistence of tumor necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients." | 3.88 | Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy. ( Bae, SC; Cho, SK; Choi, CB; Jun, JB; Kim, D; Kim, TH; Sung, YK; Won, S; Yoo, DH, 2018) |
| "Optimal testing strategies for diagnosing latent tuberculosis infection and the administration of isoniazid preventive therapy (IPT) remain uncertain among human immunodeficiency virus (HIV)-infected patients." | 3.85 | QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients. ( Apisarnthanarak, A; Khawcharoenporn, T; Phetsuksiri, B; Rudeeaneksin, J; Srisungngam, S, 2017) |
| "Randomized controlled trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%); however, 3HP has not been assessed in routine healthcare settings." | 3.85 | High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection. ( Bamrah-Morris, S; Chorba, T; Griffin, P; Ho, CS; Holcombe, JM; Hunt, G; Jereb, J; Lobato, MN; Marco, A; Marks, S; Mase, S; Moro, RN; Mukasa, L; Nwana, N; Patil, N; Sandul, AL; Shah, N; Stewart, B; Wang, SH; Webb, R, 2017) |
| "One of the reasons why Isoniazid preventive therapy (IPT) for Tuberculosis (TB) is not widely used in low income countries is concerns on cost of excluding active TB." | 3.85 | Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study. ( Aboud, S; Bakari, M; Chitama, D; Moshiro, C; Mugusi, F; Shayo, GA, 2017) |
| "A 41-year-old woman treated with isoniazid (INH) for latent tuberculosis infection and an oral corticosteroid for sarcoidosis developed severe anemia two months after initiating INH." | 3.85 | Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature. ( Hachisu, Y; Hisada, T; Kaira, K; Koga, Y; Koiso, H; Ono, A; Osaki, T; Oyama, T; Saito, Y; Sakurai, R; Sato, K; Sawada, Y; Sunaga, N; Tsukagoshi, Y; Yamada, M, 2017) |
| " For treatment of latent tuberculosis infection (LTBI) overall, 49% of the respondents would refer management to infectious disease specialist or the health department, 37% would initiate isoniazid for 9 or 12 months, and 14% would use isoniazid for 6 months." | 3.85 | Screening and Treatment of Latent Tuberculosis Among Patients Receiving Biologic Agents: A National and International Survey of Rheumatologists. ( Carbone, L; Garcia-Rosell, M; Pattanaik, D; Raza, SH; Tran, NQ, 2017) |
| "The current recommendation for the treatment of latent tuberculosis infection (LTBI) in solid organ transplant candidates is isoniazid for 9 months, but this treatment has the main problem of frequently reaching the posttransplant period." | 3.85 | Efficacy and safety of short-term treatment with isoniazid and rifampicin for latent tuberculosis infection in lung transplant candidates. ( Guirao-Arrabal, E; Redel, J; Santos, F; Torre-Cisneros, J; Vaquero, JM, 2017) |
| "Isoniazid daily for 9 months is the recommended regimen for latent tuberculosis infection (LTBI) in solid organ transplant (SOT) candidates, but its use is controversial, due to reports of hepatotoxicity and low treatment completion rates." | 3.85 | Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates. ( Dhand, A; Knoll, BM; Nog, R; Wu, Y, 2017) |
| "[Purpose] To conduct a literature review on clin- ical studies and national guidelines in various countries, for the purposes of facilitating discussion regarding whether latent tuberculosis infection (LTBI) treatment regimens com- posed of isoniazid and rifampicin should be introduced in Japan." | 3.83 | [TREATMENT OF LATENT TUBERCULOSIS INFECTION WITH A COMBINATION OF ISONIAZID AND RIFAMPICIN]. ( Ito, K, 2016) |
| "[Purpose] To investigate the frequency and risk factors of severe liver dysfunction in patients receiving isoniazid (INH) mono-therapy for latent tuberculosis infection (LTBI)." | 3.83 | [FREQUENCY AND RISK FACTORS OF SEVERE LIVER DYSFUNCTION IN ISONIAZID MONO-THERAPY FOR LATENT TUBERCULOSIS INFECTION]. ( Ito, K, 2016) |
| "To ascertain whether multiparametric flow cytometry assessment of multifunctional Mycobacterium tuberculosis (Mtb)-specific CD4(+) and CD8(+) T cells can distinguish between untreated and treated patients with latent tuberculosis infection (LTBI), we enrolled 14 LTBI subjects treated with isoniazid (INH) therapy, 16 untreated LTBI patients, and 25 healthy controls." | 3.83 | Treatment of latent tuberculosis infection induces changes in multifunctional Mycobacterium tuberculosis-specific CD4+ T cells. ( Lichtner, M; Mascia, C; Mastroianni, CM; Mengoni, F; Rossi, R; Sauzullo, I; Vullo, V, 2016) |
| " Objective The aim of this study was to present the follow-up results for Isoniazid (INH) chemoprophylaxis in patients with psoriasis receiving different biological therapies." | 3.83 | Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia. ( Cataño, J; Morales, M, 2016) |
| "Treating latent tuberculosis infection is a strategy for eliminating tuberculosis, and isoniazid is recommended as preventive therapy." | 3.81 | Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection. ( Hamana, S; Matsuoka, S; Miyazawa, S; Moriyama, M; Nagai, S; Nakamura, H; Nirei, K, 2015) |
| "Short-course directly observed isoniazid plus rifapentine (INH/RPT) combination could have potential advantages over a standard 9-month INH regimen for the treatment of latent tuberculosis infection in solid-organ transplant (SOT) candidates." | 3.80 | Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates. ( de Castilla, DL; Jain, R; Limaye, AP; Narita, M; Rakita, RM; Spitters, CE, 2014) |
| "The management of latent tuberculosis infection (LTBI) most commonly consists of a nine-month course of isoniazid (INH) therapy and is complicated by low adherence and completion rates." | 3.80 | Successful management of latent tuberculosis infection in an underserved community by a student-run free clinic. ( Bartlett, M; Chang, H; Ellis, P; Friedland, G; Hung, A; Lukasiewicz, A; Peluso, MJ; Ramallo, J, 2014) |
| "In this study, we aimed to compare QuantiFERON-TB gold in-tube test (QFT-GIT) and tuberculin skin test (TST) as a diagnosis of latent tuberculosis infection in the children with Bacille Calmette-Guerin (BCG) vaccine." | 3.80 | Comparison of QuantiFERON-TB gold in-tube test with tuberculin skin test in children who had no contact with active tuberculosis case. ( Aydin Teke, T; Bayhan, Gİ; Metin Timur, Ö; Öz, FN; Tanir, G; Tuygun, N, 2014) |
| "We report a 37-year-old patient with latent tuberculosis infection who received isoniazid (INH) antituberculosis chemoprophylaxis." | 3.80 | [Development of eosinophilic pneumonia in a patient with latent tuberculosis infection resulting from isoniazid]. ( Inada, Y; Mamoto, T; Umeda, N, 2014) |
| "To assess the cost-effectiveness ratio of rifampin for 4 months and isoniazid for 6 months in contacts with latent tuberculosis infection." | 3.79 | Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection. ( Clotet, L; Domínguez, A; Ferrer, A; Garrido, P; Pina, JM; Sala, MR; Salleras, L, 2013) |
| " The main barriers as reported by 144 HCWs working in hospitals without IPT programme, were: (1) unclear direction of national policy (60%), (2) fear of emerging Isoniazid resistant tuberculosis (52%), and (3) fear of poor adherence (30%)." | 3.79 | Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. ( Kaewkungwal, J; Lawpoolsri, S; Moolphate, S; Pungrassami, P; Sanguanwongse, N; Yamada, N, 2013) |
| "To determine if low-risk elderly patients with rheumatoid arthritis (RA) who screen positive for latent tuberculosis (TB) infection prior to anti–tumor necrosis factor (anti-TNF) therapy should be given isoniazid (INH)." | 3.79 | Prophylaxis for latent tuberculosis infection prior to anti–tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis. ( Bombardier, C; Bykerk, V; Gardam, M; Hazlewood, GS; Naimark, D, 2013) |
| "To determine the rate of and risk factors for discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis infection in a large, multi-site study." | 3.79 | Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. ( Bethel, J; Colson, PW; Hirsch-Moverman, Y; Pettit, AC; Sterling, TR, 2013) |
| "Isoniazid treatment of latent tuberculosis infection (LTBI) is commonly prescribed in refugees and immigrants." | 3.79 | Understanding of latent tuberculosis, its treatment and treatment side effects in immigrant and refugee patients. ( Biggs, BA; Butcher, K; Leder, K; Lemoh, C; Marshall, C; O'Brien, D, 2013) |
| "The purpose of this study was to evaluate the cost-effectiveness of the strategy of controlling the contacts of tuberculosis patients with latent tuberculosis infection by means of treatment with rifampin for 4 months or isoniazid for 9 months." | 3.79 | Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection. ( Clotet, L; Domínguez, A; Ferrer, A; Garrido, P; Pina, JM; Sala, MR; Salleras, L, 2013) |
| "The optimal treatment for latent tuberculosis infection consists of isoniazid (H, INH) for 9-12 months." | 3.78 | Is isoniazid for 6 months more cost-effective than isoniazid for 9 months? ( Arias, C; Clotet, L; Domínguez, A; Ferrer, A; Pina, JM; Sala, MR, 2012) |
| "Poor adherence to isoniazid (INH) preventive therapy (IPT) is an impediment to effective control of latent tuberculosis (TB) infection." | 3.78 | Point-of-care urine tests for smoking status and isoniazid treatment monitoring in adult patients. ( Menzies, D; Nicolau, I; Ostiguy, G; Pai, M; Tian, L, 2012) |
| "An Australian metropolitan TB clinic where treatment for latent tuberculosis infection (LTBI) comprises six months of isoniazid, self-administered but dispensed monthly by the clinic." | 3.78 | Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic. ( Dobler, CC; Marks, GB, 2012) |
| "During the period of observation, therapy for latent tuberculosis was dispensed to 9145 residents, of whom 95% started isoniazid and 5% started rifampin." | 3.77 | Adverse events associated with treatment of latent tuberculosis in the general population. ( Bartlett, G; Menzies, D; Schwartzman, K; Smith, BM, 2011) |
| "A 66-year-old woman with seropositive rheumatoid arthritis (RA) and latent tuberculosis infection developed minimal-change nephrotic syndrome following the initiation of anti-tuberculosis chemoprophylaxis with isoniazid." | 3.77 | Minimal-change nephrotic syndrome associated with isoniazid in anti-tuberculosis chemoprophylaxis for a patient with rheumatoid arthritis. ( Arizono, K; Matsushita, Y; Mori, S, 2011) |
| " We show that Mtb continues to acquire mutations during disease latency, which may explain why isoniazid monotherapy for latent tuberculosis is a risk factor for the emergence of isoniazid resistance." | 3.77 | Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. ( Chase, MR; Flynn, JL; Ford, CB; Fortune, SM; Galagan, J; Iartchouk, O; Ioerger, TR; Lin, PL; Lipsitch, M; Mohaideen, N; Sacchettini, JC; Shah, RR, 2011) |
| "Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability." | 3.77 | Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. ( Hamilton, CD; Holland, DP; Sanders, GD; Stout, JE, 2011) |
| "To compare rates of treatment interruption because of side effects and completion rates between subjects treated for latent tuberculosis infection (LTBI) by isoniazid (INH) for 6 months and subjects treated with rifampicin (RIF) for 4 months." | 3.77 | Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. ( Bridevaux, PO; Fresard, I; Janssens, JP; Rochat, T, 2011) |
| "A 75-year-female with a history of Isoniazid (INH) therapy for latent tuberculosis, was admitted with a 4-week duration of dyspnea, cough, and pleuritic chest pain." | 3.77 | Isoniazid (INH)-induced eosinophilic exudative pleural effusion and lupus erythematosus. A clinical reminder of drug side effects. ( Dahal, K; Khattri, S; Kushawaha, A; Lee, M; Mobarakai, N, 2011) |
| "Treatment of latent tuberculosis infection (LTBI) generally includes isoniazid (INH), a drug that can cause serious hepatotoxicity." | 3.76 | Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. ( Brooks-Wilson, A; Cook, VJ; Elwood, K; Fitzgerald, JM; Halaschek-Wiener, J; Marra, F; Richardson, K; Tang, M; Yamada, S, 2010) |
| "Since the 1960s, 6 to 9 months of isoniazid (INH) has been the mainstay of treatment for latent tuberculosis infection (LTBI), but its application has been limited by concerns about the toxicity of INH and the long duration of treatment." | 3.76 | Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. ( , 2010) |
| "BACKGROUND/SETTING: Treatment for 3 months with rifampicin (R) and isoniazid (H) (3RH) for latent tuberculosis infection (LTBI), defined as an inappropriately positive tuberculin skin test with no clinical or x-ray evidence of disease, has been used locally since 1989." | 3.76 | Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. ( Bright-Thomas, R; Morris, JA; Nandwani, S; Ormerod, LP; Smith, J, 2010) |
| "It is essential to strengthen the treatment of latent tuberculosis infection (LTBI) to break the chain of transmission." | 3.30 | Protocol for pragmatic randomized clinical trial to evaluate the completion of treatment of latent Mycobacterium tuberculosis infection with Isoniazid in the 300 mg formulation. ( Alves, BMCS; Araújo, WN; Borges, BJP; Campos, BA; Cola, JP; Jezus, SV; Noia Maciel, EL; Prado, TND; Sales, CMM; Tavares, NUL, 2023) |
| "Screening for and treatment of latent tuberculosis (TB) in patients with end-stage kidney disease (ESKD) are recommended." | 3.11 | Comparison of three short-course rifamycin-based regimens for the prevention of tuberculosis in patients with end-stage kidney disease: Study protocol for a randomised clinical trial (RIFAKiD-TB trial). ( Anibarro, L; Barcala, JM; De Souza-Galvao, ML; Gijon, P; Grijota, MD; Luque, R; Perez-Recio, S; Sanchez, F; Santin, M, 2022) |
| "The successful scale-up of a latent tuberculosis (TB) infection testing and treatment programme is essential to achieve TB elimination." | 3.11 | Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for ( Abubakar, I; Bern, H; Booth, HL; Calvert, J; Clarke, AL; Crook, A; Duong, T; Francis, M; Ghanouni, A; Griffiths, C; Hack, V; Hamada, Y; Horne, R; Kunst, H; Layton, C; Lipman, M; Mandelbaum, M; Owen-Powell, E; Rangaka, MX; Sanders, K; Surey, J; White, PJ; Zenner, D, 2022) |
| " However, the occurrence of potentially serious adverse events (AE) is a limitation of TPT regimens." | 3.01 | A Systematic Review and Meta-Analysis of Tuberculous Preventative Therapy Adverse Events. ( Lisboa Bastos, M; Melnychuk, L; Menzies, D; Perlman-Arrow, S, 2023) |
| "Isoniazid was associated with higher rates of hepatotoxicity than placebo or rifampin." | 3.01 | Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Asher, GN; Balio, C; Berry, AM; Coffey, CP; Jonas, DE; Kahwati, LC; Lee, LC; Riley, SR; Voisin, CE; Wang, SH; Williams, N, 2023) |
| "Pregnancy is accompanied by immune suppression." | 3.01 | Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. ( Aaron, L; Bradford, S; Browning, R; Costello, D; Denti, P; Gausi, K; Gupta, A; Haas, DW; Kabugho, E; LaCourse, SM; Masheto, G; Mathad, JS; McCarthy, K; Mmbaga, B; Montepiedra, G; Naik, S; Pahwa, S; Pierre, MF; Sterling, TR; Theron, G; Vhembo, T; Weinberg, A; Zimmer, B, 2021) |
| "Treatment of latent tuberculosis (TB) infection (LTBI) effectively prevents its progression to active TB." | 2.87 | Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. ( Chan, PC; Chang, LY; Chuang, YC; Huang, WC; Huang, YW; Ruan, SY; Sun, HY; Wang, JT; Wang, JY, 2018) |
| " The current standard treatment - 9 months of isoniazid - has been associated with poor adherence and toxic effects, which have hampered the effectiveness of the drug." | 2.87 | Safety and Side Effects of Rifampin versus Isoniazid in Children. ( Adjobimey, M; Apriani, L; Benedetti, A; Diallo, T; Elwood, K; Fregonese, F; Gninafon, M; Hill, PC; Hornby, K; Li, PZ; Long, R; Marks, GB; Menzies, D; Obeng Baah, J; Ruslami, R; Schwartzman, K; Sow, O; Trajman, A; Valiquette, C; Wulandari, DA; Zielinski, D, 2018) |
| "The main aim of this study is to determine the demographics, compliance, completion rates and adverse events of patients on preventive therapy (PT) for LTBI at our institution." | 2.82 | Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection. ( Goldberg, HF; Gray, EL, 2016) |
| "Treatment of persons with latent tuberculosis (TB) infection at greatest risk of reactivation is an important component of TB control and elimination strategies." | 2.80 | Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis. ( Canizales, S; Carranza, C; Cruz-Hervert, P; Delgado-Sánchez, G; Ferreira-Guerrero, E; Ferreyra-Reyes, L; García-García, L; Guio, H; Molina, S; Mongua-Rodriguez, N; Montero-Campos, R; Ponce-de Leon, A; Sada, E; Sifuentes-Osornio, J; Téllez, N; Torres, M; Wilkinson, RJ; Young, DB, 2015) |
| " We studied the effect of INH on LPV concentrations by administering INH for 7 days and performing intensive pharmacokinetic sampling in 16 human immunodeficiency virus infected patients established on LPV/r-based ART." | 2.80 | The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals. ( Decloedt, EH; Maartens, G; McIlleron, H; van der Walt, JS; Wiesner, L, 2015) |
| "Randomised controlled trial of latent tuberculosis infection (LTBI) treatment in 10 clinics in Canada, Saudi Arabia and Brazil." | 2.75 | Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. ( Al-Otaibi, B; Dion, MJ; Long, R; Menzies, D; Trajman, A; Zylberberg, D, 2010) |
| "A history of latent tuberculosis infection is not disqualifying for deployment." | 2.72 | Fatal Isoniazid Hepatotoxicity in the Deployed Environment. ( Cybulski, DJ; White, BK, 2021) |
| "Effective yet safe treatment of latent tuberculosis is important for preventing the spread of tuberculosis and the progression to active disease in pediatric patients." | 2.72 | Adverse events associated with weekly short course isoniazid and rifapentine therapy in pediatric patients with latent tuberculosis: A chart and literature review. ( Boyce, C; Huang, FS; Khalil, N; Kohlrieser, CM; Peck, GM; Schlaudecker, EP; Staat, MA, 2021) |
| "Management of latent tuberculosis infection (LTBI) is a critical element in the elimination of tuberculosis (TB)." | 2.66 | Latent tuberculosis infection: recent progress and challenges in South Korea. ( Jeon, D, 2020) |
| " We aimed to determine whether the INH/RPT-3 regimen had similar or lesser rates of adverse events compared to other LTBI regimens, namely INH for 9 months, INH for 6 months, rifampin for 3 to 4 months, and rifampin plus INH for 3 to 4 months." | 2.58 | A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. ( Alvarez, GG; Barbeau, P; Hamel, C; Hutton, B; Pease, C; Skidmore, B; Wolfe, D; Yazdi, F, 2018) |
| "Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination." | 2.58 | Latent tuberculosis infection: Opportunities and challenges. ( Belknap, R; Chee, CBE; Reves, R; Zhang, Y, 2018) |
| "Treatment of latent tuberculosis infection (LTBI) is an important component of tuberculosis (TB) control, and this study updates a previous network meta-analysis of the best LTBI treatment options to inform public health action and programmatic management of LTBI." | 2.55 | Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. ( Beer, N; Harris, RJ; Lipman, MC; Stagg, HR; van der Werf, MJ; Zenner, D, 2017) |
| "Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States." | 2.55 | Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model. ( Horsburgh, CR; Linas, BP; Marks, SM; Salomon, JA; Tasillo, A; Trikalinos, TA, 2017) |
| "The management of latent tuberculosis (LTBI) in children represents an important issue for paediatricians because of the disease burden, the lack of a gold standard for the diagnosis and the high annual risk of progression to active disease." | 2.55 | Optimizing the management of children with latent tuberculosis infection. ( Chiappini, E; de Martino, M; Galli, L; Tersigni, C; Venturini, E, 2017) |
| "The preventive treatment of latent tuberculosis infection (LTBI) is of great importance for the elimination and control of tuberculosis (TB) worldwide, but existing screening methods for LTBI are still limited in predicting the onset of TB." | 2.53 | Updates on the risk factors for latent tuberculosis reactivation and their managements. ( Ai, JW; Liu, QH; Ruan, QL; Zhang, WH, 2016) |
| "Improvements in management of latent tuberculosis will need programmatic approaches to address the losses at each step in the cascade." | 2.53 | The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. ( Alsdurf, H; Getahun, H; Hill, PC; Matteelli, A; Menzies, D, 2016) |
| "Prophylactic treatment of latent tuberculosis infection (LTBI) is necessary for controlling TB in low-incidence settings." | 2.52 | Improving Treatment Completion Rates for Latent Tuberculosis Infection: A Review of Two Treatment Regimens at a Community Health Center. ( Bleything, S; Hunter, P; Lines, G, 2015) |
| "The treatment of latent tuberculosis infection (LTBI) has been established as valid for patients at high risk for developing active tuberculosis." | 2.50 | Treatment guidelines for latent tuberculosis infection. ( , 2014) |
| "Treatment of latent tuberculosis infection (LTBI) is a key component in TB control strategies worldwide." | 2.50 | Current treatment options for latent tuberculosis infection. ( Bocchino, M; Matarese, A; Sanduzzi, A, 2014) |
| "Effective treatment of latent tuberculosis infection (LTBI) is an important component of TB elimination programs." | 2.50 | Treatment of latent tuberculosis infection: a network meta-analysis. ( Abubakar, I; Harris, RJ; Lipman, MC; Muñoz, L; Stagg, HR; Zenner, D, 2014) |
| "Treatment of latent tuberculosis (TB) infection is an important component of TB control programs in both high- and low-prevalence countries." | 2.49 | Treatment of latent tuberculosis infection. ( Parekh, MJ; Schluger, NW, 2013) |
| "The treatment of latent tuberculosis infection is well described in many national guidelines." | 2.48 | [Treatment of latent tuberculosis infection]. ( Fraisse, P, 2012) |
| "Treatment of latent tuberculosis infection reduces the risk of active TB in HIV positive individuals especially in those with a positive tuberculin skin test." | 2.46 | Treatment of latent tuberculosis infection in HIV infected persons. ( Adetifa, I; Akolo, C; Shepperd, S; Volmink, J, 2010) |
| " The use of INH for the treatment of LTBI is safe in older patients with clinical or biochemical monitoring." | 2.46 | Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. ( Khan, KS; Kunst, H, 2010) |
| " We provide suggested dolutegravir dosing considerations with concomitant rifapentine use, not currently addressed in recommended guidelines." | 1.91 | Alternative dolutegravir dosing strategies with concurrent rifapentine utilized for latent tuberculosis treatment. ( Pecora Fulco, P; Taylor, A; Winthrop, E, 2023) |
| " Adverse drug events were more frequent in the older age group (22." | 1.72 | Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases. ( Chung, C; Jo, KW; Kim, YJ; Shim, TS, 2022) |
| "In 2017, Korea implemented nationwide latent tuberculosis infection (LTBI) project targeting healthcare workers (HCWs)." | 1.72 | Latent Tuberculosis Cascade of Care Among Healthcare Workers: A Nationwide Cohort Analysis in Korea Between 2017 and 2018. ( Bae, S; Choi, JY; Jeong, H; Kang, JY; Kim, HW; Kim, JS; Koo, HK; Lee, SS; Lee, Y; Min, J; Myong, JP; Park, JS; Shin, AY; Yim, HW, 2022) |
| "Isoniazid prophylaxis treatment period is long and can cause liver damage." | 1.72 | Effectiveness and safety of available preventive tuberculosis treatment regimens for children and adolescents: protocol for a systematic review and network meta-analysis. ( Acosta-Reyes, J; Benjumea-Bedoya, D; Estupiñán-Bohorquez, AF; Florez, ID; Hoyos Mendez, Y; Sabella-Jiménez, V, 2022) |
| "Tuberculosis (TB), caused by Mycobacterium tuberculosis infection, remains a leading cause of death from an infectious agent, resulting in more than a million deaths per year." | 1.72 | A world without tuberculosis: moving from imagination to reality. ( Jacobs, WR, 2022) |
| "Isoniazid was prescribed to 684 (66." | 1.72 | Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates. ( Borekci, S; Celik, AF; Esatoglu, SN; Fresko, I; Hacioglu, A; Hamuryudan, V; Hatemi, G; Hatemi, I; Melikoglu, M; Ongen, HG; Ozdogan, H; Ozguler, Y; Seyahi, E; Ugurlu, S; Yurdakul, S, 2022) |
| "Treatment of latent tuberculosis infection (LTBI) decreases risk of progression to active tuberculosis." | 1.62 | Tele-TB: Using TeleMedicine to Increase Access to Directly Observed Therapy for Latent Tuberculosis Infection. ( Donahue, ML; Eberly, MD; Rajnik, M, 2021) |
| "2% had ≥1 adverse drug reactions (P < ." | 1.62 | Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients With Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study. ( Cheng, MH; Chin, CS; Chong, IW; Huang, HL; Huang, WC; Lee, IT; Lee, MR; Lin, KD; Liu, SS; Lu, PL; Sheu, CC; Wang, JY, 2021) |
| "Although latent tuberculosis infection (LTBI) treatment is given before anti-tumor necrosis factor (TNF) treatment, tuberculosis (TB) still develops in these patients and the risk factors are not well known." | 1.62 | Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy. ( Aksu, K; Kaptan, Y; Oksel, F; Sayiner, A; Suner, A; Taş, MN, 2021) |
| "Empiric treatment for latent tuberculosis infection (LTBI) was individually considered for immunocompromised patients." | 1.62 | Low uptake of isoniazid window prophylaxis in patients exposed to a health-care worker with pulmonary tuberculosis in a paediatric ward. ( Ang, S; Bagdasarian, N; Chan, HC; Chan, SM; Sinnathamby, A, 2021) |
| "Isoniazid treatment had an adequate tolerance and adherence." | 1.62 | Prevalence of latent tuberculosis in patients with hematological neoplasms in a cancer referral hospital in Mexico City. ( García-Tirado, J; Martin-Onraet, A; Osorio-López, EA; Vilar-Compte, D, 2021) |
| "Identification and treatment for latent tuberculosis infection (LTBI) are of great epidemiological importance of controlling tuberculosis (TB) worldwide." | 1.62 | An observational study on prevalence of latent tuberculosis infection and outcome of 3HP treatment in patients under hemodialysis in Taiwan. ( Chou, CA; Dai, LH; Lee, CT; Liu, JW; Su, HA; Wu, CH; Yang, CC, 2021) |
| "Among over 8000 patients treated for latent tuberculosis we found no evidence of acquired drug resistance, underscoring the safety of rifampin monotherapy for latent tuberculosis." | 1.56 | Clinical Characteristics of Active Tuberculosis Diagnosed After Starting Treatment for Latent Tuberculosis Infection. ( Aiona, K; Belknap, R; Flynn, AG; Haas, MK; Reves, R, 2020) |
| "Active tuberculosis was diagnosed in three of the 196 TST-positive patients who adhered to PTI (1." | 1.56 | Access and adherence to isoniazid preventive therapy and occurrence of active TB in a cohort of people living with HIV: a retrospective cohort study in Sao Paulo, Brazil. ( Avelino-Silva, VI; Freitas, AC; Gutierrez, EB; Picone, CM, 2020) |
| "Screening for latent tuberculosis infection (LTBI) is indicated before immunosuppressive therapies but is complicated by lack of a gold standard and limited by, e." | 1.56 | Trends in diagnostic methods and treatment of latent tuberculosis infection in a tertiary care center from 2000 to 2017. ( Arend, SM; Bakker, JA; Duinkerk, DL; Kroft, LJM; Ottenhoff, THM; Ramai, RSRS; Uzorka, JW, 2020) |
| "Isoniazid was prescribed if any one test was positive." | 1.56 | Comparison of single and dual latent tuberculosis screening strategies before biologic and targeted therapy in patients with rheumatic diseases: a retrospective cohort study. ( Lao, V; Luk, L; Pang, S; So, H; Tang, I; Wong, V; Yip, R, 2020) |
| "Treatment of latent tuberculosis infection (LTBI) is an important strategy for active disease prevention." | 1.56 | Advantage in privacy protection by using synchronous video observed treatment enhances treatment adherence among patients with latent tuberculosis infection. ( Chen, SH; Hsu, HL; Huang, CC; Lee, CH; Liu, YJ; Putri, DU; Wang, I, 2020) |
| " Incidents of systemic adverse reactions (SARs) and treatment interruption rates in an elderly group (≥60 years old) and a young group (<60 years old) were analyzed." | 1.56 | Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-A prospective observational study in Taiwan. ( Chen, CY; Feng, JY; Huang, WC; Lee, SS; Li, CP; Lin, CB; Lin, SM; Pan, SW; Shu, CC; Su, WJ; Tung, CL; Wang, TY; Wei, YF, 2020) |
| " The prospective cohort were HIV patients without TB disease initiated on a dosage of Isoniazid 300 mg/day for adults and 150 mg/day for children for a period of 6 months." | 1.56 | A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda. ( Calnan, J; Kadama, H; Karungi Karamagi Nkolo, E; Katureebe, C; Kiragga, D; Lawino, A; Muhire, M; Musinguzi, J; Nabwire, J; Namuwenge, P; Sensalire, S; Seyoum, D, 2020) |
| "Objective Treating latent tuberculosis infection (LTBI) is essential for eliminating the serious endemicity of tuberculosis." | 1.56 | Use of Rifampin Compared with Isoniazid for the Treatment of Latent Tuberculosis Infection in Japan: A Bayesian Inference with Markov Chain Monte Carlo Method. ( Iwata, K; Miyakoshi, C; Morishita, N; Nishiwaki, M, 2020) |
| "A study of latent tuberculosis infection (LTBI) burden by chest roentgenography (CXR) with reference to interferon-gamma release assay (IGRA) is still lacking in rheumatic patients of an intermediate tuberculosis burden area." | 1.56 | Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients. ( Chang, TH; Lin, CH; Wang, PH; Wu, CS, 2020) |
| "Risk-targeted testing and treatment of latent tuberculosis infection (LTBI) is a critical component of the United States' (US) tuberculosis (TB) elimination strategy, but relatively low treatment completion rates remain a challenge." | 1.56 | Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data. ( Annan, E; Loethen, AD; Miller, TL; Stockbridge, EL, 2020) |
| "Treatment of latent tuberculosis infection (LTBI) in high-risk groups is an effective strategy for TB control and elimination in low incidence settings." | 1.51 | Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis. ( Chapman, HJ; de Andrade Bezerra, JL; Hsu, H; Johnston, L; Lauzardo, M; Séraphin, MN; Yang, Y, 2019) |
| "There are insufficient data on the treatment of latent tuberculosis infection (LTBI) in elderly patients." | 1.51 | Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older. ( Baek, MS; Choi, H; Choi, JH; Hyun, IG; Kim, CH; Kim, HI; Kim, Y; Noh, CS, 2019) |
| "Defining occupational latent tuberculosis infection (LTBI) risk among healthcare workers is needed to support implementation of prevention guidelines." | 1.51 | High risk for latent tuberculosis infection among medical residents and nursing students in India. ( Basavaraj, A; Bollinger, R; Chandanwale, A; DeLuca, A; Dhumal, G; Girish, S; Golub, J; Gupta, A; Gupte, N; Joshi, S; Kadam, D; Kinikar, A; Lokhande, N; Mave, V; Pardeshi, G; Shelke, S, 2019) |
| "The uveitis was treated with local and systemic anti-inflammatory and immunosuppressive therapy in all patients." | 1.48 | Effect of Antituberculous Therapy on Uveitis Associated With Latent Tuberculosis. ( Leong, BCS; Lightman, S; McCluskey, PJ; Tomkins-Netzer, O; Zhang, X, 2018) |
| "Data from regular monitoring for latent tuberculosis infection [LTBI] during biologic treatment are lacking." | 1.48 | A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases. ( Chen, M; Hung, E; Ip, M; Lee, CK; Lui, G; Ng, SC; Tam, LS; Tang, W; Wong, SHV; Wu, JC, 2018) |
| "People with HIV infection with latent tuberculosis (TB) infection (LTBI) are at a 10-fold greater risk of developing active disease." | 1.48 | New and Noteworthy in Tuberculosis Diagnostics and Treatment. ( Swindells, S, 2018) |
| "Treatment of latent tuberculosis infection (LTBI) is critical to the control and elimination of tuberculosis disease (TB) in the United States." | 1.48 | Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection. ( Allen, L; Bamrah Morris, S; Borisov, AS; Burton, D; Goldberg, S; LoBue, P; Njie, GJ; Vernon, A; Winston, CA; Yelk Woodruff, R, 2018) |
| " Combinations of optimal dose and release rates were simulated such that plasma concentrations were maintained over the epidemiological cut-off or minimum inhibitory concentration for the dosing interval." | 1.48 | Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. ( Flexner, C; Moss, DM; Owen, A; Podany, AT; Rajoli, RKR; Siccardi, M; Swindells, S, 2018) |
| "Ensuring adherence and support during treatment of tuberculosis (TB) is a major public health challenge." | 1.48 | Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support. ( Bastos, M; Falzon, D; Mappin-Kasirer, B; Nsengiyumva, NP; Oxlade, O; Schwartzman, K; Trajman, A, 2018) |
| "Successful treatment of latent tuberculosis infection (LTBI) is essential to reduce tuberculosis (TB) incidence rates in low-burden countries." | 1.48 | Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. ( Andersen, HE; Arnesen, TM; Dyrhol-Riise, AM; Madebo, T; Schein, YL; Tveiten, H; White, RA; Winje, BA, 2018) |
| "Psoriatic patients with latent tuberculosis infection (LTBI) need a prophylaxis before starting a treatment with biological drugs." | 1.46 | Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. ( Conti, A; Galdo, G; Gisondi, P; Lasagni, C; Odorici, G; Pellacani, G; Piaserico, S, 2017) |
| "This is known as latent tuberculosis infection (LTBI) although, rather than a distinct entity, this probably represents part of a dynamic spectrum." | 1.46 | National position statement for the management of latent tuberculosis infection. ( Stock, D, 2017) |
| "Renal transplant candidates (RTC) with latent tuberculosis infection (LTBI) are at significant risk for tuberculosis reactivation." | 1.46 | Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates. ( Abbo, LM; Camargo, JF; Morris, MI; Rosa, R; Simkins, J, 2017) |
| "We report a rare case of Takayasu's arteritis with isolated pulmonary artery stenosis in the presence of active hepatitis B and latent Mycobacterium tuberculosis infection in a middle-aged Asian woman who initially presented with severe dyspnea on exertion and recurrent syncope, occasional burning chest pains, and fatigue." | 1.46 | Takayasu's Arteritis with Isolated Pulmonary Artery Involvement in a Middle-Aged Asian Woman with Hepatitis B and Latent Tuberculosis Infection. ( Franzen, D; Greutmann, M; Kolios, A; Liebscher, F; Pfammatter, T, 2017) |
| "Contact tracing of a case of pulmonary tuberculosis was performed in a Bolivian patient." | 1.43 | Outbreak of isoniazid-resistant tuberculosis in an immigrant community in Spain. ( Andrés García, I; Eiros Bouza, JM; Fernández Arribas, S; Fernández Espinilla, V; Hernán García, C; Moreno Cea, L; Rubio, V; Ruiz Lopez Del Prado, G; Vesenbeckh, S, 2016) |
| "The association of latent tuberculosis infection (LTBI) with subsequent cancer remains unclear." | 1.43 | Latent Tuberculosis Infection and the Risk of Subsequent Cancer. ( Chen, TJ; Chen, YM; Chou, KT; Chuang, PH; Feng, JY; Pan, SW; Su, VY; Su, WJ; Yen, YF, 2016) |
| "Targeted diagnosis and treatment of latent tuberculosis (TB) infection (LTBI) among persons with a high risk of exposure to TB or of developing TB when infected has been performed and monitored routinely in the Netherlands since 1993." | 1.43 | Monitoring latent tuberculosis infection diagnosis and management in the Netherlands. ( Cobelens, F; de Vries, G; Erkens, CG; Schimmel, H; Slump, E; van den Hof, S; Verhagen, M, 2016) |
| "Treatment of latent tuberculosis infection (LTBI) is essential for eradicating tuberculosis (TB)." | 1.43 | Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan. ( Huang, YW; Tsao, SM; Tsao, TC; Yang, SF; Yeh, YP, 2016) |
| "The reactivation of a latent tuberculosis infection is one of the possible major events that may occur during biologic therapies for inflammatory chronic diseases such as psoriasis." | 1.42 | Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida. ( Dehesa, L; Kerdel, F; Medina-Gil, C; Vega, A, 2015) |
| "Screening for latent tuberculosis infection (LTBI) is mandatory in patients with psoriasis prior to biological therapy." | 1.40 | Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. ( Girolomoni, G; Gisondi, P; Lo Cascio, G; Pezzolo, E, 2014) |
| "Reactivation of latent tuberculosis infection (LTBI) is an important complication in patients treated with tumor necrosis factor-alpha (TNF-α) blocking agents." | 1.40 | Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay. ( Byeon, JS; Jo, KW; Jung, YJ; Kim, HC; Kim, KJ; Kim, YG; Lee, CK; Shim, TS; Yang, SK; Ye, BD; Yoo, B, 2014) |
| "Further, a murine model of latent tuberculosis was used and the standard 9-month isoniazid and 4-month rifampicin regimen along with thioridazine as an adjunct drug were evaluated." | 1.40 | Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis. ( Sharma, S; Singh, A, 2014) |
| "To evaluate IPT feasibility, treatment completion and adverse events (AE) and their determinants under field conditions." | 1.39 | Isoniazid preventive treatment: predictors of adverse events and treatment completion. ( Besozzi, G; Casali, L; Codecasa, LR; Delmastro, M; Ferrara, G; Ferrarese, M; Murgia, N; Raviglione, MC; Repossi, AC, 2013) |
| "This thioridazine exposure was calculated to extinguish all three M." | 1.39 | Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. ( Gumbo, T; Leff, R; Meek, C; Musuka, S; Pasipanodya, J; Siyambalapitiyage Dona, CW; Srivastava, S, 2013) |
| "She had a 3-year history of type 1 diabetes mellitus, and was an immigrant from Ecuador." | 1.39 | [Papilledema secondary to tuberculous meningitis in a patient with type 1 diabetes mellitus]. ( Caire Estévez, JP; González-Ocampo Dorta, S; Sanz Solana, P, 2013) |
| "Notably, despite latent tuberculosis treatment, active tuberculosis was not prevented." | 1.39 | Tuberculous pleurisy diagnosed by medical thoracoscopy in an adalimumab-treated rheumatoid arthritis patient after treatment of latent tuberculosis infection. ( Fujio, K; Ishii, S; Nagafuchi, Y; Shoda, H; Sugiyama, H; Yamamoto, K, 2013) |
| "Suspected latent tuberculosis infection (LTBI) is a common reason for referral to TB clinics." | 1.39 | Does an interferon-gamma release assay change practice in possible latent tuberculosis? ( Chalmers, JD; Gilhooley, S; Hill, AT; Jones, ME; Laurenson, IF; McSparron, C; Tiernan, JF, 2013) |
| "Contacts with latent tuberculosis infection (LTBI) are offered chemoprophylaxis to prevent active disease; however, the effectiveness of this intervention is unclear as treatment completion is generally low." | 1.38 | Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. ( Ahuja, SD; Anger, HA; Harris, TG; Kreiswirth, BN; Li, J; Proops, D; Shashkina, E, 2012) |
| "This study evaluates completion of treatment for latent tuberculosis infection (LTBI) in Mexican immigrant children aged 1-18 years in a Community Health Center (CHC)." | 1.38 | Successful treatment of pediatric latent tuberculosis infection in a community health center clinic. ( Edick, T; Klee, D; O'Connor, ME; Young, J, 2012) |
| "Metronidazole (MTZ), which has activity only against anaerobic, nonreplicating bacteria, was as effective as either of these treatments in preventing reactivation of latent infection." | 1.38 | Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. ( Barry, CE; Dartois, V; Flynn, JL; Goodwin, MB; Janssen, C; Johnston, PJ; Klein, E; Lin, PL; Via, L, 2012) |
| " The average values of alanine aminotransferase pre- and posttreatment were similar (69 and 72 U/l respectively), demonstrating that tuberculosis prophylaxis with INH was safe for liver transplant candidates." | 1.38 | Is isoniazid safe for liver transplant candidates with latent tuberculosis? ( Angerami, RN; Ataide, EC; Boin, IF; Stucchi, RS; Udo, EY; Zanaga, L, 2012) |
| "The indications for treatment for latent tuberculosis infection were revised in 2007 to reflect that any subject with a higher risk of tuberculosis regardless of age should be treated." | 1.37 | [Liver dysfunction during treatment of latent tuberculosis infection]. ( Nakazono, T; Shimao, T; Sugita, H; Tagawa, H; Takase, A; Takayanagi, K; Tezuka, N; Yamaguchi, T, 2011) |
| "Isoniazid therapy was accepted by 93 of 121 refugees (76." | 1.37 | Assessment and management of latent tuberculosis infection in a refugee population in the Northern Territory. ( Krause, VL; Trauer, JM, 2011) |
| "Although treatment for latent tuberculosis infection lowers the risk of reactivation of tuberculosis due to tumor necrosis factor alpha-blockers, it cannot completely inactivate tuberculosis." | 1.37 | [Development of cervical tuberculous lymphadenitis in a patient with Crohn's disease receiving infliximab despite of chemoprophylaxis with isoniazid]. ( Furuta, K; Ikeue, T; Morita, K; Nakagawa, A; Nishiyama, H; Sugita, T, 2011) |
| "Low adherence to treatment of latent tuberculosis infection (TLTBI) diminishes TB prevention efforts." | 1.36 | Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. ( Dorsinville, M; Li, J; Munsiff, SS; Tarantino, T, 2010) |
| "To evaluate a 10-year school-based latent tuberculosis infection (LTBI) screening program, targeting immigrant children in Montreal, Canada, and to identify predictive factors for refusal and, poor adherence to treatment." | 1.36 | Evaluation of a school-based program for diagnosis and treatment of latent tuberculosis infection in immigrant children. ( Blais, D; Carle, ME; Lamarre, V; Minodier, P; Ovetchkine, P; Tapiero, B, 2010) |
| "Few studies have examined predictors of latent tuberculosis infection (LTBI) treatment completion in inner city populations in the United States." | 1.36 | Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. ( Bethel, J; Colson, PW; El-Sadr, W; Franks, J; Hirsch-Moverman, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (0.97) | 29.6817 |
| 2010's | 284 (68.93) | 24.3611 |
| 2020's | 124 (30.10) | 2.80 |
| Authors | Studies |
|---|---|
| Karabanovich, G | 1 |
| Zemanová, J | 1 |
| Smutný, T | 1 |
| Székely, R | 1 |
| Šarkan, M | 1 |
| Centárová, I | 1 |
| Vocat, A | 1 |
| Pávková, I | 1 |
| Čonka, P | 1 |
| Němeček, J | 1 |
| Stolaříková, J | 1 |
| Vejsová, M | 1 |
| Vávrová, K | 1 |
| Klimešová, V | 1 |
| Hrabálek, A | 1 |
| Pávek, P | 1 |
| Cole, ST | 1 |
| Mikušová, K | 1 |
| Roh, J | 1 |
| Santivañez-Veliz, M | 1 |
| Pérez-Silanes, S | 1 |
| Torres, E | 1 |
| Moreno-Viguri, E | 1 |
| Chatzitaki, AT | 1 |
| Mystiridou, E | 1 |
| Bouropoulos, N | 1 |
| Ritzoulis, C | 1 |
| Karavasili, C | 1 |
| Fatouros, DG | 1 |
| Lai, EC | 1 |
| Liang, HY | 1 |
| Huang, YC | 2 |
| Huang, WI | 1 |
| Chao, PH | 1 |
| Chen, WW | 3 |
| Weng, MY | 1 |
| Radtke, KK | 2 |
| Ernest, JP | 1 |
| Zhang, N | 2 |
| Ammerman, NC | 1 |
| Nuermberger, E | 2 |
| Belknap, R | 8 |
| Boyd, R | 2 |
| Sterling, TR | 14 |
| Savic, RM | 2 |
| Finnegan, R | 1 |
| Stanzelova, A | 1 |
| Verbruggen, T | 1 |
| Fahey, D | 1 |
| Harte, J | 1 |
| Smyth, B | 1 |
| Moylett, E | 1 |
| Chiu, TF | 1 |
| Yen, MY | 1 |
| Shie, YH | 1 |
| Huang, HL | 5 |
| Chen, CC | 1 |
| Yen, YF | 2 |
| Chung, C | 1 |
| Kim, YJ | 1 |
| Jo, KW | 3 |
| Shim, TS | 3 |
| Chew, R | 1 |
| Woods, ML | 1 |
| Tseng, SY | 1 |
| Huang, YS | 1 |
| Chang, TE | 1 |
| Perng, CL | 1 |
| Huang, YH | 1 |
| Xin, H | 4 |
| Cao, X | 4 |
| Zhang, H | 5 |
| Feng, B | 4 |
| Du, Y | 2 |
| Zhang, B | 2 |
| Wang, D | 4 |
| Liu, Z | 4 |
| Guan, L | 4 |
| Shen, F | 4 |
| Guan, X | 4 |
| Yan, J | 4 |
| He, Y | 4 |
| Quan, Z | 1 |
| Pan, S | 4 |
| Liu, J | 4 |
| Jin, Q | 4 |
| Gao, L | 5 |
| Liou, BH | 1 |
| Cheng, CN | 1 |
| Lin, YT | 1 |
| Lin, YJ | 1 |
| Chuang, YC | 2 |
| Lin, KY | 1 |
| Liu, WC | 1 |
| Lin, SW | 1 |
| Kuo, CH | 1 |
| Sun, HY | 2 |
| Hung, CC | 1 |
| Nolt, D | 1 |
| Starke, JR | 1 |
| Shah, M | 2 |
| Dorman, SE | 1 |
| Marzolini, C | 1 |
| Gibbons, S | 1 |
| van Oosterhout, JJ | 1 |
| Khoo, S | 1 |
| Egorova, A | 1 |
| Salina, EG | 1 |
| Makarov, V | 1 |
| Lee, JY | 1 |
| Lo, YS | 1 |
| Liu, IH | 1 |
| Huang, SH | 1 |
| Huang, YW | 4 |
| Lee, MR | 3 |
| Lee, CH | 3 |
| Cheng, MH | 3 |
| Lu, PL | 4 |
| Wang, JY | 6 |
| Yang, JM | 1 |
| Chong, IW | 3 |
| Alvarez, GG | 4 |
| Sullivan, K | 2 |
| Pease, C | 5 |
| Van Dyk, D | 2 |
| Mallick, R | 3 |
| Taljaard, M | 1 |
| Grimshaw, JM | 1 |
| Amaratunga, K | 1 |
| Allen, C | 2 |
| Brethour, K | 3 |
| Mulpuru, S | 3 |
| Pakhale, S | 1 |
| Aaron, SD | 1 |
| Cameron, DW | 1 |
| Alsdurf, H | 3 |
| Hui, C | 1 |
| Zwerling, AA | 3 |
| Megna, M | 1 |
| Patruno, C | 1 |
| Bongiorno, MR | 1 |
| Gambardella, A | 1 |
| Guarneri, C | 1 |
| Foti, C | 1 |
| Lembo, S | 1 |
| Loconsole, F | 1 |
| Fabbrocini, G | 1 |
| Ghayumi, SMA | 1 |
| Shamsaeefar, A | 1 |
| Motazedian, N | 1 |
| Mashhadiagha, A | 1 |
| Sayadi, M | 1 |
| Nikeghbalian, S | 1 |
| Malekhosseini, SA | 1 |
| Wen, Z | 1 |
| Li, T | 2 |
| Zhu, W | 1 |
| Chen, W | 1 |
| Wang, W | 1 |
| Min, J | 1 |
| Kim, HW | 1 |
| Choi, JY | 2 |
| Shin, AY | 1 |
| Kang, JY | 1 |
| Lee, Y | 1 |
| Myong, JP | 1 |
| Jeong, H | 1 |
| Bae, S | 1 |
| Koo, HK | 1 |
| Lee, SS | 2 |
| Park, JS | 1 |
| Yim, HW | 1 |
| Kim, JS | 2 |
| Ntinginya, NE | 1 |
| Te Brake, L | 1 |
| Sabi, I | 1 |
| Chamba, N | 1 |
| Kilonzo, K | 1 |
| Laizer, S | 1 |
| Andia-Biraro, I | 1 |
| Kibirige, D | 1 |
| Kyazze, AP | 1 |
| Ninsiima, S | 1 |
| Critchley, JA | 1 |
| Romeo, R | 1 |
| van de Maat, J | 1 |
| Olomi, W | 1 |
| Mrema, L | 1 |
| Magombola, D | 1 |
| Mwayula, IH | 1 |
| Sharples, K | 1 |
| Hill, PC | 5 |
| van Crevel, R | 1 |
| Sharan, R | 1 |
| Ganatra, SR | 1 |
| Singh, DK | 2 |
| Cole, J | 1 |
| Foreman, TW | 2 |
| Thippeshappa, R | 1 |
| Peloquin, CA | 1 |
| Shivanna, V | 1 |
| Gonzalez, O | 1 |
| Day, CL | 2 |
| Gandhi, NR | 3 |
| Dick, EJ | 1 |
| Hall-Ursone, S | 1 |
| Mehra, S | 2 |
| Schlesinger, LS | 1 |
| Rengarajan, J | 2 |
| Kaushal, D | 2 |
| Campbell, JR | 5 |
| Nsengiyumva, P | 1 |
| Chiang, LY | 2 |
| Jamieson, F | 1 |
| Khadawardi, H | 1 |
| Mah, HK | 1 |
| Oxlade, O | 3 |
| Rasberry, H | 1 |
| Rea, E | 1 |
| Romanowski, K | 3 |
| Sabur, NF | 1 |
| Sander, B | 1 |
| Uppal, A | 1 |
| Johnston, JC | 4 |
| Schwartzman, K | 12 |
| Brode, SK | 1 |
| Singh, P | 1 |
| Moulton, LH | 2 |
| Barnes, GL | 1 |
| Gupta, A | 5 |
| Msandiwa, R | 1 |
| Chaisson, RE | 15 |
| Martinson, NA | 2 |
| Sabella-Jiménez, V | 1 |
| Hoyos Mendez, Y | 1 |
| Benjumea-Bedoya, D | 2 |
| Estupiñán-Bohorquez, AF | 1 |
| Acosta-Reyes, J | 1 |
| Florez, ID | 1 |
| Santos, JM | 1 |
| Fachi, MM | 1 |
| Beraldi-Magalhães, F | 1 |
| Böger, B | 1 |
| Junker, AM | 1 |
| Domingos, EL | 1 |
| Imazu, P | 1 |
| Fernandez-Llimos, F | 1 |
| Tonin, FS | 1 |
| Pontarolo, R | 1 |
| Lee, MC | 1 |
| Fujita, Y | 1 |
| Muraki, S | 1 |
| Ieiri, I | 1 |
| Jacobs, WR | 1 |
| Hartman-Adams, H | 1 |
| Gerbo, RM | 1 |
| George, S | 1 |
| Grasa Lozano, CD | 1 |
| Baro-Fernández, M | 1 |
| Rubio-San-Simón, A | 1 |
| Blázquez-Gamero, D | 1 |
| López-Roa, P | 1 |
| Liébana, C | 1 |
| Guerra-García, P | 1 |
| Moraleda, C | 1 |
| Epalza, C | 1 |
| Holmes, RH | 1 |
| Sun, S | 1 |
| Kazi, S | 1 |
| Ranganathan, S | 1 |
| Tosif, S | 1 |
| Graham, SM | 1 |
| Graham, HR | 1 |
| Santin, M | 1 |
| Perez-Recio, S | 1 |
| Grijota, MD | 1 |
| Anibarro, L | 1 |
| Barcala, JM | 1 |
| De Souza-Galvao, ML | 2 |
| Gijon, P | 1 |
| Luque, R | 1 |
| Sanchez, F | 1 |
| Fortún, J | 1 |
| Navas, E | 1 |
| Lai, WA | 2 |
| D'Silva, O | 2 |
| Jarrett, RT | 1 |
| van der Heijden, Y | 1 |
| Shotwell, MS | 1 |
| Chihota, V | 1 |
| Marzinke, MA | 1 |
| Dooley, KE | 2 |
| Churchyard, GJ | 2 |
| Du, J | 1 |
| Zhang, Z | 2 |
| Villegas Arbeláez, E | 1 |
| Martínez-Peñaloza, D | 1 |
| Beltrán-Arroyave, CP | 1 |
| Restrepo Gouzy, AV | 1 |
| Marín, D | 1 |
| Cadavid Álvarez, LM | 1 |
| Molinares, B | 1 |
| Montes Zuluaga, FN | 1 |
| Pulido Duarte, H | 1 |
| Suárez Parra, PM | 1 |
| Alzate Ángel, JC | 1 |
| Vélez-Parra, G | 1 |
| Realpe, T | 1 |
| Vásquez Villa, M | 1 |
| Ríos Buitrago, SY | 1 |
| Puerta Zapata, J | 1 |
| Arango García, LM | 1 |
| Perea Torres, Y | 1 |
| Pérez Doncel, N | 1 |
| Arbeláez Montoya, MP | 1 |
| Robledo, J | 1 |
| Rangaka, MX | 3 |
| Hamada, Y | 3 |
| Duong, T | 1 |
| Bern, H | 1 |
| Calvert, J | 1 |
| Francis, M | 2 |
| Clarke, AL | 1 |
| Ghanouni, A | 1 |
| Layton, C | 1 |
| Hack, V | 2 |
| Owen-Powell, E | 1 |
| Surey, J | 2 |
| Sanders, K | 1 |
| Booth, HL | 1 |
| Crook, A | 1 |
| Griffiths, C | 1 |
| Horne, R | 1 |
| Kunst, H | 3 |
| Lipman, M | 2 |
| Mandelbaum, M | 1 |
| White, PJ | 2 |
| Zenner, D | 3 |
| Abubakar, I | 4 |
| Blumenfeld, A | 1 |
| Rubinstein, F | 1 |
| Mancini, P | 1 |
| Knopoff, EG | 1 |
| Chevrier, C | 1 |
| Diaz, MH | 1 |
| Rueda, ZV | 1 |
| Balakumar, S | 1 |
| Haworth-Brockman, M | 1 |
| Marin, DM | 1 |
| Oliver, A | 1 |
| Plourde, P | 1 |
| Keynan, Y | 1 |
| Chaisson, LH | 1 |
| Semitala, FC | 2 |
| Nangobi, F | 1 |
| Steinmetz, S | 1 |
| Marquez, C | 1 |
| Armstrong, DT | 1 |
| Opira, B | 1 |
| Kamya, MR | 2 |
| Phillips, PPJ | 2 |
| Dowdy, DW | 4 |
| Yoon, C | 1 |
| Cola, JP | 1 |
| Prado, TND | 1 |
| Campos, BA | 1 |
| Borges, BJP | 1 |
| Alves, BMCS | 1 |
| Jezus, SV | 1 |
| Sales, CMM | 1 |
| Araújo, WN | 1 |
| Tavares, NUL | 1 |
| Noia Maciel, EL | 1 |
| Sadowski, C | 2 |
| Holland, DP | 4 |
| Moro, RN | 9 |
| Chen, MP | 2 |
| Wright, A | 2 |
| Millet, JP | 4 |
| Caylà, JA | 4 |
| Scott, NA | 7 |
| Borisov, A | 3 |
| Ying, C | 1 |
| He, C | 1 |
| Xu, K | 1 |
| Li, Y | 1 |
| Zhang, Y | 2 |
| Wu, W | 1 |
| Winters, N | 1 |
| Benedetti, A | 6 |
| Chan, PC | 6 |
| Martinson, N | 3 |
| Nahid, P | 1 |
| Sizemore, E | 1 |
| Villarino, ME | 8 |
| Menzies, D | 23 |
| Vernon, A | 6 |
| Arevalo, B | 3 |
| Beer, K | 1 |
| Chen, M | 2 |
| Feng, PJ | 2 |
| Miro, JM | 2 |
| Malhotra, S | 1 |
| Dasgupta-Tsinikas, S | 1 |
| Yumul, J | 1 |
| Kaneta, K | 1 |
| Lenz, A | 1 |
| Kizzee, R | 1 |
| Bihm, D | 1 |
| Jung, C | 1 |
| Neely, M | 1 |
| Guevara, RE | 1 |
| Higashi, J | 1 |
| Bender, JM | 1 |
| Hussain, H | 2 |
| Jaswal, M | 2 |
| Farooq, S | 1 |
| Safdar, N | 2 |
| Madhani, F | 1 |
| Noorani, S | 1 |
| Shahbaz, SS | 1 |
| Salahuddin, N | 1 |
| Amanullah, F | 1 |
| Khowaja, S | 1 |
| Manzar, S | 1 |
| Shah, JA | 1 |
| Islam, Z | 1 |
| Dahri, AA | 1 |
| Shahzad, M | 1 |
| Keshavjee, S | 2 |
| Becerra, MC | 2 |
| Khan, AJ | 2 |
| Malik, AA | 2 |
| Melnychuk, L | 1 |
| Perlman-Arrow, S | 1 |
| Lisboa Bastos, M | 1 |
| Jonas, DE | 1 |
| Riley, SR | 1 |
| Lee, LC | 1 |
| Coffey, CP | 1 |
| Wang, SH | 2 |
| Asher, GN | 1 |
| Berry, AM | 1 |
| Williams, N | 1 |
| Balio, C | 1 |
| Voisin, CE | 1 |
| Kahwati, LC | 1 |
| Taylor, A | 1 |
| Winthrop, E | 1 |
| Pecora Fulco, P | 1 |
| Yoopetch, P | 1 |
| Anothaisintawee, T | 1 |
| Gunasekara, ADM | 1 |
| Jittikoon, J | 1 |
| Udomsinprasert, W | 1 |
| Thavorncharoensap, M | 1 |
| Youngkong, S | 1 |
| Thakkinstian, A | 1 |
| Chaikledkaew, U | 1 |
| Séraphin, MN | 1 |
| Hsu, H | 1 |
| Chapman, HJ | 1 |
| de Andrade Bezerra, JL | 1 |
| Johnston, L | 1 |
| Yang, Y | 2 |
| Lauzardo, M | 1 |
| Noh, CS | 1 |
| Kim, HI | 1 |
| Choi, H | 1 |
| Kim, Y | 1 |
| Kim, CH | 1 |
| Choi, JH | 1 |
| Hyun, IG | 1 |
| Baek, MS | 1 |
| Han, SS | 1 |
| Lee, SJ | 2 |
| Yim, JJ | 1 |
| Song, JH | 1 |
| Lee, EH | 3 |
| Kang, YA | 3 |
| Swift, MD | 1 |
| Molella, RG | 1 |
| Vaughn, AIS | 1 |
| Breeher, LE | 1 |
| Newcomb, RD | 1 |
| Abdellatif, S | 1 |
| Murad, MH | 1 |
| Bucşan, AN | 1 |
| Peloquin, C | 1 |
| Doyle, LA | 1 |
| Russell-Lodrigue, K | 1 |
| Altman, J | 1 |
| Ernst, JD | 1 |
| Blumberg, HM | 2 |
| Nagano, H | 1 |
| Miura, T | 1 |
| Ueda, T | 1 |
| Hedges, KNC | 1 |
| Borisov, AS | 6 |
| Saukkonen, JJ | 1 |
| Hecker, EJ | 1 |
| Bozeman, L | 1 |
| Dukes Hamilton, C | 1 |
| Kerrigan, A | 2 |
| Bessler, P | 1 |
| Moreno-Martinez, A | 1 |
| Goldberg, SV | 3 |
| Harries, AD | 1 |
| Kumar, AMV | 1 |
| Satyanarayana, S | 1 |
| Takarinda, KC | 1 |
| Timire, C | 1 |
| Dlodlo, RA | 1 |
| Bishai, W | 1 |
| Cook, V | 2 |
| Long, R | 6 |
| Ruslami, R | 5 |
| Flynn, AG | 1 |
| Aiona, K | 2 |
| Haas, MK | 3 |
| Reves, R | 3 |
| Trajman, A | 10 |
| Cook, VJ | 4 |
| Adjobimey, M | 4 |
| Eisenbeis, L | 1 |
| Fregonese, F | 2 |
| Valiquette, C | 4 |
| Tiberi, S | 1 |
| Migliori, GB | 3 |
| de Oyarzabal, E | 1 |
| García-García, L | 2 |
| Rangel-Escareño, C | 1 |
| Ferreyra-Reyes, L | 2 |
| Orozco, L | 1 |
| Herrera, MT | 1 |
| Carranza, C | 2 |
| Sada, E | 2 |
| Juárez, E | 1 |
| Ponce-de-León, A | 1 |
| Sifuentes-Osornio, J | 2 |
| Wilkinson, RJ | 3 |
| Torres, M | 2 |
| Yu, YY | 1 |
| Tsao, SM | 2 |
| Yang, WT | 1 |
| Huang, WC | 4 |
| Lin, CH | 2 |
| Yang, SF | 2 |
| Chiou, HL | 1 |
| Ronald, LA | 1 |
| FitzGerald, JM | 2 |
| Bartlett-Esquilant, G | 1 |
| Boivin, JF | 1 |
| Picone, CM | 2 |
| Freitas, AC | 1 |
| Gutierrez, EB | 2 |
| Avelino-Silva, VI | 1 |
| Jakeman, B | 1 |
| Logothetis, SJ | 1 |
| Roberts, MH | 1 |
| Bachyrycz, A | 1 |
| Fortune, D | 1 |
| Borrego, ME | 1 |
| Ferreira, J | 1 |
| Burgos, M | 1 |
| Li, X | 2 |
| Li, H | 2 |
| Zhang, M | 1 |
| Yang, Q | 1 |
| Uzorka, JW | 1 |
| Duinkerk, DL | 1 |
| Kroft, LJM | 1 |
| Bakker, JA | 1 |
| Ramai, RSRS | 1 |
| Ottenhoff, THM | 1 |
| Arend, SM | 1 |
| Araújo, NCN | 1 |
| Cruz, CMS | 1 |
| Arriaga, MB | 1 |
| Cubillos-Angulo, JM | 1 |
| Rocha, MS | 1 |
| Silveira-Mattos, PS | 1 |
| Matos, GM | 1 |
| Marques, IMB | 1 |
| Espirito Santo, ICP | 1 |
| Almeida, LL | 1 |
| Andrade, CM | 1 |
| Souza, LA | 1 |
| Netto, EM | 1 |
| Andrade, BB | 1 |
| Aksenova, VA | 1 |
| Vasilyeva, IA | 1 |
| Kasaeva, TC | 1 |
| Samoilova, AG | 1 |
| Pshenichnaya, NY | 1 |
| Tyulkova, TE | 1 |
| Cui, X | 1 |
| Cao, B | 1 |
| Jeon, D | 1 |
| Al Abri, S | 1 |
| Kowada, A | 1 |
| Yaqoubi, F | 1 |
| Al Khalili, S | 1 |
| Ndunda, N | 1 |
| Petersen, E | 1 |
| Schmit, KM | 1 |
| Wortham, JM | 1 |
| Ho, CS | 2 |
| Powell, KM | 1 |
| Mushtaq, A | 1 |
| Tang, I | 1 |
| So, H | 1 |
| Luk, L | 1 |
| Wong, V | 1 |
| Pang, S | 1 |
| Lao, V | 1 |
| Yip, R | 1 |
| Robert, M | 1 |
| Todd, J | 1 |
| Ngowi, BJ | 1 |
| Msuya, SE | 1 |
| Ramadhani, A | 1 |
| Sambu, V | 1 |
| Jerry, I | 1 |
| Mujuni, MR | 1 |
| Mahande, MJ | 1 |
| Ngocho, JS | 1 |
| Maokola, W | 1 |
| Swindells, S | 4 |
| Hughes, M | 1 |
| Stout, JE | 3 |
| Turner, NA | 1 |
| Belknap, RW | 4 |
| Horsburgh, CR | 5 |
| Chung, SJ | 1 |
| Lee, H | 1 |
| Koo, GW | 1 |
| Min, JH | 1 |
| Yeo, Y | 1 |
| Park, DW | 1 |
| Park, TS | 1 |
| Moon, JY | 1 |
| Kim, SH | 2 |
| Kim, TH | 2 |
| Sohn, JW | 1 |
| Yoon, HJ | 1 |
| Chen, SH | 1 |
| Wang, I | 1 |
| Hsu, HL | 1 |
| Huang, CC | 1 |
| Liu, YJ | 1 |
| Putri, DU | 1 |
| Feng, JY | 2 |
| Lin, SM | 1 |
| Wang, TY | 1 |
| Shu, CC | 1 |
| Pan, SW | 2 |
| Chen, CY | 1 |
| Lin, CB | 1 |
| Wei, YF | 1 |
| Tung, CL | 1 |
| Li, CP | 1 |
| Su, WJ | 3 |
| Sensalire, S | 1 |
| Karungi Karamagi Nkolo, E | 1 |
| Nabwire, J | 1 |
| Lawino, A | 1 |
| Kiragga, D | 1 |
| Muhire, M | 1 |
| Kadama, H | 1 |
| Katureebe, C | 1 |
| Namuwenge, P | 1 |
| Musinguzi, J | 1 |
| Calnan, J | 1 |
| Seyoum, D | 1 |
| De Biasio, F | 1 |
| Aratari, A | 1 |
| Caporuscio, S | 1 |
| Simeoni, I | 1 |
| Papi, C | 1 |
| Festa, S | 1 |
| Bastos, ML | 2 |
| Kim, HJ | 2 |
| Baah, JO | 1 |
| Toelle, BG | 1 |
| Hoeppner, V | 2 |
| Elwood, K | 4 |
| Al-Jahdali, H | 2 |
| Apriani, L | 3 |
| Sharma, N | 1 |
| Basu, S | 1 |
| Chopra, KK | 1 |
| Sharma, P | 1 |
| Singh, VK | 1 |
| Mishra, A | 1 |
| Bark, S | 1 |
| Mani, A | 1 |
| Subbian, S | 1 |
| Hunter, RL | 1 |
| Jagannath, C | 1 |
| Khan, A | 1 |
| Podany, AT | 2 |
| Ngugi, SK | 1 |
| Muiruri, P | 1 |
| Odero, T | 1 |
| Gachuno, O | 1 |
| Iwata, K | 1 |
| Morishita, N | 1 |
| Nishiwaki, M | 1 |
| Miyakoshi, C | 1 |
| Nishiura, H | 1 |
| Bettelli, F | 1 |
| Giusti, D | 1 |
| Morselli, M | 1 |
| Colaci, E | 1 |
| Nasillo, V | 1 |
| Pioli, V | 1 |
| Gilioli, A | 1 |
| Iotti, S | 1 |
| Galassi, L | 1 |
| Giubbolini, R | 1 |
| Colasante, C | 1 |
| Catellani, H | 1 |
| Barozzi, P | 1 |
| Lagreca, I | 1 |
| Vallerini, D | 1 |
| Maffei, R | 1 |
| Franceschini, E | 1 |
| Mussini, C | 1 |
| Banchelli, F | 1 |
| D'Amico, R | 1 |
| Marasca, R | 1 |
| Narni, F | 1 |
| Potenza, L | 1 |
| Comoli, P | 1 |
| Luppi, M | 1 |
| Forghieri, F | 1 |
| Hibma, JE | 1 |
| Hesseling, AC | 2 |
| Prater, C | 1 |
| Holzman, S | 1 |
| Weinberg, A | 1 |
| Aaron, L | 1 |
| Montepiedra, G | 2 |
| Browning, R | 1 |
| Mmbaga, B | 1 |
| Vhembo, T | 1 |
| Naik, S | 1 |
| Kabugho, E | 1 |
| Masheto, G | 2 |
| Pahwa, S | 1 |
| Mathad, JS | 2 |
| LaCourse, SM | 1 |
| McCarthy, K | 1 |
| Bradford, S | 2 |
| Theron, G | 1 |
| Costello, D | 1 |
| Zimmer, B | 1 |
| Pierre, MF | 1 |
| Gausi, K | 1 |
| Denti, P | 1 |
| Haas, DW | 1 |
| Kilinc, AA | 1 |
| Onal, P | 1 |
| Oztosun, B | 1 |
| Yildiz, M | 1 |
| Adrovic, A | 1 |
| Sahin, S | 1 |
| Barut, K | 1 |
| Cokugras, H | 1 |
| Kasapcopur, O | 1 |
| Baumann, B | 1 |
| Kumar, D | 2 |
| Djurdjev, O | 1 |
| Morshed, M | 1 |
| Sekirov, I | 1 |
| Levin, A | 1 |
| Wang, PH | 1 |
| Chang, TH | 1 |
| Wu, CS | 1 |
| Erlandson, KM | 1 |
| Shrestha, S | 1 |
| Parriott, A | 1 |
| Menzies, NA | 1 |
| Shete, PB | 1 |
| Hill, AN | 1 |
| Marks, SM | 4 |
| Yamana, H | 1 |
| Iba, A | 1 |
| Tomio, J | 1 |
| Ono, S | 1 |
| Jo, T | 1 |
| Yasunaga, H | 1 |
| Ferguson, O | 1 |
| Jo, Y | 1 |
| Pennington, J | 1 |
| Johnson, K | 2 |
| Churchyard, G | 1 |
| Dowdy, D | 2 |
| Cybulski, DJ | 1 |
| White, BK | 1 |
| Yoo, H | 1 |
| Chun Ji, S | 1 |
| Cho, JY | 1 |
| Yoon, JG | 1 |
| Goo Lee, M | 1 |
| Yu, KS | 1 |
| Jang, IJ | 1 |
| Oh, J | 1 |
| Huang, CK | 1 |
| Sheu, CC | 2 |
| Lai, PC | 1 |
| Chen, TC | 2 |
| Machado, Á | 1 |
| Abreu, M | 1 |
| Torres, T | 1 |
| Stockbridge, EL | 1 |
| Loethen, AD | 1 |
| Annan, E | 1 |
| Miller, TL | 1 |
| Kaur, S | 1 |
| Angrish, N | 1 |
| Gupta, K | 1 |
| Tyagi, AK | 1 |
| Khare, G | 1 |
| Yuen, CM | 1 |
| Majidulla, A | 1 |
| Lu, C | 1 |
| Stagg, HR | 4 |
| Yates, TA | 1 |
| Charlett, A | 1 |
| Muñoz, L | 2 |
| Gosce, L | 1 |
| Donahue, ML | 1 |
| Eberly, MD | 1 |
| Rajnik, M | 1 |
| Lim, RK | 1 |
| Atuhumuza, E | 1 |
| Sabiti, L | 1 |
| Namakula-Katende, J | 1 |
| Muyindike, WR | 1 |
| Cattamanchi, A | 1 |
| Kristensen, KL | 1 |
| Nordholm, AC | 1 |
| Clausen, MR | 1 |
| Katzenstein, TL | 1 |
| Lin, KD | 1 |
| Liu, SS | 1 |
| Chin, CS | 1 |
| Lee, IT | 1 |
| Kaptan, Y | 1 |
| Suner, A | 1 |
| Taş, MN | 1 |
| Oksel, F | 1 |
| Aksu, K | 1 |
| Sayiner, A | 1 |
| Komukai, J | 1 |
| Matsumoto, K | 1 |
| Kudoh, S | 1 |
| Okado, A | 1 |
| Yoshiyama, T | 2 |
| Yoshida, H | 1 |
| Shimouchi, A | 1 |
| Sinnathamby, A | 1 |
| Ang, S | 1 |
| Bagdasarian, N | 1 |
| Chan, HC | 1 |
| Chan, SM | 1 |
| Peck, GM | 1 |
| Staat, MA | 1 |
| Huang, FS | 1 |
| Khalil, N | 1 |
| Boyce, C | 1 |
| Kohlrieser, CM | 1 |
| Schlaudecker, EP | 1 |
| Alvarez, G | 1 |
| Patterson, M | 1 |
| Finn, S | 1 |
| Habis, Y | 1 |
| Kilabuk, E | 1 |
| Zwerling, A | 2 |
| Osorio-López, EA | 1 |
| Vilar-Compte, D | 1 |
| García-Tirado, J | 1 |
| Martin-Onraet, A | 1 |
| Wu, CH | 1 |
| Su, HA | 1 |
| Chou, CA | 1 |
| Liu, JW | 1 |
| Lee, CT | 1 |
| Dai, LH | 1 |
| Yang, CC | 1 |
| Belay, M | 1 |
| Tulu, B | 1 |
| Younis, S | 1 |
| Jolliffe, DA | 1 |
| Tayachew, D | 1 |
| Manwandu, H | 1 |
| Abozen, T | 1 |
| Tirfie, EA | 1 |
| Tegegn, M | 1 |
| Zewude, A | 1 |
| Forrest, S | 1 |
| Mayito, J | 1 |
| Huggett, JF | 1 |
| Jones, GM | 1 |
| O'Sullivan, DM | 1 |
| Martineau, HM | 1 |
| Noursadeghi, M | 1 |
| Chandran, A | 1 |
| Harris, KA | 1 |
| Nikolayevskyy, V | 1 |
| Demaret, J | 1 |
| Berg, S | 1 |
| Vordermeier, M | 1 |
| Balcha, TT | 1 |
| Aseffa, A | 1 |
| Ameni, G | 1 |
| Abebe, M | 1 |
| Reece, ST | 1 |
| Martineau, AR | 1 |
| Mollan, KR | 1 |
| Eron, JJ | 1 |
| Krajewski, TJ | 1 |
| Painter, W | 1 |
| Duke, ER | 1 |
| Morse, CG | 1 |
| Goecker, EA | 1 |
| Premkumar, L | 1 |
| Wolfe, CR | 1 |
| Szewczyk, LJ | 1 |
| Alabanza, PL | 1 |
| Loftis, AJ | 1 |
| Degli-Angeli, EJ | 1 |
| Brown, AJ | 1 |
| Dragavon, JA | 1 |
| Won, JJ | 1 |
| Keys, J | 1 |
| Hudgens, MG | 1 |
| Fang, L | 1 |
| Wohl, DA | 1 |
| Cohen, MS | 1 |
| Baric, RS | 1 |
| Coombs, RW | 1 |
| Sheahan, TP | 1 |
| Fischer, WA | 1 |
| Li, B | 1 |
| Wang, X | 1 |
| Hong, S | 1 |
| Wang, Q | 1 |
| Li, L | 1 |
| Eltayeb, O | 1 |
| Dong, C | 1 |
| Shuang, S | 1 |
| Yang, H | 1 |
| Hu, ZD | 1 |
| Xia, L | 1 |
| Liu, XH | 1 |
| Yu, X | 1 |
| Ma, JY | 1 |
| Lu, SH | 1 |
| Hacioglu, A | 1 |
| Borekci, S | 1 |
| Melikoglu, M | 1 |
| Ozguler, Y | 1 |
| Esatoglu, SN | 1 |
| Ugurlu, S | 1 |
| Seyahi, E | 1 |
| Fresko, I | 1 |
| Hamuryudan, V | 1 |
| Ozdogan, H | 1 |
| Yurdakul, S | 1 |
| Hatemi, I | 1 |
| Celik, AF | 1 |
| Ongen, HG | 1 |
| Hatemi, G | 1 |
| Savic, R | 1 |
| Britto, P | 1 |
| Jayachandran, P | 1 |
| Wiesner, L | 2 |
| Norman, J | 1 |
| Townley, E | 1 |
| Chakhtoura, N | 1 |
| Patil, S | 1 |
| Popson, S | 1 |
| Chipato, T | 1 |
| Rouzier, V | 1 |
| Langat, D | 2 |
| Chalermchockcharoentkit, A | 1 |
| Kamthunzi, P | 1 |
| Chadwick, A | 1 |
| Thwaites, V | 1 |
| Holland, M | 1 |
| Shahidi, M | 1 |
| Khawcharoenporn, T | 2 |
| Phetsuksiri, B | 1 |
| Rudeeaneksin, J | 1 |
| Srisungngam, S | 1 |
| Apisarnthanarak, A | 2 |
| Hutton, B | 2 |
| Yazdi, F | 2 |
| Wolfe, D | 2 |
| Hamel, C | 2 |
| Quach, P | 1 |
| Skidmore, B | 2 |
| Moher, D | 1 |
| Johnston, V | 1 |
| Farmer, B | 1 |
| Krause, VL | 2 |
| Holzschuh, EL | 1 |
| Province, S | 1 |
| Walls, C | 1 |
| Shemwell, C | 1 |
| Martin, G | 1 |
| Showalter, A | 1 |
| Dunlay, J | 1 |
| Conyers, A | 1 |
| Griffin, P | 2 |
| Tausz, N | 1 |
| Haley, CA | 1 |
| Momose, M | 1 |
| Asahina, A | 1 |
| Hayashi, M | 1 |
| Yanaba, K | 1 |
| Umezawa, Y | 1 |
| Nakagawa, H | 1 |
| Conti, A | 1 |
| Piaserico, S | 1 |
| Gisondi, P | 2 |
| Odorici, G | 1 |
| Galdo, G | 1 |
| Lasagni, C | 1 |
| Pellacani, G | 1 |
| Sandul, AL | 1 |
| Nwana, N | 2 |
| Holcombe, JM | 1 |
| Lobato, MN | 1 |
| Marks, S | 1 |
| Webb, R | 1 |
| Stewart, B | 1 |
| Hunt, G | 1 |
| Shah, N | 1 |
| Marco, A | 1 |
| Patil, N | 1 |
| Mukasa, L | 1 |
| Jereb, J | 1 |
| Mase, S | 1 |
| Chorba, T | 1 |
| Bamrah-Morris, S | 1 |
| Moon, HH | 1 |
| Park, SY | 1 |
| Kim, JM | 1 |
| Park, JB | 1 |
| Kwon, CHD | 1 |
| Peck, KR | 1 |
| Kim, SJ | 2 |
| Lee, SK | 1 |
| Joh, JW | 1 |
| Shayo, GA | 2 |
| Chitama, D | 1 |
| Moshiro, C | 2 |
| Aboud, S | 2 |
| Bakari, M | 2 |
| Mugusi, F | 1 |
| Huang, SF | 1 |
| Chen, MH | 1 |
| Wang, FD | 1 |
| Tsai, CY | 1 |
| Fung, CP | 1 |
| Leem, AY | 2 |
| Park, MS | 2 |
| Kim, YS | 2 |
| Kim, SK | 1 |
| Chang, J | 1 |
| Kim, SY | 2 |
| Beer, N | 1 |
| Harris, RJ | 2 |
| Lipman, MC | 2 |
| van der Werf, MJ | 2 |
| Bonnet, M | 1 |
| Kyakwera, C | 1 |
| Kyomugasho, N | 1 |
| Atwine, D | 1 |
| Mugabe, F | 1 |
| Nansumba, M | 1 |
| Ii, YB | 1 |
| Mwanga-Amumpaire, J | 1 |
| Kiwanuka, J | 1 |
| Khan, MZ | 1 |
| Bhaskar, A | 1 |
| Upadhyay, S | 1 |
| Kumari, P | 1 |
| Rajmani, RS | 1 |
| Jain, P | 1 |
| Singh, A | 2 |
| Bhavesh, NS | 1 |
| Nandicoori, VK | 1 |
| Minh, HV | 1 |
| Mai, VQ | 1 |
| Nhung, NV | 1 |
| Hoi, LV | 1 |
| Giang, KB | 1 |
| Chung, LH | 1 |
| Kien, VD | 1 |
| Duyen, NT | 1 |
| Ngoc, NB | 1 |
| Anh, TT | 1 |
| Phuong, TB | 1 |
| Ngan, TT | 1 |
| Khanh, PH | 1 |
| Jinbo, J | 1 |
| Lustik, M | 1 |
| West, GF | 1 |
| Kloetzel, M | 1 |
| Saito, Y | 1 |
| Sawada, Y | 1 |
| Koga, Y | 1 |
| Sunaga, N | 1 |
| Tsukagoshi, Y | 1 |
| Hachisu, Y | 1 |
| Osaki, T | 1 |
| Sakurai, R | 1 |
| Kaira, K | 1 |
| Ono, A | 1 |
| Sato, K | 1 |
| Koiso, H | 1 |
| Oyama, T | 1 |
| Hisada, T | 1 |
| Yamada, M | 1 |
| Shepherd, JG | 1 |
| Chapman, ALN | 1 |
| Arguello Perez, E | 1 |
| Seo, SK | 1 |
| Schneider, WJ | 1 |
| Eisenstein, C | 1 |
| Brown, AE | 1 |
| Tasillo, A | 1 |
| Salomon, JA | 1 |
| Trikalinos, TA | 1 |
| Linas, BP | 1 |
| Lee, M | 2 |
| Rees, CA | 1 |
| Munden, MM | 1 |
| Holland, D | 1 |
| Weiner, M | 2 |
| Denholm, JT | 1 |
| McBryde, ES | 2 |
| Eisen, D | 1 |
| Street, A | 1 |
| Matchett, E | 1 |
| Chen, C | 1 |
| Shultz, TR | 1 |
| Biggs, B | 1 |
| Leder, K | 2 |
| Kondo, M | 1 |
| Iwata, Y | 1 |
| Numata, S | 1 |
| Saito, K | 1 |
| Watanabe, S | 1 |
| Kobayashi, T | 1 |
| Nagai, A | 1 |
| Iwata, T | 1 |
| Arima, M | 1 |
| Sugiura, K | 1 |
| Tepper, NK | 1 |
| Leung, CC | 2 |
| Schluger, NW | 2 |
| Narita, M | 3 |
| Machado, ES | 1 |
| Lopez, M | 1 |
| Sanchez, J | 1 |
| Brooks, KM | 1 |
| George, JM | 1 |
| Pau, AK | 1 |
| Rupert, A | 1 |
| Mehaffy, C | 1 |
| De, P | 1 |
| Dobos, KM | 1 |
| Kellogg, A | 1 |
| McLaughlin, M | 1 |
| McManus, M | 1 |
| Alfaro, RM | 1 |
| Hadigan, C | 1 |
| Kovacs, JA | 1 |
| Kumar, P | 1 |
| van der Kop, ML | 1 |
| Smillie, K | 1 |
| Ogilvie, G | 1 |
| Marra, F | 2 |
| Sadatsafavi, M | 1 |
| Budd, MA | 1 |
| Hajek, J | 1 |
| Lester, RT | 1 |
| Cranmer, LM | 1 |
| Draper, HR | 1 |
| Mandalakas, AM | 1 |
| Kim, S | 1 |
| McSherry, G | 1 |
| Krezinski, E | 1 |
| Coetzee, J | 1 |
| Mitchell, C | 1 |
| Nachman, S | 2 |
| van der Linde, M | 1 |
| Cotton, MF | 1 |
| Tersigni, C | 2 |
| Venturini, E | 2 |
| Cordola, C | 1 |
| Piccini, P | 1 |
| Bianchi, L | 1 |
| Montagnani, C | 1 |
| Sollai, S | 1 |
| Chiappini, E | 2 |
| de Martino, M | 2 |
| Galli, L | 2 |
| Baričević, D | 1 |
| Popović Grle, S | 1 |
| Morović Vergles, J | 1 |
| Čuković Čavka, S | 1 |
| Jakopović, M | 1 |
| Redžepi, G | 1 |
| Boras, Z | 1 |
| Baričević, M | 1 |
| Samaržija, M | 1 |
| Komai, T | 1 |
| Sumitomo, S | 1 |
| Teruya, S | 1 |
| Fujio, K | 2 |
| Barbeau, P | 1 |
| Tomkins-Netzer, O | 1 |
| Leong, BCS | 1 |
| Zhang, X | 1 |
| Lightman, S | 1 |
| McCluskey, PJ | 1 |
| Chen, YM | 2 |
| Liao, TL | 1 |
| Chen, HH | 1 |
| Chen, DY | 1 |
| Stock, D | 1 |
| Assefa, Y | 2 |
| Woldeyohannes, S | 1 |
| Getahun, H | 7 |
| Lee, CK | 3 |
| Wong, SHV | 1 |
| Lui, G | 1 |
| Tang, W | 1 |
| Tam, LS | 1 |
| Ip, M | 1 |
| Hung, E | 1 |
| Wu, JC | 1 |
| Ng, SC | 1 |
| Kim, KJ | 3 |
| Choi, EY | 1 |
| Chee, CBE | 1 |
| Lin, SY | 1 |
| Chiu, YW | 1 |
| Hwang, SJ | 1 |
| Hsieh, MH | 1 |
| Chen, YH | 1 |
| Njie, GJ | 2 |
| Morris, SB | 2 |
| Woodruff, RY | 1 |
| Vernon, AA | 1 |
| Bamrah Morris, S | 1 |
| Winston, CA | 1 |
| Burton, D | 1 |
| Goldberg, S | 2 |
| Yelk Woodruff, R | 1 |
| Allen, L | 1 |
| LoBue, P | 3 |
| Rajoli, RKR | 1 |
| Moss, DM | 1 |
| Flexner, C | 1 |
| Owen, A | 1 |
| Siccardi, M | 1 |
| Chang, LY | 3 |
| Ruan, SY | 1 |
| Wang, JT | 1 |
| Diallo, T | 1 |
| Sow, O | 2 |
| Obeng Baah, J | 2 |
| Marks, GB | 5 |
| Zielinski, D | 1 |
| Gninafon, M | 2 |
| Wulandari, DA | 1 |
| Hornby, K | 2 |
| Li, PZ | 2 |
| Kim, H | 1 |
| Koesoemadinata, RC | 1 |
| Kritski, A | 1 |
| Rolla, V | 1 |
| Bah, B | 1 |
| Camara, A | 1 |
| Boakye, I | 1 |
| Goldberg, H | 1 |
| Dion, MJ | 3 |
| Snast, I | 1 |
| Bercovici, E | 1 |
| Avni, T | 1 |
| Shitenberg, D | 1 |
| Hodak, E | 1 |
| Pavlovsky, L | 1 |
| Nsengiyumva, NP | 1 |
| Mappin-Kasirer, B | 1 |
| Bastos, M | 1 |
| Falzon, D | 2 |
| Doan, TN | 1 |
| Fox, GJ | 1 |
| Meehan, MT | 1 |
| Scott, N | 2 |
| Ragonnet, R | 1 |
| Viney, K | 1 |
| Trauer, JM | 2 |
| Ha, EJ | 1 |
| Park, ES | 1 |
| Chen, Y | 1 |
| Cui, W | 1 |
| Ma, Y | 1 |
| Chen, X | 1 |
| Zhou, X | 1 |
| Fröberg, G | 1 |
| Jansson, L | 1 |
| Bruchfeld, J | 2 |
| Schein, YL | 1 |
| Madebo, T | 1 |
| Andersen, HE | 1 |
| Arnesen, TM | 1 |
| Dyrhol-Riise, AM | 2 |
| Tveiten, H | 1 |
| White, RA | 1 |
| Winje, BA | 1 |
| Lam, CK | 1 |
| McGinnis Pilote, K | 1 |
| Haque, A | 1 |
| Burzynski, J | 1 |
| Chuck, C | 1 |
| Macaraig, M | 2 |
| Porter, BW | 1 |
| Venkatappa, TK | 2 |
| Ford, N | 3 |
| Schenkel, K | 1 |
| Kim, HY | 1 |
| Hanrahan, CF | 1 |
| Golub, JE | 2 |
| Ito, K | 2 |
| Meremikwu, M | 1 |
| Zumla, A | 2 |
| Lan, E | 1 |
| Chang, AH | 2 |
| Holcombe, M | 1 |
| Ramchandani, R | 1 |
| Benson, CA | 1 |
| Leon-Cruz, J | 1 |
| Mwelase, N | 1 |
| Jean Juste, MA | 1 |
| Lama, JR | 1 |
| Valencia, J | 1 |
| Omoz-Oarhe, A | 1 |
| Supparatpinyo, K | 1 |
| Mohapi, L | 1 |
| da Silva Escada, RO | 1 |
| Mawlana, S | 1 |
| Banda, P | 1 |
| Severe, P | 1 |
| Hakim, J | 1 |
| Kanyama, C | 1 |
| Moran, L | 1 |
| Andersen, J | 1 |
| Fletcher, CV | 2 |
| Lee, PH | 2 |
| Lu, MJ | 1 |
| Feng, TY | 1 |
| Lee, CC | 1 |
| Huang, YF | 1 |
| Chiang, CY | 1 |
| Akyuz, F | 1 |
| Cavus, B | 1 |
| Iliaz, R | 1 |
| Soyer, OM | 1 |
| Ormeci, A | 1 |
| Evirgen, S | 1 |
| Onder, S | 1 |
| Koksalan, K | 1 |
| Keskin, M | 1 |
| Karaca, C | 1 |
| Demir, K | 1 |
| Gulluoglu, M | 1 |
| Cagatay, T | 1 |
| Besisik, F | 1 |
| Kaymakoglu, S | 1 |
| Kelly, AM | 1 |
| Thee, S | 1 |
| Krüger, R | 1 |
| von Bernuth, H | 1 |
| Meisel, C | 1 |
| Kölsch, U | 1 |
| Kirchberger, V | 1 |
| Feiterna-Sperling, C | 1 |
| Kinikar, A | 1 |
| Chandanwale, A | 1 |
| Kadam, D | 1 |
| Joshi, S | 1 |
| Basavaraj, A | 1 |
| Pardeshi, G | 1 |
| Girish, S | 1 |
| Shelke, S | 1 |
| DeLuca, A | 1 |
| Dhumal, G | 1 |
| Golub, J | 1 |
| Lokhande, N | 1 |
| Gupte, N | 1 |
| Bollinger, R | 1 |
| Mave, V | 1 |
| Plourde, PJ | 1 |
| Basham, CA | 1 |
| Derksen, S | 1 |
| Schultz, J | 1 |
| McCulloch, S | 1 |
| Larcombe, L | 1 |
| Kinew, KA | 1 |
| Lix, LM | 1 |
| Partarrieu-Mejías, F | 1 |
| Hernández-Bel, P | 1 |
| Giácaman-von der Weth, M | 1 |
| Pérez-Ferriols, A | 1 |
| Silva, JT | 1 |
| San-Juan, R | 1 |
| Fernández-Ruiz, M | 1 |
| Aguado, JM | 1 |
| Chee, CB | 2 |
| Jiménez-Fuentes, MA | 1 |
| Mila Augé, C | 1 |
| Solsona Peiró, J | 1 |
| Altet-Gómez, MN | 1 |
| Yi, PH | 1 |
| Veltre, DR | 1 |
| Kuttab, JS | 1 |
| Rangan, V | 1 |
| Norton, L | 1 |
| Pina, JM | 3 |
| Clotet, L | 3 |
| Ferrer, A | 3 |
| Sala, MR | 3 |
| Garrido, P | 2 |
| Salleras, L | 2 |
| Domínguez, A | 3 |
| Boglou, P | 1 |
| Steiropoulos, P | 1 |
| Papanas, N | 1 |
| Bouros, D | 1 |
| Codecasa, LR | 1 |
| Murgia, N | 1 |
| Ferrarese, M | 1 |
| Delmastro, M | 1 |
| Repossi, AC | 1 |
| Casali, L | 1 |
| Besozzi, G | 1 |
| Ferrara, G | 1 |
| Raviglione, MC | 1 |
| Gwee, A | 1 |
| Coghlan, B | 1 |
| Curtis, N | 1 |
| Science, M | 1 |
| Ito, S | 1 |
| Kitai, I | 1 |
| Dierberg, KL | 1 |
| Morano, JP | 1 |
| Walton, MR | 1 |
| Zelenev, A | 1 |
| Bruce, RD | 1 |
| Altice, FL | 1 |
| Belo, MT | 2 |
| Teixeira, EG | 1 |
| de Abreu, ST | 1 |
| Antas, PR | 1 |
| Moolphate, S | 1 |
| Lawpoolsri, S | 1 |
| Pungrassami, P | 1 |
| Sanguanwongse, N | 1 |
| Yamada, N | 1 |
| Kaewkungwal, J | 1 |
| Sánchez-Moya, AI | 2 |
| Dauden, E | 2 |
| Caldera, F | 1 |
| Grimes, I | 1 |
| Soni, A | 1 |
| Rivest, P | 1 |
| Street, MC | 1 |
| Allard, R | 1 |
| Sharma, SK | 2 |
| Sharma, A | 1 |
| Kadhiravan, T | 1 |
| Tharyan, P | 1 |
| Saag, KG | 1 |
| Winthrop, K | 1 |
| Curtis, JR | 1 |
| Hazlewood, GS | 1 |
| Naimark, D | 1 |
| Gardam, M | 1 |
| Bykerk, V | 1 |
| Bombardier, C | 1 |
| Pettit, AC | 1 |
| Bethel, J | 3 |
| Hirsch-Moverman, Y | 4 |
| Colson, PW | 3 |
| Albanna, AS | 1 |
| Bachmann, K | 1 |
| White, D | 1 |
| Butcher, K | 1 |
| Biggs, BA | 1 |
| Lemoh, C | 1 |
| O'Brien, D | 1 |
| Marshall, C | 1 |
| Yang, CH | 2 |
| Liao, ST | 1 |
| Cheng, SH | 1 |
| Wong, WW | 1 |
| Huang, LM | 3 |
| Hsueh, PR | 2 |
| Chiou, HY | 1 |
| Sarivalasis, A | 1 |
| Bodenmann, P | 1 |
| Langenskiold, E | 1 |
| Lutchmaya-Flick, C | 1 |
| Daher, O | 1 |
| Zellweger, JP | 2 |
| Neunhöffer, H | 1 |
| Gold, A | 1 |
| Hoerauf, H | 1 |
| Herbort, C | 1 |
| Heiligenhaus, A | 1 |
| Zimmermann, O | 1 |
| Feltgen, N | 1 |
| Musuka, S | 1 |
| Srivastava, S | 1 |
| Siyambalapitiyage Dona, CW | 1 |
| Meek, C | 1 |
| Leff, R | 1 |
| Pasipanodya, J | 1 |
| Gumbo, T | 1 |
| Parekh, MJ | 1 |
| Caire Estévez, JP | 1 |
| González-Ocampo Dorta, S | 1 |
| Sanz Solana, P | 1 |
| Kurt, OK | 1 |
| Kurt, B | 1 |
| Talay, F | 1 |
| Tug, T | 1 |
| Soy, M | 1 |
| Bes, C | 1 |
| Hayran, M | 1 |
| Polesky, A | 1 |
| Bhatia, G | 1 |
| de Castilla, DL | 1 |
| Rakita, RM | 1 |
| Spitters, CE | 1 |
| Jain, R | 1 |
| Limaye, AP | 1 |
| Diel, R | 2 |
| Loddenkemper, R | 2 |
| Sotgiu, G | 2 |
| Shepardson, D | 2 |
| Chesson, H | 1 |
| Tian, X | 1 |
| Shang, N | 3 |
| Heilig, CM | 1 |
| Mac Kenzie, WR | 1 |
| Shinn-Forng Peng, S | 1 |
| Chiou, MY | 1 |
| Ling, DL | 1 |
| Wang, KF | 2 |
| Fang, CT | 2 |
| Lin, PL | 3 |
| Ford, CB | 2 |
| Coleman, MT | 1 |
| Myers, AJ | 1 |
| Gawande, R | 1 |
| Ioerger, T | 1 |
| Sacchettini, J | 1 |
| Fortune, SM | 2 |
| Flynn, JL | 3 |
| Logsdon, S | 1 |
| Ramirez-Avila, L | 1 |
| Castells, M | 1 |
| Dioun, A | 1 |
| Valls, V | 1 |
| Ena, J | 1 |
| Sauzullo, I | 3 |
| Scrivo, R | 2 |
| Mengoni, F | 3 |
| Ermocida, A | 1 |
| Coppola, M | 1 |
| Valesini, G | 2 |
| Vullo, V | 3 |
| Mastroianni, CM | 3 |
| Fiske, CT | 1 |
| Yan, FX | 1 |
| Reichler, MR | 1 |
| Bocchino, M | 1 |
| Matarese, A | 1 |
| Sanduzzi, A | 1 |
| Johnson, DF | 2 |
| Malone, LL | 1 |
| Zalwango, S | 1 |
| Mukisa Oketcho, J | 1 |
| Chervenak, KA | 1 |
| Thiel, B | 1 |
| Mayanja-Kizza, H | 1 |
| Stein, CM | 1 |
| Boom, WH | 3 |
| Lancioni, CL | 1 |
| Hatherill, M | 2 |
| Geldenhuys, H | 2 |
| Pienaar, B | 2 |
| Suliman, S | 2 |
| Chheng, P | 2 |
| Debanne, SM | 1 |
| Hoft, DF | 2 |
| Hanekom, WA | 2 |
| Johnson, JL | 3 |
| Redditt, VJ | 1 |
| Bunce, PE | 1 |
| Riccieri, V | 1 |
| Altieri, AM | 1 |
| Cantoro, L | 1 |
| Peluso, MJ | 1 |
| Hung, A | 1 |
| Lukasiewicz, A | 1 |
| Chang, H | 1 |
| Ramallo, J | 1 |
| Bartlett, M | 1 |
| Friedland, G | 1 |
| Ellis, P | 1 |
| Pezzolo, E | 1 |
| Lo Cascio, G | 1 |
| Girolomoni, G | 1 |
| MacKenzie, WR | 1 |
| Kumar, N | 1 |
| Kedarisetty, CK | 1 |
| Kumar, S | 1 |
| Khillan, V | 1 |
| Sarin, SK | 1 |
| Metin Timur, Ö | 1 |
| Tanir, G | 1 |
| Öz, FN | 1 |
| Bayhan, Gİ | 1 |
| Aydin Teke, T | 1 |
| Tuygun, N | 1 |
| Fluegge, KR | 1 |
| Kim, HC | 2 |
| Jung, YJ | 1 |
| Yoo, B | 2 |
| Kim, YG | 2 |
| Yang, SK | 2 |
| Byeon, JS | 2 |
| Ye, BD | 2 |
| Bonfiglioli, KR | 1 |
| Ribeiro, AC | 1 |
| Moraes, JC | 1 |
| Saad, CG | 1 |
| Souza, FH | 1 |
| Calich, AL | 1 |
| Bonfa, E | 1 |
| Laurindo, IM | 1 |
| Tousif, S | 1 |
| Ahmad, S | 1 |
| Moodley, P | 1 |
| Bhattacharyya, M | 1 |
| Van Kaer, L | 1 |
| Das, G | 1 |
| Dutta, NK | 1 |
| Karakousis, PC | 1 |
| Frick, M | 1 |
| Seaworth, B | 1 |
| McKenna, L | 1 |
| Elnour, T | 1 |
| Lee, C | 1 |
| Sharma, S | 1 |
| Cruz-Hervert, P | 1 |
| Guio, H | 1 |
| Canizales, S | 1 |
| Molina, S | 1 |
| Ferreira-Guerrero, E | 1 |
| Téllez, N | 1 |
| Montero-Campos, R | 1 |
| Delgado-Sánchez, G | 1 |
| Mongua-Rodriguez, N | 1 |
| Ponce-de Leon, A | 1 |
| Young, DB | 1 |
| Andrews, JR | 1 |
| Azadi, M | 1 |
| Bishai, DM | 1 |
| Cavalcante, S | 2 |
| Saraceni, V | 1 |
| Pacheco, AG | 1 |
| Cohn, S | 1 |
| Durovni, B | 1 |
| Rubinowicz, A | 1 |
| Bartlett, G | 2 |
| MacGibbon, B | 1 |
| Greenaway, C | 1 |
| Ronald, L | 1 |
| Munoz, M | 1 |
| Shrestha-Kuwahara, R | 1 |
| Hall, J | 1 |
| Elliott, C | 1 |
| Weis, SE | 1 |
| Conde, MB | 1 |
| Jones, B | 1 |
| Oliveira, R | 1 |
| Marais, BJ | 1 |
| Park, SJ | 1 |
| Park, SH | 2 |
| Niepolski, L | 1 |
| Grzegorzewska, AE | 1 |
| Umeda, N | 1 |
| Inada, Y | 1 |
| Mamoto, T | 1 |
| Cataño, JC | 1 |
| Morales, M | 2 |
| Miyazawa, S | 1 |
| Matsuoka, S | 1 |
| Hamana, S | 1 |
| Nagai, S | 1 |
| Nakamura, H | 1 |
| Nirei, K | 1 |
| Moriyama, M | 1 |
| Phillips, E | 1 |
| Shepherd, G | 1 |
| Adkinson, NF | 1 |
| Weis, S | 1 |
| Ho, C | 1 |
| Matteelli, A | 4 |
| Raviglione, M | 3 |
| Daher, A | 1 |
| Pitta, L | 1 |
| Santos, T | 1 |
| Barreira, D | 2 |
| Pinto, D | 1 |
| Bishara, H | 1 |
| Ore, L | 1 |
| Vinitsky, O | 1 |
| Bshara, H | 1 |
| Armaly, N | 1 |
| Weiler-Ravell, D | 1 |
| Mathew, JL | 1 |
| John, TJ | 1 |
| Parakh, A | 1 |
| Medina-Gil, C | 1 |
| Dehesa, L | 1 |
| Vega, A | 1 |
| Kerdel, F | 1 |
| Mascia, C | 1 |
| Rossi, R | 1 |
| Lichtner, M | 1 |
| Dedicoat, M | 1 |
| Lange, C | 2 |
| Bliven-Sizemore, EE | 1 |
| Benator, D | 1 |
| Drobeniuc, J | 1 |
| Bock, N | 1 |
| Mugusi, FM | 1 |
| Stennis, NL | 1 |
| Burzynski, JN | 1 |
| Herbert, C | 1 |
| Nilsen, D | 2 |
| Jones, JG | 1 |
| King, TC | 1 |
| Ogbuagu, O | 1 |
| Ogbuagu, A | 1 |
| Tam, JK | 1 |
| Flood, J | 1 |
| Scott, J | 1 |
| Devrim, İ | 2 |
| Devrim, F | 1 |
| Bayram, N | 1 |
| Aktürk, H | 1 |
| Aksay, A | 1 |
| Can, D | 2 |
| Apa, H | 1 |
| Aziz, MA | 1 |
| Baddeley, A | 1 |
| Den Boon, S | 2 |
| Borroto Gutierrez, SM | 1 |
| Burhan, E | 1 |
| Cedillos, R | 1 |
| Chaisson, R | 1 |
| Chesire, L | 1 |
| Corbett, E | 1 |
| Dara, M | 1 |
| Denholm, J | 1 |
| de Vries, G | 2 |
| Gale-Rowe, M | 1 |
| Gilpin, C | 1 |
| Girardi, E | 1 |
| Go, UY | 1 |
| Govindasamy, D | 1 |
| D Grant, A | 1 |
| Grzemska, M | 1 |
| Harris, R | 1 |
| Ismayilov, A | 1 |
| Jaramillo, E | 1 |
| Kik, S | 1 |
| Kranzer, K | 1 |
| Lienhardt, C | 1 |
| Lönnroth, K | 1 |
| Marks, G | 1 |
| Mosca, D | 1 |
| Mukadi, YD | 1 |
| Mwinga, A | 1 |
| Nelson, L | 1 |
| Nishikiori, N | 1 |
| Oordt-Speets, A | 1 |
| Reis, A | 1 |
| Rotz, L | 1 |
| Sandgren, A | 1 |
| Sañé Schepisi, M | 1 |
| Schünemann, HJ | 1 |
| Tayeb, T | 1 |
| Uplekar, M | 1 |
| Vandevelde, W | 1 |
| van Kessel, F | 1 |
| van't Hoog, A | 1 |
| Varma, JK | 1 |
| Vezhnina, N | 1 |
| Voniatis, C | 1 |
| Vonk Noordegraaf-Schouten, M | 1 |
| Weil, D | 1 |
| Weyer, K | 1 |
| Dobler, CC | 3 |
| Martin, A | 2 |
| Decloedt, EH | 1 |
| van der Walt, JS | 1 |
| McIlleron, H | 1 |
| Maartens, G | 1 |
| Biraro, IA | 1 |
| Egesa, M | 1 |
| Kimuda, S | 1 |
| Smith, SG | 1 |
| Toulza, F | 1 |
| Levin, J | 1 |
| Joloba, M | 1 |
| Katamba, A | 1 |
| Cose, S | 1 |
| Dockrell, HM | 1 |
| Elliott, AM | 1 |
| Lines, G | 1 |
| Hunter, P | 1 |
| Bleything, S | 1 |
| Hernán García, C | 1 |
| Moreno Cea, L | 1 |
| Fernández Espinilla, V | 1 |
| Ruiz Lopez Del Prado, G | 1 |
| Fernández Arribas, S | 1 |
| Andrés García, I | 1 |
| Rubio, V | 1 |
| Vesenbeckh, S | 1 |
| Eiros Bouza, JM | 1 |
| Gray, EL | 1 |
| Goldberg, HF | 1 |
| Singer-Leshinsky, S | 1 |
| Krause, V | 1 |
| Su, VY | 1 |
| Chuang, PH | 1 |
| Chou, KT | 1 |
| Chen, TJ | 1 |
| Ai, JW | 1 |
| Ruan, QL | 1 |
| Liu, QH | 1 |
| Zhang, WH | 1 |
| Hamadah, AM | 1 |
| Beaulieu, LM | 1 |
| Wilson, JW | 1 |
| Aksamit, TR | 1 |
| Gregoire, JR | 1 |
| Williams, AW | 1 |
| Dillon, JJ | 1 |
| Albright, RC | 1 |
| Onuigbo, M | 1 |
| Iyer, VK | 1 |
| Hickson, LJ | 1 |
| Aquino, DS | 1 |
| Moura, LC | 1 |
| Maruza, M | 1 |
| Silva, AP | 2 |
| Ximenes, RA | 1 |
| Lacerda, HR | 1 |
| Miranda Filho, Dde B | 1 |
| Albuquerque, Mde F | 1 |
| Erkens, CG | 1 |
| Slump, E | 1 |
| Verhagen, M | 1 |
| Schimmel, H | 1 |
| Cobelens, F | 1 |
| van den Hof, S | 1 |
| Garcia, MJ | 1 |
| Lopez, MR | 1 |
| Hill, P | 1 |
| Rabelo, SG | 1 |
| Kyanko, KA | 1 |
| Tsay, JC | 1 |
| Yun, K | 1 |
| Parent, B | 1 |
| Cataño, J | 1 |
| Cho, YJ | 1 |
| Jeong, YY | 1 |
| Lee, JD | 1 |
| Mendonça, AM | 1 |
| Kritski, AL | 1 |
| Land, MG | 1 |
| Sant'Anna, CC | 1 |
| Gerona, R | 1 |
| Wen, A | 1 |
| Chin, AT | 1 |
| Koss, CA | 1 |
| Bacchetti, P | 1 |
| Metcalfe, J | 1 |
| Gandhi, M | 1 |
| Agudo, B | 1 |
| Díaz, G | 1 |
| González-Lama, Y | 1 |
| Hughes, JE | 1 |
| Smit, E | 1 |
| Murphy, M | 1 |
| Toefy, A | 1 |
| Lerumo, L | 1 |
| Hopley, C | 1 |
| Nemes, E | 1 |
| Scriba, TJ | 1 |
| Rennert-May, E | 1 |
| Hansen, E | 1 |
| Zadeh, T | 1 |
| Krinke, V | 1 |
| Houston, S | 1 |
| Cooper, R | 1 |
| Jensen, TO | 1 |
| Darley, DR | 1 |
| Goeman, EE | 1 |
| Shaw, K | 1 |
| Marriott, DJ | 1 |
| Glanville, AR | 1 |
| Simkins, J | 2 |
| Abbo, LM | 2 |
| Camargo, JF | 2 |
| Rosa, R | 1 |
| Morris, MI | 2 |
| Yeh, YP | 1 |
| Tsao, TC | 1 |
| Houben, RM | 1 |
| Dodd, PJ | 1 |
| Usui, T | 1 |
| Meng, X | 1 |
| Saide, K | 1 |
| Farrell, J | 1 |
| Thomson, P | 1 |
| Whitaker, P | 1 |
| Watson, J | 1 |
| French, NS | 1 |
| Kevin Park, B | 1 |
| Naisbitt, DJ | 1 |
| Furukawa, NW | 1 |
| Haider, MZ | 1 |
| Allen, SJ | 1 |
| Carlson, SL | 1 |
| Lindquist, SW | 1 |
| Brugueras, S | 1 |
| Orcau, À | 1 |
| Espinosa, L | 1 |
| de Andrés, A | 1 |
| Gorrindo, P | 1 |
| Tran, NQ | 1 |
| Garcia-Rosell, M | 1 |
| Pattanaik, D | 1 |
| Raza, SH | 1 |
| Carbone, L | 1 |
| Guirao-Arrabal, E | 1 |
| Santos, F | 1 |
| Redel, J | 1 |
| Vaquero, JM | 1 |
| Torre-Cisneros, J | 1 |
| Saukkonen, J | 1 |
| Hamilton, CD | 2 |
| Liebscher, F | 1 |
| Pfammatter, T | 1 |
| Kolios, A | 1 |
| Greutmann, M | 1 |
| Franzen, D | 1 |
| McClintock, AH | 1 |
| Eastment, M | 1 |
| McKinney, CM | 1 |
| Pitney, CL | 1 |
| Park, DR | 1 |
| Dhanireddy, S | 1 |
| Molnar, A | 1 |
| Reichman, LB | 1 |
| Knoll, BM | 1 |
| Nog, R | 1 |
| Wu, Y | 1 |
| Dhand, A | 1 |
| Sung, YK | 1 |
| Cho, SK | 1 |
| Kim, D | 1 |
| Won, S | 1 |
| Choi, CB | 1 |
| Jun, JB | 1 |
| Yoo, DH | 1 |
| Bae, SC | 1 |
| Ziganshina, LE | 1 |
| Garner, P | 1 |
| Li, J | 2 |
| Munsiff, SS | 1 |
| Tarantino, T | 1 |
| Dorsinville, M | 1 |
| Schaberg, T | 1 |
| Welte, T | 1 |
| Nienhaus, A | 1 |
| Bliven, EE | 1 |
| Podewils, LJ | 1 |
| Gomes, V | 1 |
| Suga, H | 1 |
| Atomiya, AN | 1 |
| Akolo, C | 1 |
| Adetifa, I | 1 |
| Shepperd, S | 1 |
| Volmink, J | 1 |
| Yamada, S | 1 |
| Richardson, K | 1 |
| Tang, M | 1 |
| Halaschek-Wiener, J | 1 |
| Brooks-Wilson, A | 1 |
| Olukman, O | 1 |
| Dizdarer, C | 1 |
| Gran, G | 1 |
| Wentzel-Larsen, T | 1 |
| Blomberg, B | 1 |
| Haanshuus, CG | 1 |
| Mørkve, O | 1 |
| Zylberberg, D | 1 |
| Al-Otaibi, B | 1 |
| Schmitz, KE | 1 |
| Hovell, MF | 1 |
| Wong, CA | 1 |
| Kelley, NJ | 1 |
| Blumberg, EJ | 1 |
| Hill, LL | 1 |
| Sipan, CL | 1 |
| Kolody, B | 1 |
| Chatfield, DA | 1 |
| Bright-Thomas, R | 1 |
| Nandwani, S | 1 |
| Smith, J | 1 |
| Morris, JA | 1 |
| Ormerod, LP | 1 |
| Aspler, A | 2 |
| Khan, K | 1 |
| Haroon, M | 1 |
| Martin, U | 1 |
| Devlin, J | 1 |
| Rieder, HL | 1 |
| Yew, WW | 1 |
| Minodier, P | 1 |
| Lamarre, V | 1 |
| Carle, ME | 1 |
| Blais, D | 1 |
| Ovetchkine, P | 1 |
| Tapiero, B | 1 |
| Salinas, C | 1 |
| Pascual Erquicia, S | 1 |
| Diez, R | 1 |
| Aguirre, U | 1 |
| Egurrola, M | 1 |
| Altube, L | 1 |
| Capelastegui, A | 1 |
| Franks, J | 1 |
| El-Sadr, W | 1 |
| Khan, KS | 1 |
| Bark, CM | 1 |
| Morrison, CS | 1 |
| Salata, RA | 1 |
| Byamugisha, JK | 1 |
| Katalemwa, NH | 1 |
| Mugerwa, RD | 1 |
| Mukasa, JB | 1 |
| Musoke, RN | 1 |
| Nankya-Mutyoba, J | 1 |
| Rwambuya, S | 1 |
| Walker, CJ | 1 |
| Mahan, CS | 1 |
| Curley, C | 1 |
| van der Kuyp, F | 1 |
| Smith, BM | 2 |
| Sungkanuparph, S | 1 |
| Woeltje, KF | 1 |
| Fraser, VJ | 1 |
| Mori, S | 1 |
| Matsushita, Y | 1 |
| Arizono, K | 1 |
| Atun, R | 1 |
| Maeurer, M | 1 |
| Mwaba, P | 1 |
| Ma, Z | 1 |
| O'Grady, J | 1 |
| Bates, M | 1 |
| Dheda, K | 1 |
| Hoelscher, M | 1 |
| Grange, J | 1 |
| Jafri, SM | 1 |
| Singal, AG | 1 |
| Kaul, D | 1 |
| Fontana, RJ | 1 |
| Nakazono, T | 1 |
| Tezuka, N | 1 |
| Tagawa, H | 1 |
| Takayanagi, K | 1 |
| Sugita, H | 1 |
| Takase, A | 1 |
| Yamaguchi, T | 1 |
| Shimao, T | 1 |
| Seersholm, N | 1 |
| Wilcke, T | 1 |
| Cardona, PJ | 1 |
| Ivanyi, J | 1 |
| Chase, MR | 1 |
| Shah, RR | 1 |
| Iartchouk, O | 1 |
| Galagan, J | 1 |
| Mohaideen, N | 1 |
| Ioerger, TR | 1 |
| Sacchettini, JC | 1 |
| Lipsitch, M | 1 |
| Zhu, R | 1 |
| Kiser, JJ | 1 |
| Seifart, HI | 1 |
| Werely, CJ | 1 |
| Mitchell, CD | 1 |
| D'Argenio, DZ | 1 |
| Sanders, GD | 1 |
| Nobre, CA | 1 |
| Callado, MR | 1 |
| Lima, JR | 1 |
| Gomes, KW | 1 |
| Martiniano, GV | 1 |
| Vieira, WP | 1 |
| Fresard, I | 1 |
| Bridevaux, PO | 1 |
| Rochat, T | 1 |
| Janssens, JP | 1 |
| Khongphatthanayothin, M | 1 |
| Avihingsanon, A | 1 |
| Teeratakulpisarn, N | 1 |
| Phanuphak, N | 1 |
| Buajoom, R | 1 |
| Suwanmala, P | 1 |
| Phanuphak, P | 1 |
| Magro-Checa, C | 1 |
| Navas-Parejo Casado, A | 1 |
| Borrego-García, E | 1 |
| Raya-Álvarez, E | 1 |
| Rosales-Alexander, JL | 1 |
| Salvatierra, J | 1 |
| Caballero-Morales, T | 1 |
| Gómez-Morales, M | 1 |
| Daskalaki, I | 1 |
| Byun, J | 1 |
| Dogbey, MC | 1 |
| Tolbert-Warren, C | 1 |
| Watson, BM | 1 |
| Yano, S | 1 |
| Khattri, S | 1 |
| Kushawaha, A | 1 |
| Dahal, K | 1 |
| Mobarakai, N | 1 |
| Rudd, A | 1 |
| Dolianitis, C | 1 |
| Varigos, G | 1 |
| Howard, A | 1 |
| Ikeue, T | 1 |
| Nakagawa, A | 1 |
| Furuta, K | 1 |
| Morita, K | 1 |
| Sugita, T | 1 |
| Nishiyama, H | 1 |
| Esfahani, K | 1 |
| Perry, A | 1 |
| Angoulvant, F | 1 |
| Chadelat, K | 1 |
| De Lauzanne, A | 1 |
| Houdouin, V | 1 |
| Kheniche, A | 1 |
| Lorrot, M | 1 |
| Mesples, B | 1 |
| Nouyrigat, V | 1 |
| Aujard, Y | 1 |
| Gaudelus, J | 1 |
| Grimprel, E | 1 |
| Faye, A | 1 |
| Lu, BY | 1 |
| Lu, CY | 1 |
| Shao, PL | 1 |
| Anger, HA | 1 |
| Proops, D | 1 |
| Harris, TG | 1 |
| Kreiswirth, BN | 1 |
| Shashkina, E | 1 |
| Ahuja, SD | 1 |
| White, MC | 1 |
| Tulsky, JP | 1 |
| Lee, JR | 1 |
| Chen, L | 1 |
| Goldenson, J | 1 |
| Spetz, J | 1 |
| Kawamura, LM | 1 |
| Arias, C | 1 |
| Young, J | 1 |
| Edick, T | 1 |
| Klee, D | 1 |
| O'Connor, ME | 1 |
| Fraisse, P | 1 |
| Person, AK | 1 |
| Kufa, T | 1 |
| Mngomezulu, V | 1 |
| Charalambous, S | 1 |
| Hanifa, Y | 1 |
| Fielding, K | 1 |
| Grant, AD | 1 |
| Wada, N | 1 |
| Gounder, CR | 1 |
| Duarte, R | 1 |
| Carvalho, A | 1 |
| Correia, A | 1 |
| Fábrega, E | 1 |
| Sampedro, B | 1 |
| Cabezas, J | 1 |
| Casafont, F | 1 |
| Mieses, MÁ | 1 |
| Moraleja, I | 1 |
| Crespo, J | 1 |
| Pons-Romero, F | 1 |
| Hsia, EC | 1 |
| Cush, JJ | 1 |
| Matteson, EL | 1 |
| Beutler, A | 1 |
| Doyle, MK | 1 |
| Hsu, B | 1 |
| Xu, S | 1 |
| Rahman, MU | 1 |
| Tsai, TF | 2 |
| Ho, V | 1 |
| Song, M | 2 |
| Szapary, P | 1 |
| Kato, T | 1 |
| Wasfi, Y | 1 |
| Li, S | 1 |
| Shen, YK | 1 |
| Leonardi, C | 1 |
| Chiu, HY | 1 |
| Chan, D | 1 |
| Dartois, V | 1 |
| Johnston, PJ | 1 |
| Janssen, C | 1 |
| Via, L | 1 |
| Goodwin, MB | 1 |
| Klein, E | 1 |
| Barry, CE | 1 |
| Nagafuchi, Y | 1 |
| Shoda, H | 1 |
| Ishii, S | 1 |
| Sugiyama, H | 1 |
| Yamamoto, K | 1 |
| Stucchi, RS | 1 |
| Boin, IF | 1 |
| Angerami, RN | 1 |
| Zanaga, L | 1 |
| Ataide, EC | 1 |
| Udo, EY | 1 |
| Nicolau, I | 1 |
| Tian, L | 1 |
| Ostiguy, G | 1 |
| Pai, M | 1 |
| Chang, FY | 1 |
| Shear, NH | 1 |
| Tiernan, JF | 1 |
| Gilhooley, S | 1 |
| Jones, ME | 1 |
| Chalmers, JD | 1 |
| McSparron, C | 1 |
| Laurenson, IF | 1 |
| Hill, AT | 1 |
| Lytras, T | 1 |
| Spala, G | 1 |
| Bonovas, S | 1 |
| Panagiotopoulos, T | 1 |
| Adetifa, IM | 1 |
| Ota, MO | 1 |
| Jeffries, DJ | 1 |
| Lugos, MD | 1 |
| Hammond, AS | 1 |
| Battersby, NJ | 1 |
| Owiafe, PK | 1 |
| Donkor, SD | 1 |
| Antonio, M | 1 |
| Ibanga, HB | 1 |
| Brookes, RH | 1 |
| Aka, P | 1 |
| Walton, R | 1 |
| Adegbola, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double Blind Placebo Controlled Trial of Rifapentine and Isoniazid for Prevention of Tuberculosis in People With Diabetes[NCT04600167] | Phase 3 | 3,000 participants (Anticipated) | Interventional | 2022-06-17 | Recruiting | ||
| Novel TB Prevention Regimens for HIV-Infected Adults[NCT00057122] | Phase 3 | 1,148 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Comparison of 3-month Once-weekly Isoniazid Plus Rifapentine, 4-month Daily Rifampicin, and 3-month Daily Isoniazid Plus Rifampicin for the Treatment Latent Tuberculosis in Patients With End-stage Kidney Disease: A Randomised Clinical Trial[NCT05021731] | Phase 4 | 225 participants (Anticipated) | Interventional | 2022-04-01 | Not yet recruiting | ||
| TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection[NCT00023452] | Phase 3 | 8,053 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| A Randomized Trial to Compare Effectiveness of 4 Months Rifampin (4 RIF) With 9 Months Isoniazid (9 INH) in the Prevention of Active TB in Children: The P4v9 Trial[NCT00170209] | Phase 3 | 844 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Randomized Clinical Trial of 4 Months of Rifampin vs. 9 Months of Isoniazid for Latent Tuberculosis Infection. Part 3 - Effectiveness[NCT00931736] | Phase 3 | 6,031 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection[NCT02651259] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2017-03-13 | Completed | ||
| Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority Trial[NCT02901288] | Phase 4 | 3,900 participants (Anticipated) | Interventional | 2016-08-31 | Recruiting | ||
| Efficacy of Risk-Targeted Video Based Directly on Observed Therapy for Latent TB[NCT03783728] | 0 participants (Actual) | Observational | 2019-06-30 | Withdrawn (stopped due to Investigator is leaving the University) | |||
| Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention: the 3HP Options Implementation Trial[NCT03934931] | 1,656 participants (Actual) | Interventional | 2020-07-13 | Active, not recruiting | |||
| TBTC Study 33. An Evaluation of Adherence to Latent Tuberculosis Infection (LTBI) Treatment With 12 Doses of Once Weekly Rifapentine (RPT) and Isoniazid (INH) Given as Self-administered (SAT) Versus Directly-observed Therapy (DOT): iAdhere.[NCT01582711] | Phase 3 | 1,002 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers[NCT02771249] | Phase 1 | 37 participants (Actual) | Interventional | 2016-06-03 | Completed | ||
| The Effect of Weekly Text-message Communication on Treatment Completion Among Patients With Latent Tuberculosis Infection: a Randomised Controlled Trial (WelTel LTBI)[NCT01549457] | Early Phase 1 | 350 participants (Anticipated) | Interventional | 2012-04-30 | Active, not recruiting | ||
| Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan[NCT02208427] | Phase 3 | 283 participants (Actual) | Interventional | 2014-08-31 | Active, not recruiting | ||
| One-month Latent Tuberculosis Treatment for Renal Transplant Candidates[NCT05411744] | Phase 4 | 25 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial.[NCT03988933] | Phase 2 | 1,368 participants (Actual) | Interventional | 2019-09-20 | Active, not recruiting | ||
| Early Risk Assessment in TB contactS by New Diagnostic tEsts[NCT04781257] | 2,100 participants (Anticipated) | Observational | 2021-03-01 | Active, not recruiting | |||
| Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection[NCT01404312] | Phase 3 | 3,000 participants (Actual) | Interventional | 2012-05-23 | Completed | ||
| URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
| Primary Prophylaxis for Prevention of TB in Prison's Populations[NCT03028129] | Phase 4 | 467 participants (Actual) | Interventional | 2017-09-04 | Terminated (stopped due to Interim analysis showed efficacy less than 2.5%.) | ||
| Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial[NCT04373291] | Phase 3 | 1,293 participants (Actual) | Interventional | 2020-05-18 | Completed | ||
| Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses[NCT04348370] | Phase 4 | 1,800 participants (Anticipated) | Interventional | 2020-04-20 | Active, not recruiting | ||
| Novel Use of an Existing Vaccine (BCG) Alliance: The NUEVA Trial[NCT04632537] | Phase 3 | 0 participants (Actual) | Interventional | 2020-12-07 | Withdrawn (stopped due to Due to funding - project never enrolled) | ||
| Bacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity Trial[NCT04534803] | Phase 3 | 0 participants (Actual) | Interventional | 2021-09-30 | Withdrawn (stopped due to At this time it has been decided by the study team the the study will no longer take place in the United States.) | ||
| Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly (PARITIE)[NCT04938323] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2022-05-31 | Withdrawn (stopped due to Covid-19 related delays in project launch) | ||
| Phase I Study of Whether Preclearance of Latent M. Tuberculosis (MTB) Infection With Isoniazid (INH) Enhances Specific Immune Responses to MTB Following Subsequent BCG Revaccination in Healthy, HIV-Uninfected, Tuberculin Skin Test Positive Adults[NCT01119521] | Phase 1 | 82 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| BCG Vaccine to Reduce Unplanned Absenteeism Due to Illness of Health Care Workers During the COVID-19 Pandemic. A Multi-center Randomised Controlled Trial (BCG-COVID-RCT)[NCT04641858] | Phase 4 | 668 participants (Actual) | Interventional | 2020-12-03 | Completed | ||
| The Role of the Bacillus Calmette-Guérin Vaccine (BCG) in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) Vaccines[NCT05507671] | Phase 3 | 556 participants (Anticipated) | Interventional | 2021-05-27 | Active, not recruiting | ||
| Drugs for Treatment of Latent Tuberculosis Infection Objective 4: Identify Biomarkers for Clinical Trials of Drugs Active Against Latent TB[NCT00293228] | Phase 4 | 200 participants (Anticipated) | Interventional | 2007-02-28 | Completed | ||
| Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2[NCT03278483] | Phase 4 | 396 participants (Actual) | Interventional | 2019-02-28 | Completed | ||
| A Randomised, Pragmatic, Open-Label Trial To Evaluate The Effect Of Three Months Of High Dose Rifapentine Plus Isoniazid Administered As A Single Round Or Given Annually In HIV-Positive Individuals[NCT02980016] | Phase 3 | 4,027 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Acceptability and Completion Rates of a New 12 Dose Treatment (3 Month) Compared to the Standard Treatment for Latent TB Infection Treatment[NCT02689089] | Phase 4 | 182 participants (Actual) | Interventional | 2016-11-28 | Completed | ||
| Prevalence of Latent Tuberculosis in High Risk Children Attending Pediatric Hospital of Assiut University[NCT03910946] | 100 participants (Anticipated) | Observational | 2020-07-01 | Not yet recruiting | |||
| Study of Adherence to Antihypertensive Drugs and Statins in the Population of Subjects With Hypertension Followed at SIIA Centers, Using an Innovative Monitoring Based on Hair Analysis[NCT05347823] | 200 participants (Anticipated) | Observational | 2022-05-15 | Not yet recruiting | |||
| A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High Tuberculosis (TB) Incidence Setting[NCT01494038] | Phase 4 | 956 participants (Actual) | Interventional | 2014-08-19 | Completed | ||
| Promoting Adherence to TB Regimens in High Risk Youth[NCT00233168] | 263 participants (Actual) | Interventional | 2003-09-30 | Completed | |||
| Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison[NCT00767975] | Phase 3 | 2,384 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Clinical Trial of Short Course Rifampin Versus INH for LTBI in Jail[NCT00128206] | Phase 3 | 364 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| TB Screening Improves Preventive Therapy Uptake Trial[NCT04557176] | 1,719 participants (Actual) | Interventional | 2020-11-16 | Active, not recruiting | |||
| Behavior Change and Digital Health Interventions for Improved TB Treatment Outcomes: a RCT[NCT04119375] | 16,146 participants (Actual) | Interventional | 2018-04-13 | Completed | |||
| A Double Blind Placebo-controlled Randomized Trial of Isoniazid for the Reversion of a Positive IFNg ELISPOT in TB Case Contacts[NCT00130325] | 214 participants (Actual) | Interventional | 2004-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cumulative TB disease rate was defined as number of participants (regardless of age) with culture-confirmed TB disease (defined as positive culture for MTB]) or probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, CT scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for AFB, or caseating granulomata at autopsy or biopsy) between enrollment and the 990th Day of the Trial (33 months after enrollment, or end of the trial) per 100 participants w/33 months of follow-up and was calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to 33 Months
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.49 |
| 3RPT/INH | 0.24 |
Cumulative TB disease rate was defined as number of participants ≥18 years old with culture-confirmed TB disease (defined as positive culture for MTB) and <18 years old with probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, CT scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for AFB], or caseating granulomata at autopsy or biopsy) between enrollment and 33 months after enrollment (for those who completed therapy within 33 months) per 100 participants w/33 months of follow-up and was calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to Month 33
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.11 |
| 3RPT/INH | 0.05 |
Cumulative TB disease rate was defined as number of participants ≥18 years old with culture-confirmed TB disease (defined as positive culture for MTB) and those <18 years old with probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, CT scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for AFB], or caseating granulomata at autopsy or biopsy) between enrollment and 24 months after completion of study therapy per 100 participants with up to 33 months of follow-up and was calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to Month 27 (3RPT/INH) or Month 33 (9INH)
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.37 |
| 3RPT/INH | 0.16 |
Cumulative TB disease rate defined as number of participants ≥18 years old with culture-confirmed TB disease (defined as positive culture for Mycobacterium tuberculosis [MTB]) and those <18 years old with probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, computed tomography [CT] scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for acid-fast bacilli [AFB], or caseating granulomata at autopsy or biopsy) between enrollment and the 990th Day of the Trial (33 months after enrollment, or end of the trial) per 100 participants with (w/)33 months of follow-up calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to Month 33
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.43 |
| 3RPT/INH | 0.19 |
Completion in the 3RPT/INH arm was defined as: received 12 doses of RPT/INH within 16 weeks (12 weeks optimal). However, participants were considered to have completed therapy if at least 11 doses of RPT/INH had been received (~90%) during the 16-week time period. Completion in the 9INH arm was defined as: received 270 doses of INH within 52 weeks (39 weeks optimal). However, participants were considered to have completed therapy if at least 240 doses of INH were received (~90%) during the 52-week period. (NCT00023452)
Timeframe: Baseline up to Month 3 (3RPT/INH) or Month 9 (9INH)
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 69.0 |
| 3RPT/INH | 82.1 |
(NCT00023452)
Timeframe: Baseline up to Month 35
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 1.0 |
| 3RPT/INH | 0.8 |
Discontinuation of study drug due to an adverse drug reaction associated with either 3RPT/INH or 9INH was defined as discontinuing treatment and/or study due to a treatment-related adverse event (AE) (considered either possibly, probably, or definitely related to the study drug by the investigator). (NCT00023452)
Timeframe: Baseline up to 60 days after the last dose of study drug (Month 5 [3RPT/INH] or Month 11 [9INH])
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 3.8 |
| 3RPT/INH | 4.9 |
Drug discontinuations for any reason associated with 3RPT/INH or 9INH included all reasons for discontinuation from study treatment, regardless of relationship to treatment. (NCT00023452)
Timeframe: Baseline up to Month 3 (3RPT/INH) or Month 9 (9INH)
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 31.0 |
| 3RPT/INH | 17.9 |
Drug-susceptibility testing (DST) was performed on isolates of MTB obtained from participants who developed signs and symptoms of active TB disease (including sputum specimens or specimens from appropriate body site for extrapulmonary TB disease). DST was performed at site's local laboratory and sent to Sponsor for confirmatory susceptibility testing. DST included all drugs currently used to treat TB disease, including pyrazinamide (PZA) and fluoroquinolones. Susceptibility was tested for other drugs at the Sponsor laboratory at the following concentrations: INH, 0.02, 1.0, and 5.0 micrograms per milliliter (µg/mL) and rifampin (RIF), 1.0 µg/mL. Isolates resistant to RIF were assumed to be resistant to RPT. (NCT00023452)
Timeframe: Baseline up to Month 33
| Intervention | percentage of participants (Number) | |
|---|---|---|
| INH monoresistance | RIF and PZA resistant | |
| 3RPT/INH | 0 | 14 |
| 9INH | 15 | 0 |
Drug toxicities (or AEs) were graded using Common Toxicity Criteria (CTC version 2.0, Publish Date April 30, 1999, Cancer Therapy Evaluation Program). Grade 3 and 4 drug toxicities associated with 3RPT/INH or 9INH were defined as treatment-related Grade 3 or 4 AEs (considered either possibly, probably, or definitely related to the study drug by the investigator). (NCT00023452)
Timeframe: Baseline up to 60 days after the last dose of study drug (Month 5 [3RPT/INH] or Month 11 [9INH])
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Grade 3 | Grade 4 | |
| 3RPT/INH | 2.7 | 0.4 |
| 9INH | 2.2 | 0.4 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~• Estimated a single absorption rate constant (ka) for the whole population" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | hr-1 (Mean) |
|---|---|
| All Cohorts | 1.74 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Estimated the transit compartment rate constant (ktr), which is synonymous with the absorption constant (ka), for the whole population Note that the mean stated below is actually the value that is obtained from a population analysis and represents a population estimate" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | hr-1 (Mean) |
|---|---|
| All Cohorts | 1.43 |
"PK parameters from postpartum women were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Calculated an average CL for all post-partum individuals" (NCT02651259)
Timeframe: Data used in the population PK analysis for postpartum women included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L/hr (Mean) |
|---|---|
| All Cohorts | 1.64 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Calculated an average CL for all women in the 2nd trimester (cohort I) and all women in the 3rd trimester (cohort II)" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L/hr (Mean) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 1.4 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 1.50 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption and a separate compartment for metabolite formation~Estimated a single des-RPT CLmet/F for the whole population Note: that the mean stated below is actually the value that is obtained from a population analysis and represents a population estimate with the relative standard error" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L/hr (Mean) |
|---|---|
| All Cohorts | 2.82 |
Cord blood concentrations were summarized using using R (version 3.5.1). (NCT02651259)
Timeframe: at delivery (within 3 days of life for infants).
| Intervention | mcg/mL (Mean) |
|---|---|
| All Cohorts | 3.24 |
Cord blood concentrations were summarized using using R (version 3.5.1). (NCT02651259)
Timeframe: at delivery - (within 3 days of life for infants)
| Intervention | mcg/mL (Mean) |
|---|---|
| All Cohorts | 2.97 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from entry through participants' last study visit at 24 weeks after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 0 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
Based on site-specified confirmatory TB test. If women and infants were diagnosed with active TB during study they would be referred to local care for TB management and treatment. (NCT02651259)
Timeframe: Measured from birth through participants' last study visit at 24 weeks after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1(Infants Born to Women Enrolled in Second Trimester) | 0 |
| Cohort 2 (Infants Born to Women Enrolled in Third Trimester) | 0 |
Based on site-specified confirmatory TB test. If women and infants were diagnosed with active TB during study they would be referred to local care for TB management and treatment. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 0 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses will be recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that result in discontinuation of study drug regimen, and that meet criteria for EAE reporting will be further evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 0 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study treatment dispensation (approximately for 12 weeks)
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 0 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 20 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 16 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 8 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 12 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) and were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 4 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from birth through infants' last study visit at 24 weeks after birth
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Infants Born to Women Enrolled in Second Trimester) | 0 |
| Cohort 2 (Infants Born to Women Enrolled in Third Trimester) | 0 |
Plasma blood concentrations were summarized using using R (version 3.5.1). (NCT02651259)
Timeframe: at delivery - (within 3 days of life for infants).
| Intervention | mcg/mL (Mean) |
|---|---|
| All Cohorts | 5.31 |
Plasma concentrations were summarized using using R (version 3.5.1). (NCT02651259)
Timeframe: at delivery - (within 3 days of life for infants).
| Intervention | mcg/mL (Mean) |
|---|---|
| All Cohorts | 2.47 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~• Estimated a single INH Vc/F for the whole population" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L (Mean) |
|---|---|
| All Cohorts | 107 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Estimated a single RPT Vc/F for for the whole population Note: that the mean stated below is actually the value that is obtained from a population analysis and represents a population estimate with the relative standard error" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L (Mean) |
|---|---|
| All Cohorts | 30.1 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Obtained AUC by model-based integration" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | hour*mg/L (Mean) | |
|---|---|---|
| AUC (0-24) for RPT | AUC (0-24) for des-RPT | |
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 424.7 | 158.7 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 406.8 | 153.7 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with 2 mixtures to characterize subpopulations based on acetylation status~Estimated a separate INH CL/F based on acetylation status (fast, slow)" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L/hr (Mean) | |
|---|---|---|
| CL/F (slow acetylators) | CL/F (fast acetylators) | |
| All Cohorts | 8.98 | 32.7 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Obtained Cmax by model-based estimation" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | mg/L (Mean) | |
|---|---|---|
| Cmax for RPT | Cmax for des-RPT | |
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 30.2 | 8.76 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 28.6 | 8.50 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Obtained Cmin by model-based estimation" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | mg/L (Mean) | |
|---|---|---|
| Cmin for RPT | Cmin for des-RPT | |
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 1.45 | 1.06 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 1.58 | 1.20 |
The count of eligible people living with HIV (PLHIV) offered 3HP who accept to initiate treatment (by age, gender, CD4 stratum, viral load suppression) divided by the count of those randomized. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation
| Intervention | proportion of participants (Number) |
|---|---|
| Facilitated Directly Observed Therapy (DOT) | 0.998 |
| Facilitated Self-Administered Therapy (SAT) | 1.00 |
| Patient Choice Between Facilitated DOT and Facilitated SAT | 0.995 |
The count of eligible participants who accept treatment and take at least 11 of 12 once weekly doses of rifapentine (RPT)/isoniazid (INH) within 16 weeks of treatment initiation divided by the count of those randomized. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation
| Intervention | proportion of participants (Number) |
|---|---|
| Facilitated Directly Observed Therapy (DOT) | 0.946 |
| Facilitated Self-Administered Therapy (SAT) | 0.922 |
| Patient Choice Between Facilitated DOT and Facilitated SAT | 0.944 |
Count of participants who take at least 11 of 12 doses within 16 weeks of treatment initiation divided by the count those who take at least one dose of 3HP. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation
| Intervention | proportion of participants (Number) |
|---|---|
| Facilitated Directly Observed Therapy (DOT) | 0.947 |
| Facilitated Self-Administered Therapy (SAT) | 0.922 |
| Patient Choice Between Facilitated DOT and Facilitated SAT | 0.949 |
Count of participants for whom treatment is discontinued due to adverse events or intolerance divided by the count of those who initiated 3HP. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation
| Intervention | proportion of participants (Number) |
|---|---|
| Facilitated Directly Observed Therapy (DOT) | 0.0054 |
| Facilitated Self-Administered Therapy (SAT) | 0.013 |
| Patient Choice Between Facilitated DOT and Facilitated SAT | 0.0073 |
Incidence rate (events per 100 person-years) was estimated, and 95.1% confidence interval used to account for interim analysis of primary efficacy outcome. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
| Intervention | Events per 100 person-years (Number) |
|---|---|
| RPT Plus INH Regimen (Arm A) | 0.6506 |
| INH Regimen (Arm B) | 0.6736 |
Cumulative incidence function estimated nonparametrically, treating TB-related deaths as competing risks. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
| Intervention | events per 100 participants (Number) | |||
|---|---|---|---|---|
| Cumulative incidence by 1 year post-randomization | Cumulative incidence by 2 years post-randomization | Cumulative incidence by 3 years post-randomization | Cumulative incidence by 4 years post-randomization | |
| INH Regimen (Arm B) | 0.5 | 1.0 | 1.5 | 2.0 |
| RPT Plus INH Regimen (Arm A) | 0.3 | 0.4 | 0.9 | 1.6 |
Data table estimates for percentage who died by each time point were estimated using Kaplan-Meier at 1, 2, 3, and 4 years post-entry. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
| Intervention | events per 100 participants (Number) | |||
|---|---|---|---|---|
| 1 year post-entry | 2 years post-entry | 3 years post-entry | 4 years post-entry | |
| INH Regimen (Arm B) | 0.63 | 1.15 | 1.62 | 2.29 |
| RPT Plus INH Regimen (Arm A) | 0.35 | 0.49 | 1.05 | 2.00 |
"Mean and standard deviation.~Week 16 samples have not yet been analyzed because the metabolite assay is being validated, and requires submission for approval by the Clinical Pharmacology Quality Assurance Program. Analysis of week 16 samples are anticipated to be available in September 2019." (NCT01404312)
Timeframe: Measured at Weeks 0, 2, 4, and 16
| Intervention | nanograms per mL (Mean) | ||
|---|---|---|---|
| Week 0 | Week 2 | Week 4 | |
| RPT Plus INH Regimen (Arm A) | 3787 | 3870 | 4082 |
Mean and standard deviation (NCT01404312)
Timeframe: Measured at Weeks 0, 2, and 4
| Intervention | nanograms per mL (Mean) | ||
|---|---|---|---|
| Week0 | Week 2 | Week 4 | |
| RPT Plus INH Regimen (Arm A) | 7573 | 6234 | 5797 |
Among MTB-diagnosed participants who underwent drug-susceptibility testing, the number who had any resistance to a particular drug. (NCT01404312)
Timeframe: After TB diagnosis
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rifampin72268104 | Rifampin72268105 | Isoniazid72268104 | Isoniazid72268105 | Ethambutol72268104 | Ethambutol72268105 | Pyrazinamide72268104 | Pyrazinamide72268105 | |||||||||
| Developed Resistance | Did not Develop Resistance | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 1 | |||||||||||||||
| INH Regimen (Arm B) | 1 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 14 | |||||||||||||||
| INH Regimen (Arm B) | 11 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 2 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 12 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 0 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 7 | |||||||||||||||
| INH Regimen (Arm B) | 7 | |||||||||||||||
| INH Regimen (Arm B) | 0 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 6 | |||||||||||||||
| INH Regimen (Arm B) | 6 | |||||||||||||||
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | percent (Number) |
|---|---|
| INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
| Intervention | pmol/mg (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
| Intervention | days (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At 3 months72558043 | At 6 months72558043 | |||||||||||
| Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
| INH and Vitamin B6 | 160 | |||||||||||
| INH and Vitamin B6 | 79 | |||||||||||
| INH and Vitamin B6 | 38 | |||||||||||
| INH and Vitamin B6 | 2 | |||||||||||
| INH and Vitamin B6 | 124 | |||||||||||
| INH and Vitamin B6 | 90 | |||||||||||
| INH and Vitamin B6 | 41 | |||||||||||
| INH and Vitamin B6 | 4 | |||||||||||
| INH and Vitamin B6 | 0 | |||||||||||
| INH and Vitamin B6 | 1 | |||||||||||
Number of participants who had a Quantiferon TB Gold Plus (QIAGEN®) score greater than or equal to 0.35 international units per milliliter, at the time of the premature exclusion visit, on all participants in the group. (NCT03028129)
Timeframe: up to 6 months
| Intervention | participants (Number) |
|---|---|
| Treatment | 49 |
| Control | 77 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata (NCT01494038)
Timeframe: Measured from study entry through end of pregnancy
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 15.93 |
| Arm B (Deferred INH Treatment) | 13.79 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through 12 weeks after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 16.98 |
| Arm B (Deferred INH Treatment) | 10.09 |
Incidence rate, calculated by Mantel-Haenszel (MH), weighted by gestational age strata 1) gestational age at entry less than 24 weeks or 2) gestational age at entry greater than or equal to 24 weeks. AE's include laboratory results, signs/symptoms, or diagnoses; graded as per Division of AIDS (DAIDS) or by protocol-defined hepatotoxicity measures. Related to treatment indicates possibly, probably, or definitely related to INH or Placebo for INH as judged by Independent Endpoint Review Committee. Discontinuation refers to permanent discontinuation of study treatment. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 15.03 |
| Arm B (Deferred INH Treatment) | 14.93 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 2.99 |
| Arm B (Deferred INH Treatment) | 4.68 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.00 |
| Arm B (Deferred INH Treatment) | 1.38 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 3.42 |
| Arm B (Deferred INH Treatment) | 4.72 |
Incidence rate was calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 2.99 |
| Arm B (Deferred INH Treatment) | 4.42 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 0.40 |
| Arm B (Deferred INH Treatment) | 0.78 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Probable or confirmed TB infection, as judged by Secondary Endpoint Review Committee (NCT01494038)
Timeframe: Measured from study entry to Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 0.60 |
| Arm B (Deferred INH Treatment) | 0.59 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Probable or confirmed TB, or congenital TB as defined using the Cantwell criteria (see reference), judged by the Secondary Endpoint Review Committee. Includes an infant death due to unknown cause. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 0.54 |
| Arm B (Deferred INH Treatment) | 0.52 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through end of pregnancy
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 56.36 |
| Arm B (Deferred INH Treatment) | 50.88 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through delivery
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.77 |
| Arm B (Deferred INH Treatment) | 2.59 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Hepatotoxicity definition as defined by DAIDS AE grading criteria 1.0. (NCT01494038)
Timeframe: Measured from study entry through delivery
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.77 |
| Arm B (Deferred INH Treatment) | 2.59 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. Protocol-specific definition of hepatotoxicity: Any one of the following: 1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 5 times the upper limit of normal (ULN), where ULN is specified by the clinic physician; 2) Total bilirubin > 3 X ULN; 3) ALT greater than 3 X ULN and total bilirubin greater than 2 X ULN; or 4) ALT > 3 X ULN and persistent symptomatic clinical hepatitis (NCT01494038)
Timeframe: Measured from study entry through delivery
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.77 |
| Arm B (Deferred INH Treatment) | 2.59 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through delivery
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.77 |
| Arm B (Deferred INH Treatment) | 2.59 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 8.37 |
| Arm B (Deferred INH Treatment) | 4.98 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata (NCT01494038)
Timeframe: Measured from study entry through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 7.91 |
| Arm B (Deferred INH Treatment) | 4.52 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 56.48 |
| Arm B (Deferred INH Treatment) | 40.59 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study start through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 8.37 |
| Arm B (Deferred INH Treatment) | 4.98 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata (NCT01494038)
Timeframe: Measured from study start through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 7.91 |
| Arm B (Deferred INH Treatment) | 4.52 |
Hospitalization due to reasons other than birth (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 73 |
| Arm B (Deferred INH Treatment) | 75 |
Laboratory, sign/symptom, or diagnoses graded as 3 or higher by DAIDS criteria. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 193 |
| Arm B (Deferred INH Treatment) | 196 |
As before, but AE is judged to be possibly, probably, or definitely related to INH or Placebo for INH, by clinic medical staff (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 5 |
| Arm B (Deferred INH Treatment) | 6 |
Fetal deaths include both stillbirths and spontaneous abortions; in case of a multiple birth, mothers who had at least one fetal death (NCT01494038)
Timeframe: Measured from study entry through end of pregnancy
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 17 |
| Arm B (Deferred INH Treatment) | 9 |
Premature birth is defined as gestational age of < 37 weeks at delivery. (NCT01494038)
Timeframe: Measured at delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 48 |
| Arm B (Deferred INH Treatment) | 40 |
Resistance to INH from isolates of Mycobacterium tuberculosis, as a percentage of mothers who develop culture-confirmed TB (NCT01494038)
Timeframe: Measured from study entry through Week 48 postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 1 |
| Arm B (Deferred INH Treatment) | 0 |
Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data. AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program. A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used, (NCT01494038)
Timeframe: Measured at antepartum (third trimester and >= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.
| Intervention | hour*mg/L (Mean) | |
|---|---|---|
| Third trimester of pregnancy | Week 16 postpartum | |
| Fast Metabolizers | 38.5 | 46.9 |
| Intermediate Metabolizers | 62.5 | 76.2 |
| Slow Metabolizers | 153.02 | 186 |
Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data. AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program. A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used, (NCT01494038)
Timeframe: Measured at antepartum (third trimester and >= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.
| Intervention | hour*mg/L (Mean) | |
|---|---|---|
| Third trimester of pregnancy | Week 16 postpartum | |
| Fast Metabolizers | 3.63 | 4.25 |
| Intermediate Metabolizers | 6.55 | 7.67 |
| Slow Metabolizers | 21.6 | 25.3 |
(NCT00128206)
Timeframe: course of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Isoniazid | 47 |
| Rifampin | 60 |
Liver function tests were taken at regular intervals and clinical symptoms were reviewed at regular intervals in both study groups. On the basis of these tests and examinations, physicians determined whether the study drug needed to be stopped. (NCT00128206)
Timeframe: up to one year
| Intervention | participants (Number) |
|---|---|
| Isoniazid | 6 |
| Rifampin | 3 |
57 reviews available for isoniazid and Latent Tuberculosis
| Article | Year |
|---|---|
Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Latent Tube | 2021 |
Latent Tuberculosis Infection.
Topics: Adult; Algorithms; Antitubercular Agents; Child; Drug Therapy, Combination; Humans; Isoniazid; Laten | 2021 |
Targeting Non-Replicating
Topics: Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2021 |
Systematic review with network meta-analysis on the treatments for latent tuberculosis infection in children and adolescents.
Topics: Adolescent; Antitubercular Agents; Bayes Theorem; Child; Humans; Isoniazid; Latent Tuberculosis; Net | 2022 |
Latent tuberculosis infection: approach and therapeutic schemes.
Topics: Humans; Interferon-gamma Release Tests; Isoniazid; Latent Tuberculosis; Rifamycins; Tuberculosis | 2022 |
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
Topics: Canada; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2022 |
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
Topics: Canada; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2022 |
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
Topics: Canada; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2022 |
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
Topics: Canada; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2022 |
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Network Me | 2023 |
A Systematic Review and Meta-Analysis of Tuberculous Preventative Therapy Adverse Events.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Drug Therapy, Combinati | 2023 |
Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Latent Tube | 2023 |
Efficacy of anti-tuberculosis drugs for the treatment of latent tuberculosis infection: a systematic review and network meta-analysis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Network Me | 2023 |
Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Developing Countries; Drug Therapy, Combination; HI | 2020 |
Latent tuberculosis infection: recent progress and challenges in South Korea.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Republic of Korea; Tuberculosis | 2020 |
Fatal Isoniazid Hepatotoxicity in the Deployed Environment.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Latent Tuberculosi | 2021 |
Adverse events associated with weekly short course isoniazid and rifapentine therapy in pediatric patients with latent tuberculosis: A chart and literature review.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Humans | 2021 |
Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Male; Netw | 2017 |
Treatment of Latent Tuberculosis Infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Medication Adherence; Mycobacterium t | 2017 |
Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Drug Combinations; Huma | 2017 |
Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.
Topics: Antitubercular Agents; Bayes Theorem; Comorbidity; Cost-Benefit Analysis; Decision Trees; Emigrants | 2017 |
Rhabdomyolysis Induced by Isoniazid in a Patient with Rheumatoid Arthritis and End-stage Renal Disease: A Case Report and Review of the Literature.
Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Arthritis, Rheumatoid; Humans; Isoniazid; Kidney | 2018 |
A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dose-Respon | 2018 |
3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.
Topics: Adolescent; Antitubercular Agents; Child; Drug Administration Schedule; Drug Therapy, Combination; H | 2018 |
Latent tuberculosis infection: Opportunities and challenges.
Topics: Antitubercular Agents; Host-Pathogen Interactions; Humans; Interferon-gamma Release Tests; Isoniazid | 2018 |
Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.
Topics: Directly Observed Therapy; Humans; Isoniazid; Latent Tuberculosis; Rifampin; Time Factors; United St | 2018 |
Updates in the Treatment of Active and Latent Tuberculosis.
Topics: Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Monitoring; Dru | 2018 |
Uncloaking an ancient adversary: Can pathogen biomarker elicitors play a role in confirming extrapulmonary TB and latent TB infection?
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Bacteriological Techniques; Biomarkers; DNA, Bac | 2018 |
Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Child; Directly Observed Therapy; Drug Administratio | 2018 |
Tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Early Diagnosis; Humans; Isoniazid; Latent Tuberc | 2019 |
Fluoroquinolones for the treatment of latent
Topics: Allografts; Antitubercular Agents; Chemical and Drug Induced Liver Injury; End Stage Liver Disease; | 2019 |
Treatment of latent tuberculosis infection.
Topics: Antitubercular Agents; Disease Progression; Drug Resistance, Bacterial; Drug Therapy, Combination; H | 2013 |
Question 1: what are the options for treating latent TB infection in children?
Topics: Antitubercular Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Humans; Isoniazid; | 2013 |
Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Drug Interacti | 2013 |
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Topics: Adult; Antibiotics, Antitubercular; Child; Directly Observed Therapy; Drug Administration Schedule; | 2013 |
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Topics: Adult; Antibiotics, Antitubercular; Child; Directly Observed Therapy; Drug Administration Schedule; | 2013 |
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Topics: Adult; Antibiotics, Antitubercular; Child; Directly Observed Therapy; Drug Administration Schedule; | 2013 |
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Topics: Adult; Antibiotics, Antitubercular; Child; Directly Observed Therapy; Drug Administration Schedule; | 2013 |
Treatment of latent tuberculosis infection.
Topics: Animals; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Iso | 2013 |
Treatment guidelines for latent tuberculosis infection.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Immunosuppress | 2014 |
Current treatment options for latent tuberculosis infection.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Humans; Isoniazid; Latent Tuberculosis; Tumor Necrosis | 2014 |
The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature.
Topics: Adalimumab; Adult; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Crohn Disease | 2016 |
Antitubercular therapy in patients with cirrhosis: challenges and options.
Topics: Antitubercular Agents; Ethambutol; Humans; Immune System Diseases; Isoniazid; Latent Tuberculosis; L | 2014 |
Treatment of latent tuberculosis infection: a network meta-analysis.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Th | 2014 |
Latent Mycobacterium tuberculosis infection.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; L | 2015 |
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
Topics: Antirheumatic Agents; Antitubercular Agents; Coinfection; Comorbidity; Disease Management; Drug User | 2015 |
Improving Treatment Completion Rates for Latent Tuberculosis Infection: A Review of Two Treatment Regimens at a Community Health Center.
Topics: Community Health Centers; Directly Observed Therapy; Drug Therapy, Combination; Hispanic or Latino; | 2015 |
Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV.
Topics: Antitubercular Agents; Botswana; HIV Infections; Humans; India; Isoniazid; Latent Tuberculosis; Sout | 2016 |
Pulmonary tuberculosis: Improving diagnosis and management.
Topics: Antitubercular Agents; Disease Management; Humans; Isoniazid; Latent Tuberculosis; Symptom Assessmen | 2016 |
Updates on the risk factors for latent tuberculosis reactivation and their managements.
Topics: Antitubercular Agents; Disease Management; Female; HIV Infections; Humans; Isoniazid; Latent Tubercu | 2016 |
The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.
Topics: Antirheumatic Agents; Antitubercular Agents; Continuity of Patient Care; Humans; Isoniazid; Latent T | 2016 |
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.
Topics: Antitubercular Agents; Global Health; Humans; Incidence; Isoniazid; Latent Tuberculosis; Mycobacteri | 2016 |
Optimizing the management of children with latent tuberculosis infection.
Topics: Antitubercular Agents; Biomarkers; Chemokine CXCL10; Child; Disease Management; Enzyme-Linked Immuno | 2017 |
Tuberculosis (HIV-negative people).
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Low-Level Light Thera | 2009 |
The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Evidence-Based Medicine; Hepatitis B, | 2009 |
Treatment of latent tuberculosis infection in HIV infected persons.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniaz | 2010 |
Treatment of latent tuberculosis infection in HIV infected persons.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniaz | 2010 |
Treatment of latent tuberculosis infection in HIV infected persons.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniaz | 2010 |
Treatment of latent tuberculosis infection in HIV infected persons.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniaz | 2010 |
Treatment of latent tuberculosis infection: An update.
Topics: Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Animals; Antitubercular Agent | 2010 |
Treatment of latent infection with Mycobacterium tuberculosis: update 2010.
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Communicable Disease Control; Drug | 2011 |
Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review.
Topics: Age Factors; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Laten | 2010 |
Tuberculin skin test and isoniazid prophylaxis among health care workers in high tuberculosis prevalence areas.
Topics: Antitubercular Agents; Attitude of Health Personnel; Drug Administration Schedule; Evidence-Based Me | 2011 |
The secret trumps, impelling the pathogenicity of tubercle bacilli.
Topics: Aerosols; Antigen Presentation; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; Cyto | 2011 |
[Treatment of latent tuberculosis infection].
Topics: Antitubercular Agents; Cost of Illness; Drug Combinations; Humans; Incidence; Isoniazid; Latent Tube | 2012 |
Treatment of latent tuberculosis infection in HIV: shorter or longer?
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Drug Administration S | 2012 |
55 trials available for isoniazid and Latent Tuberculosis
| Article | Year |
|---|---|
Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial.
Topics: Antitubercular Agents; China; Follow-Up Studies; Humans; Isoniazid; Latent Tuberculosis; Rural Popul | 2022 |
Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial.
Topics: Adult; Antitubercular Agents; Cohort Studies; Diabetes Mellitus, Type 2; HIV Infections; Humans; Iso | 2022 |
Pregnancy in Women With HIV in a Tuberculosis Preventive Therapy Trial.
Topics: Antitubercular Agents; Contraceptive Agents; Drug Administration Schedule; Drug Therapy, Combination | 2022 |
Comparison of three short-course rifamycin-based regimens for the prevention of tuberculosis in patients with end-stage kidney disease: Study protocol for a randomised clinical trial (RIFAKiD-TB trial).
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Kidney Failure, Chronic; | 2022 |
Tuberculosis preventive treatment among individuals with inactive tuberculosis suggested by untreated radiographic abnormalities: a community-based randomized controlled trial.
Topics: Antitubercular Agents; Humans; Interferon-gamma Release Tests; Isoniazid; Latent Tuberculosis; Tuber | 2023 |
Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Middle Aged; | 2022 |
Protocol for pragmatic randomized clinical trial to evaluate the completion of treatment of latent Mycobacterium tuberculosis infection with Isoniazid in the 300 mg formulation.
Topics: Adolescent; Adult; Antitubercular Agents; Brazil; Humans; Isoniazid; Latent Tuberculosis; Multicente | 2023 |
Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Self Repor | 2023 |
Dynamic changes of interferon gamma release assay results with latent tuberculosis infection treatment.
Topics: Antitubercular Agents; Biomarkers; China; Drug Administration Schedule; Drug Therapy, Combination; F | 2020 |
Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.
Topics: Adult; Antitubercular Agents; Child; Costs and Cost Analysis; Developed Countries; Developing Countr | 2020 |
Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.
Topics: Adult; Antitubercular Agents; Child; Costs and Cost Analysis; Developed Countries; Developing Countr | 2020 |
Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.
Topics: Adult; Antitubercular Agents; Child; Costs and Cost Analysis; Developed Countries; Developing Countr | 2020 |
Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.
Topics: Adult; Antitubercular Agents; Child; Costs and Cost Analysis; Developed Countries; Developing Countr | 2020 |
Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV.
Topics: Female; HIV Infections; Humans; Interferon-gamma; Interferon-gamma Release Tests; Isoniazid; Latent | 2021 |
A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Dose-Response Relationship, Drug; Femal | 2021 |
An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; F | 2021 |
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Topics: Adult; Antitubercular Agents; Child; Drug Therapy, Combination; Female; HIV Infections; Humans; Ison | 2022 |
Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Directly Observed Therapy; Drug Administr | 2017 |
Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Directly Observed Therapy; Drug Administr | 2017 |
Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Directly Observed Therapy; Drug Administr | 2017 |
Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Directly Observed Therapy; Drug Administr | 2017 |
SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Australia; Cost-Benefit | 2017 |
Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.
Topics: Adolescent; Adult; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Administration Sche | 2018 |
Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.
Topics: Adolescent; Adult; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Administration Sche | 2018 |
Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.
Topics: Adolescent; Adult; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Administration Sche | 2018 |
Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.
Topics: Adolescent; Adult; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Administration Sche | 2018 |
Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Cytokines; Drug Administration Schedule; Drug | 2018 |
The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial.
Topics: Adult; Antitubercular Agents; British Columbia; Female; Humans; Isoniazid; Latent Tuberculosis; Male | 2018 |
High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy Trial.
Topics: Antitubercular Agents; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Female; HIV | 2018 |
Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Therapy, Co | 2018 |
Safety and Side Effects of Rifampin versus Isoniazid in Children.
Topics: Adolescent; Antibiotics, Antitubercular; Child; Child, Preschool; Drug Administration Schedule; Fema | 2018 |
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Drug Administration Schedul | 2018 |
Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study.
Topics: Aged; Antibiotics, Antitubercular; China; Communicable Disease Control; Drug Administration Schedule | 2018 |
Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa.
Topics: Adolescent; Adult; Antitubercular Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Int | 2018 |
Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
Topics: Adolescent; Adult; Antitubercular Agents; Chi-Square Distribution; Child; Drug Administration Schedu | 2013 |
Changes in QuantiFERON®-TB Gold In-Tube results during treatment for tuberculous infection.
Topics: Adult; Antitubercular Agents; Brazil; Female; Humans; Interferon-gamma Release Tests; Isoniazid; Lat | 2013 |
Isoniazid therapy for latent tuberculosis in psoriasis patients receiving biological agents: is it safe and efficacious?
Topics: Adult; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Female; Humans; Immunosuppressive A | 2014 |
Serum lipids as biomarkers for therapeutic monitoring of latent tuberculosis infection.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Apolipoproteins A; Apolipopro | 2013 |
Strategy to better select HIV-infected individuals for latent TB treatment in BCG-vaccinated population.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Female; Follow-Up Studies; HIV Infections; Hu | 2013 |
Short-course treatment of latent tuberculosis infection in patients with rheumatic conditions proposed for anti-TNF therapy.
Topics: Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; | 2015 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Topics: Adult; BCG Vaccine; Female; Humans; Immunization, Secondary; Isoniazid; Latent Tuberculosis; Male; S | 2014 |
Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis.
Topics: Adolescent; Adult; Antigens, Bacterial; Bacterial Proteins; Biomarkers; Female; Humans; Hypoxia; Int | 2015 |
Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis.
Topics: Adolescent; Adult; Antigens, Bacterial; Bacterial Proteins; Biomarkers; Female; Humans; Hypoxia; Int | 2015 |
Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis.
Topics: Adolescent; Adult; Antigens, Bacterial; Bacterial Proteins; Biomarkers; Female; Humans; Hypoxia; Int | 2015 |
Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis.
Topics: Adolescent; Adult; Antigens, Bacterial; Bacterial Proteins; Biomarkers; Female; Humans; Hypoxia; Int | 2015 |
Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.
Topics: Allied Health Personnel; Antitubercular Agents; Bacteriological Techniques; Brazil; Coinfection; Cos | 2014 |
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Human | 2015 |
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Human | 2015 |
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Human | 2015 |
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Human | 2015 |
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Human | 2015 |
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Human | 2015 |
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Human | 2015 |
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Human | 2015 |
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Human | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; H | 2015 |
Using a single tablet daily to treat latent tuberculosis infection in Brazil: bioequivalence of two different isoniazid formulations (300 mg and 100 mg) demonstrated by a sensitive and rapid high-performance liquid chromatography-tandem mass spectrometry
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Biological Availability; Chromatography, | 2015 |
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Topics: Adult; Antitubercular Agents; Aspartate Aminotransferases; Brazil; Canada; Case-Control Studies; Che | 2015 |
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Topics: Adult; Antitubercular Agents; Aspartate Aminotransferases; Brazil; Canada; Case-Control Studies; Che | 2015 |
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Topics: Adult; Antitubercular Agents; Aspartate Aminotransferases; Brazil; Canada; Case-Control Studies; Che | 2015 |
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Topics: Adult; Antitubercular Agents; Aspartate Aminotransferases; Brazil; Canada; Case-Control Studies; Che | 2015 |
The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Disease Pr | 2015 |
Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study.
Topics: Adolescent; Adult; Antibody Formation; Antitubercular Agents; Bacterial Proteins; Child; Cytokines; | 2015 |
Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug In | 2016 |
A prospective cohort study of latent tuberculosis in adult close contacts of active pulmonary tuberculosis patients in Korea.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Contact Tracing; Drug Administration Schedule; Femal | 2016 |
Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.
Topics: Adolescent; Adult; Antitubercular Agents; BCG Vaccine; Female; Flow Cytometry; Humans; Immunization, | 2016 |
Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.
Topics: Adolescent; Adult; Antitubercular Agents; BCG Vaccine; Female; Flow Cytometry; Humans; Immunization, | 2016 |
Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.
Topics: Adolescent; Adult; Antitubercular Agents; BCG Vaccine; Female; Flow Cytometry; Humans; Immunization, | 2016 |
Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.
Topics: Adolescent; Adult; Antitubercular Agents; BCG Vaccine; Female; Flow Cytometry; Humans; Immunization, | 2016 |
Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.
Topics: Adolescent; Adult; Antitubercular Agents; BCG Vaccine; Female; Flow Cytometry; Humans; Immunization, | 2016 |
Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.
Topics: Adolescent; Adult; Antitubercular Agents; BCG Vaccine; Female; Flow Cytometry; Humans; Immunization, | 2016 |
Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.
Topics: Adolescent; Adult; Antitubercular Agents; BCG Vaccine; Female; Flow Cytometry; Humans; Immunization, | 2016 |
Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.
Topics: Adolescent; Adult; Antitubercular Agents; BCG Vaccine; Female; Flow Cytometry; Humans; Immunization, | 2016 |
Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.
Topics: Adolescent; Adult; Antitubercular Agents; BCG Vaccine; Female; Flow Cytometry; Humans; Immunization, | 2016 |
Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Female; Follow-Up Studies; Humans; Ill-Hous | 2017 |
Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Brazil; Canada; Female; Follow-Up | 2010 |
Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB.
Topics: Adult; Antibiotics, Antitubercular; Brazil; Canada; Cost-Benefit Analysis; Drug Administration Sched | 2010 |
The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.
Topics: Administration, Oral; Age Factors; Antitubercular Agents; Arylamine N-Acetyltransferase; Child, Pres | 2012 |
Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.
Topics: Adult; Antitubercular Agents; Brazil; Canada; Cost-Benefit Analysis; Decision Support Techniques; Dr | 2011 |
Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Follow-Up Studies; Humans; Interferon-gamma Release | 2012 |
Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Female; Humans; Isoniazid; Latent Tuberculo | 2012 |
Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials.
Topics: Adult; Aged; Antibodies, Monoclonal; Antitubercular Agents; Arthritis; Chemical and Drug Induced Liv | 2013 |
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Case-Contro | 2012 |
Interferon-γ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial.
Topics: Adult; Antitubercular Agents; Biomarkers; Double-Blind Method; Enzyme-Linked Immunospot Assay; Femal | 2013 |
300 other studies available for isoniazid and Latent Tuberculosis
| Article | Year |
|---|---|
Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Bacteria; Cell Line; Cell Survival; Drug Design; Drug Resistance, Mu | 2016 |
Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.
Topics: Animals; Antitubercular Agents; Cell Line; Cyclic N-Oxides; Drug Resistance, Multiple, Bacterial; La | 2016 |
Semi-solid extrusion 3D printing of starch-based soft dosage forms for the treatment of paediatric latent tuberculosis infection.
Topics: Child; Dosage Forms; Drug Liberation; Excipients; Humans; Infant; Isoniazid; Latent Tuberculosis; Pr | 2022 |
Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors.
Topics: Adult; Aged; Antitubercular Agents; Arthritis, Rheumatoid; Female; Hepatitis; Hospitalization; Human | 2021 |
Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Latent Tuberculosis; Mice; Rif | 2021 |
Paediatric management of a tuberculosis outbreak in an Irish Direct Provision Centre.
Topics: Adult; Child; Disease Outbreaks; Humans; Isoniazid; Latent Tuberculosis; Retrospective Studies; Tube | 2022 |
Determinants of latent tuberculosis infection and treatment interruption in long-term care facilities: A retrospective cohort study in Taiwan.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Long-Term | 2022 |
Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases.
Topics: Aged; Antitubercular Agents; Female; Humans; Isoniazid; Latent Tuberculosis; Middle Aged; Retrospect | 2022 |
Multibacillary Mid-Borderline Leprosy with Type 1 Lepra Reaction and Concurrent Latent Tuberculosis.
Topics: Abattoirs; Anti-Inflammatory Agents; Antitubercular Agents; Clofazimine; Dapsone; Diagnosis, Differe | 2021 |
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infect | 2021 |
Tuberculosis Infection in Children and Adolescents: Testing and Treatment.
Topics: Adolescent; Age Factors; Antitubercular Agents; BCG Vaccine; Child; Child, Preschool; Cross Reaction | 2021 |
Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection.
Topics: Antitubercular Agents; Drug Interactions; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuber | 2022 |
Whole-Blood 3-Gene Signature as a Decision Aid for Rifapentine-based Tuberculosis Preventive Therapy.
Topics: Antitubercular Agents; Decision Support Techniques; Drug Therapy, Combination; Drug-Related Side Eff | 2022 |
Effect of implementation of a 12-dose once-weekly treatment (3HP) in addition to standard regimens to prevent TB on completion rates: Interrupted time series design.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Interrupted Time Series Analysis; I | 2022 |
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection.
Topics: Antibodies, Monoclonal, Humanized; Humans; Isoniazid; Latent Tuberculosis; Psoriasis; Retrospective | 2022 |
Isoniazid prophylaxis in liver transplant recipient with latent tuberculosis: Is it harmful for transplanted liver?
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Liver; Liver Transplantation; Retrosp | 2022 |
Effect of different interventions for latent tuberculosis infections in China: a model-based study.
Topics: Adolescent; Aged; Antitubercular Agents; China; Humans; Incidence; Isoniazid; Latent Tuberculosis; T | 2022 |
Latent Tuberculosis Cascade of Care Among Healthcare Workers: A Nationwide Cohort Analysis in Korea Between 2017 and 2018.
Topics: Adult; Antitubercular Agents; Cohort Studies; Health Personnel; Humans; Isoniazid; Latent Tuberculos | 2022 |
Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs.
Topics: Animals; Antitubercular Agents; Isoniazid; Latent Tuberculosis; Lung; Macaca mulatta; Mycobacterium | 2022 |
Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010-2016.
Topics: Antitubercular Agents; Canada; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis; R | 2022 |
Effectiveness and safety of available preventive tuberculosis treatment regimens for children and adolescents: protocol for a systematic review and network meta-analysis.
Topics: Adolescent; Child; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Network Meta-Analysis; Sy | 2022 |
Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: A population pharmacokinetic analysis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; H | 2023 |
A world without tuberculosis: moving from imagination to reality.
Topics: Animals; Imagination; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis; Tuberculosis | 2022 |
Tuberculosis: Common Questions and Answers.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Latent Tuberculosis; Pyrazinamide; Rifampin; T | 2022 |
Tuberculosis screening after detection of a case in a paediatric haemato-oncology unit in a low prevalence country.
Topics: Adult; Antitubercular Agents; Child; Humans; Isoniazid; Latent Tuberculosis; Prevalence; Tuberculosi | 2022 |
Management of tuberculosis infection in Victorian children: A retrospective clinical audit of factors affecting treatment completion.
Topics: Adolescent; Antitubercular Agents; Child; Clinical Audit; Drug-Related Side Effects and Adverse Reac | 2022 |
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Body Weight; Drug Therapy, Combination; | 2023 |
Implementation of an integrated care strategy for child contacts of tuberculosis patients: a quasi-experimental study protocol.
Topics: Child; Child, Preschool; Delivery of Health Care, Integrated; Humans; Isoniazid; Latent Tuberculosis | 2023 |
Prevalence of latent tuberculosis infection and incidence of tuberculin conversion among school contacts older than 5 years in the City of Buenos Aires.
Topics: Adolescent; Child; Humans; Incidence; Isoniazid; Latent Tuberculosis; Prevalence; Tuberculin; Tuberc | 2023 |
Introduction of short course treatment for latent tuberculosis infection at a primary care facility for refugees in Winnipeg, Canada: A mixed methods evaluation.
Topics: Canada; Humans; Isoniazid; Latent Tuberculosis; Middle Aged; Primary Health Care; Refugees; Retrospe | 2022 |
Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; | 2023 |
Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection.
Topics: Antitubercular Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; F | 2023 |
Progress on diagnosis and treatment of latent tuberculosis infection.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2022 |
Variation in Treatment of Pediatric Tuberculosis Infection in Different Provider Settings.
Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Humans; Infant; Isoniazid; Latent Tuberculo | 2023 |
Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Male; Tube | 2023 |
Alternative dolutegravir dosing strategies with concurrent rifapentine utilized for latent tuberculosis treatment.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; | 2023 |
Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Infant; Infant, N | 2019 |
Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older.
Topics: Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Interferon-gamma Release Tes | 2019 |
Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea: A multicentre cohort analysis.
Topics: Adult; Aged; Antitubercular Agents; Asian People; Female; Health Personnel; Humans; Interferon-gamma | 2019 |
Determinants of Latent Tuberculosis Treatment Acceptance and Completion in Healthcare Personnel.
Topics: Antitubercular Agents; Delivery of Health Care; Health Personnel; Humans; Isoniazid; Latent Tubercul | 2020 |
Isoniazid and Rifapentine Treatment Eradicates Persistent
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; L | 2020 |
Mania induced by isoniazid preventive therapy during steroid treatment for rheumatoid arthritis and organising pneumonia.
Topics: Aged, 80 and over; Antitubercular Agents; Arthritis, Rheumatoid; Bipolar Disorder; Female; Humans; I | 2019 |
Nonparticipation reasons in a randomized international trial of a new latent tuberculosis infection regimen.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Clinical Trials, Phase III as Top | 2020 |
Modeling Treatment of Latent Tuberculosis: Shortening the Leap of Faith?
Topics: Animals; Isoniazid; Latent Tuberculosis; Macaca; Mycobacterium tuberculosis; Rifampin | 2020 |
No evidence of increased risk of acquired rifampin resistance.
Topics: Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis; Rifampin | 2019 |
Clinical Characteristics of Active Tuberculosis Diagnosed After Starting Treatment for Latent Tuberculosis Infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Rifampin; Tuberculosis | 2020 |
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
Topics: Adult; Africa; Americas; Antitubercular Agents; Asia; Australia; Clinical Trials, Phase II as Topic; | 2020 |
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
Topics: Adult; Africa; Americas; Antitubercular Agents; Asia; Australia; Clinical Trials, Phase II as Topic; | 2020 |
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
Topics: Adult; Africa; Americas; Antitubercular Agents; Asia; Australia; Clinical Trials, Phase II as Topic; | 2020 |
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
Topics: Adult; Africa; Americas; Antitubercular Agents; Asia; Australia; Clinical Trials, Phase II as Topic; | 2020 |
What is the best regimen to treat latent tuberculosis infection?
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Humans; Isoniazid; Latent Tuberculosis; | 2020 |
Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid.
Topics: Adult; Antitubercular Agents; Biomarkers; Female; Gene Expression; Humans; Interferon-gamma Release | 2019 |
Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Cytochrome P-450 Enzyme System; Drug Ad | 2019 |
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs.
Topics: Antitubercular Agents; Canada; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; | 2020 |
Access and adherence to isoniazid preventive therapy and occurrence of active TB in a cohort of people living with HIV: a retrospective cohort study in Sao Paulo, Brazil.
Topics: Adult; Antitubercular Agents; Brazil; Cohort Studies; Female; HIV Infections; Humans; Isoniazid; Lat | 2020 |
Addressing Latent Tuberculosis Infection Treatment Through a Collaborative Care Model With Community Pharmacies and a Health Department.
Topics: Adult; Antibiotics, Antitubercular; Drug Therapy, Combination; Feasibility Studies; Female; Humans; | 2020 |
Trends in diagnostic methods and treatment of latent tuberculosis infection in a tertiary care center from 2000 to 2017.
Topics: Adult; Aged; Antitubercular Agents; Female; Follow-Up Studies; Humans; Interferon-gamma Release Test | 2020 |
Determinants of losses in the latent tuberculosis cascade of care in Brazil: A retrospective cohort study.
Topics: Adult; Age Factors; Antitubercular Agents; Brazil; Cohort Studies; Contact Tracing; Delivery of Heal | 2020 |
Latent tuberculosis infection in children and adolescents in Russia.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Humans; Incidence; Infant; Infant, Newbo | 2020 |
Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries.
Topics: Antitubercular Agents; China; Humans; Incidence; Interferon-gamma Release Tests; Isoniazid; Latent T | 2020 |
Cost-effectiveness of IGRA/QFT-Plus for TB screening of migrants in Oman.
Topics: Cost-Benefit Analysis; Female; Humans; Interferon-gamma Release Tests; Isoniazid; Latent Tuberculosi | 2020 |
Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection-United States, 2012-2016.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; L | 2020 |
New guidelines for latent tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Child; Clinical Trials as Topic; Drug Therapy, Combination; Guid | 2020 |
Comparison of single and dual latent tuberculosis screening strategies before biologic and targeted therapy in patients with rheumatic diseases: a retrospective cohort study.
Topics: Adult; Aged; Biological Products; Female; Humans; Incidence; Infliximab; Interferon-gamma Release Te | 2020 |
Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Age | 2020 |
Trials of Tuberculosis-Preventive Therapy in People with HIV Infection.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Latent Tuberculosi | 2020 |
Reply to Swindells
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2020 |
Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
Topics: Adult; Alanine Transaminase; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Adm | 2020 |
Advantage in privacy protection by using synchronous video observed treatment enhances treatment adherence among patients with latent tuberculosis infection.
Topics: Adolescent; Adult; Antitubercular Agents; Directly Observed Therapy; Female; Humans; Isoniazid; Late | 2020 |
Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-A prospective observational study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; In | 2020 |
A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Female; HIV Infections; Humans; Incidence; Intersec | 2020 |
Acute kidney injury: an unexpected Isoniazid-related adverse event in a patient with Crohn's disease receiving prophylactic treatment for latent tuberculosis.
Topics: Acute Kidney Injury; Aged; Crohn Disease; Humans; Isoniazid; Latent Tuberculosis; Male; Tumor Necros | 2020 |
Awareness and perspectives on expansion of latent TB management among public-sector physicians and medical trainees in Delhi, India.
Topics: Adult; Antitubercular Agents; Attitude of Health Personnel; Clinical Competence; Cross-Sectional Stu | 2020 |
Human mesenchymal stem cell based intracellular dormancy model of Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; Bone | 2020 |
Simplifying Rifapentine Dosing for Tuberculosis Treatment and Prevention.
Topics: Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2020 |
Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; Counse | 2020 |
Use of Rifampin Compared with Isoniazid for the Treatment of Latent Tuberculosis Infection in Japan: A Bayesian Inference with Markov Chain Monte Carlo Method.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bayes Theorem; Drug Administration Schedule; | 2020 |
Bayesian Modeling Method for an Observational Data Analysis.
Topics: Bayes Theorem; Data Analysis; Humans; Isoniazid; Japan; Latent Tuberculosis; Markov Chains; Monte Ca | 2020 |
Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antitubercular Agents; BCG Vaccine; Co | 2020 |
Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Therapy, Combination; Humans; Isonia | 2021 |
Programmatic Effectiveness of Latent Tuberculosis Care Cascade in a Community Health Center.
Topics: Antitubercular Agents; Community Health Centers; Humans; Isoniazid; Latent Tuberculosis; Retrospecti | 2021 |
Determination of tuberculin skin test for isoniazid prophylaxis in BCG vaccinated children who are using anti-TNF agents for rheumatologic diseases.
Topics: Adolescent; Antibiotic Prophylaxis; Antitubercular Agents; Arthritis, Rheumatoid; BCG Vaccine; Child | 2020 |
Latent Tuberculosis Therapy Outcomes in Dialysis Patients: A Retrospective Cohort.
Topics: Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cohort Studies; Exanthema; Fema | 2021 |
Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients.
Topics: Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Arthritis, Psoriatic; Arthritis, Rheumatoi | 2020 |
Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; | 2021 |
Estimated Population-Level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Rifampin; | 2020 |
Treatment of latent tuberculosis infection in patients receiving biologic agents.
Topics: Antitubercular Agents; Biological Factors; Humans; Isoniazid; Japan; Latent Tuberculosis; Retrospect | 2021 |
Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
Topics: Anti-HIV Agents; Antitubercular Agents; Cost-Benefit Analysis; Drug Administration Schedule; Drug Th | 2020 |
Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.
Topics: Aged; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Midd | 2021 |
Safety of secukinumab in psoriasis patients with latent tuberculosis infection.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Contraindications, Drug; Dermatologi | 2020 |
Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Infant; Insurance | 2020 |
Inhibition of ABCG2 efflux pumps renders the Mycobacterium tuberculosis hiding in mesenchymal stem cells responsive to antibiotic treatment.
Topics: Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Bac | 2021 |
Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Isoniazid; Latent T | 2021 |
Tele-TB: Using TeleMedicine to Increase Access to Directly Observed Therapy for Latent Tuberculosis Infection.
Topics: Antitubercular Agents; Child, Preschool; Directly Observed Therapy; Humans; Isoniazid; Latent Tuberc | 2021 |
Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda.
Topics: Adult; Decision Making; Directly Observed Therapy; Female; HIV Infections; Humans; Isoniazid; Latent | 2021 |
[Isoniazid-inducedtoxic hepatitis].
Topics: Adult; Antitubercular Agents; Hepatitis; Humans; Isoniazid; Latent Tuberculosis; Male | 2021 |
Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients With Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study.
Topics: Aged; Antitubercular Agents; Diabetes Mellitus; Drug Therapy, Combination; Humans; Isoniazid; Latent | 2021 |
Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Infection; Latent Tuberculosis; Tuberculin Test; Tu | 2021 |
[Treatment outcome of latent tuberculosis infection in persons with fibrotic pulmonary lesions].
Topics: Aged; Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Rifampin; Tr | 2021 |
Low uptake of isoniazid window prophylaxis in patients exposed to a health-care worker with pulmonary tuberculosis in a paediatric ward.
Topics: Child; Child, Preschool; Humans; Infant; Interferon-gamma Release Tests; Isoniazid; Latent Tuberculo | 2021 |
Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.
Topics: Antitubercular Agents; Canada; Cost-Benefit Analysis; Humans; Isoniazid; Latent Tuberculosis; Rifamp | 2021 |
Seven-year retrospective study understanding the latent TB infection treatment cascade of care among adults in a low incidence country.
Topics: Adult; Aged; Antitubercular Agents; Canada; Female; Humans; Incidence; Isoniazid; Latent Tuberculosi | 2021 |
Prevalence of latent tuberculosis in patients with hematological neoplasms in a cancer referral hospital in Mexico City.
Topics: Adult; Antitubercular Agents; Cancer Care Facilities; Female; Hematologic Neoplasms; Humans; Isoniaz | 2021 |
An observational study on prevalence of latent tuberculosis infection and outcome of 3HP treatment in patients under hemodialysis in Taiwan.
Topics: Antitubercular Agents; Drug Therapy, Combination; Follow-Up Studies; Humans; Isoniazid; Latent Tuber | 2021 |
Topics: Cross-Sectional Studies; DNA; Ethiopia; HeLa Cells; HIV Infections; Humans; Hydrogen Peroxide; Isoni | 2021 |
High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; China; Drug Administration Schedule; Dru | 2021 |
Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates.
Topics: Adult; Azathioprine; BCG Vaccine; Humans; Isoniazid; Latent Tuberculosis; Male; Prednisolone; Reprod | 2022 |
Half-and-half nails in a patient on antituberculosis treatment.
Topics: Antitubercular Agents; Female; Humans; Isoniazid; Latent Tuberculosis; Nail Diseases; Young Adult | 2017 |
QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Diagnostic Tests, Routine; Disease Transmission, Inf | 2017 |
Treatment of latent tuberculosis infections in the Darwin region.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Infant; Inf | 2017 |
Use of Video Directly Observed Therapy for Treatment of Latent Tuberculosis Infection - Johnson County, Kansas, 2015.
Topics: Antitubercular Agents; Contact Tracing; Directly Observed Therapy; Humans; Isoniazid; Kansas; Latent | 2017 |
Biologic treatments for elderly patients with psoriasis.
Topics: Adalimumab; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Biological Products; Cerebr | 2017 |
Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting.
Topics: Aged; Antitubercular Agents; Biological Products; Dermatologic Agents; Female; Follow-Up Studies; Hu | 2017 |
High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool | 2017 |
Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area.
Topics: Adolescent; Adult; Aged; Antibiotic Prophylaxis; Antitubercular Agents; Child; Child, Preschool; Fem | 2017 |
Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
Topics: Antitubercular Agents; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2017 |
Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders - A retrospective cohort study in Taiwan.
Topics: Adult; Aged; Antitubercular Agents; Female; Humans; Immunocompromised Host; Incidence; Inflammation; | 2018 |
Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Female; Humans; Incidence; Interferon-gamma R | 2017 |
Prospective cohort study of the feasibility and yield of household child tuberculosis contact screening in Uganda.
Topics: Algorithms; Antitubercular Agents; Child, Preschool; Cohort Studies; Contact Tracing; Cough; Feasibi | 2017 |
Protein kinase G confers survival advantage to
Topics: Amino Acid Motifs; Amino Acid Substitution; Animals; Antibiotics, Antitubercular; Antigens, Bacteria | 2017 |
Costs of providing tuberculosis diagnosis and treatment services in Viet Nam.
Topics: Adult; Antitubercular Agents; Child; Costs and Cost Analysis; Health Facilities; Humans; Isoniazid; | 2017 |
Use of Rifapentine and Isoniazid Directly Observed Therapy for the Treatment of Latent Tuberculosis Infection in a Military Clinic.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Antitubercular Agents; Directly Observed Therapy; Fem | 2017 |
Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature.
Topics: Adrenal Cortex Hormones; Adult; Antitubercular Agents; Female; Humans; Isoniazid; Latent Tuberculosi | 2017 |
Assessment and management of active and latent TB.
Topics: Antitubercular Agents; Contact Tracing; Humans; Isoniazid; Latent Tuberculosis; Mass Screening; Prac | 2016 |
Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
Topics: Adult; Antitubercular Agents; Disease Management; Drug Therapy, Combination; Female; Health Personne | 2017 |
Child With a Serpinginous Structure in the Bowel.
Topics: Alanine Transaminase; Albendazole; Animals; Anthelmintics; Ascariasis; Ascaris lumbricoides; Asparta | 2017 |
Case of lichenoid-lichen scrofulosorum: A rare variety of lichen scrofulosorum mimicking lichen planus in an elderly patient.
Topics: Aged, 80 and over; Antitubercular Agents; Biopsy; Diagnosis, Differential; Humans; Isoniazid; Latent | 2018 |
Latent tuberculosis in childhood: tolerability of two different therapeutic approaches.
Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 2018 |
QuantiFERON-TB Gold In-Tube Test in the Diagnosis of Latent Tuberculosis Infection in Arthritis Patients Treated with Tumor Necrosis Factor Antagonists.
Topics: Analysis of Variance; Antirheumatic Agents; Antitubercular Agents; Arthritis, Infectious; Biological | 2017 |
Effect of Antituberculous Therapy on Uveitis Associated With Latent Tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; | 2018 |
Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis.
Topics: Aged; Antitubercular Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Drug Therapy, Comb | 2018 |
National position statement for the management of latent tuberculosis infection.
Topics: Antitubercular Agents; Australia; Chemoprevention; Communicable Disease Control; Disease Notificatio | 2017 |
A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
Topics: Adult; Antirheumatic Agents; Antitubercular Agents; Biological Therapy; Female; Gastrointestinal Age | 2018 |
Minimal change disease related to rifampicin presenting with acute renal failure during treatment for latent tuberculosis infection: A case report.
Topics: Acute Kidney Injury; Antitubercular Agents; Female; Glucocorticoids; Humans; Isoniazid; Latent Tuber | 2018 |
New and Noteworthy in Tuberculosis Diagnostics and Treatment.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; | 2018 |
Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, C | 2019 |
Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
Topics: Adolescent; Antibiotics, Antitubercular; Centers for Disease Control and Prevention, U.S.; Child; Ch | 2018 |
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.
Topics: Adolescent; Adult; Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Liber | 2018 |
Tuberculosis Screening in Patients with Psoriasis Receiving Biologic Therapy: A Retrospective Cohort Study.
Topics: Adult; Aged; Antitubercular Agents; Biological Products; Chemoprevention; Female; Humans; Isoniazid; | 2018 |
Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support.
Topics: Adult; Antitubercular Agents; Brazil; Cost Savings; Directly Observed Therapy; Female; Humans; Isoni | 2018 |
Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cost-Benefit Analysis; Decision Support Techniques; | 2019 |
Treatment of latent tuberculous infection among health care workers at a tertiary hospital in Korea.
Topics: Adult; Antibiotics, Antitubercular; Drug Administration Schedule; Drug Therapy, Combination; Female; | 2018 |
Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Late | 2019 |
Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Child, Preschool; Female; | 2018 |
Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Data Collection; Directly Observed Therapy | 2018 |
New short regimens for latent tuberculosis treatment: safety first!
Topics: Aged; Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2018 |
[TREATMENT OF LATENT TUBERCULOSIS INFECTION WITH A COMBINATION OF ISONIAZID AND RIFAMPICIN].
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Drug Therapy, Combination; Humans; Infant; Infant, | 2016 |
[FREQUENCY AND RISK FACTORS OF SEVERE LIVER DYSFUNCTION IN ISONIAZID MONO-THERAPY FOR LATENT TUBERCULOSIS INFECTION].
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Laten | 2016 |
Isoniazid preventive therapy for children in sub-Saharan Africa.
Topics: Africa South of the Sahara; Antitubercular Agents; Chemoprevention; Child; Disease Progression; HIV | 2019 |
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly.
Topics: Aged; Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2019 |
Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
Topics: Adult; Aged; Antitubercular Agents; Chemoprevention; Female; Humans; Inflammatory Bowel Diseases; In | 2019 |
Screening and treatment for tuberculosis in a cohort of unaccompanied minor refugees in Berlin, Germany.
Topics: Adolescent; Berlin; Chemoprevention; Female; Germany; Hepatitis B; Humans; Isoniazid; Latent Tubercu | 2019 |
High risk for latent tuberculosis infection among medical residents and nursing students in India.
Topics: Adult; Antitubercular Agents; Cohort Studies; Female; Humans; Incidence; India; Interferon-gamma Rel | 2019 |
Latent tuberculosis treatment completion rates from prescription drug administrative data.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Child; Child, Preschool; Databases, Fac | 2019 |
Severe psoriasis entering remission after treatment for latent tuberculosis with isoniazid: Report of two cases.
Topics: Aged; Antitubercular Agents; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Psor | 2019 |
Immigrants with latent tuberculosis infection: a moving target?
Topics: Antitubercular Agents; Emigrants and Immigrants; Female; Humans; Isoniazid; Latent Tuberculosis; Mal | 2013 |
Acute groove pancreatitis due to isoniazid.
Topics: Aged; Antitubercular Agents; Female; Humans; Isoniazid; Latent Tuberculosis; Pancreatitis; Tomograph | 2013 |
Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cost-Benefit Analy | 2013 |
Hypoglycaemia due to interaction of glimepiride with isoniazid in a patient with type 2 diabetes mellitus.
Topics: Aged; Antitubercular Agents; Diabetes Mellitus, Type 2; Drug Interactions; Female; Humans; Hypoglyce | 2013 |
Isoniazid preventive treatment: predictors of adverse events and treatment completion.
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; Databases, Factual; Feasibility Studies; Fema | 2013 |
Isoniazid toxicity in a 5-year-old boy.
Topics: Abdominal Pain; Antitubercular Agents; Child, Preschool; Diagnosis, Differential; Humans; Isoniazid; | 2013 |
Latent tuberculosis infection: screening and treatment in an urban setting.
Topics: Adult; Antitubercular Agents; Coinfection; Connecticut; Directly Observed Therapy; Emigrants and Imm | 2013 |
Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice | 2013 |
Reactivation of latent tuberculosis in a Crohn's patient after TB prophylaxis treated with adalimumab.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Ant | 2013 |
Completion rates of treatment for latent tuberculosis infection in Quebec, Canada from 2006 to 2010.
Topics: Adult; Aged; Antitubercular Agents; Databases, Factual; Female; Humans; Isoniazid; Latent Tuberculos | 2013 |
Tumor necrosis factor, tuberculosis, testing, and treatment: teeing up the questions.
Topics: Arthritis, Rheumatoid; Decision Support Techniques; Female; Humans; Isoniazid; Latent Tuberculosis; | 2013 |
Prophylaxis for latent tuberculosis infection prior to anti–tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Arthritis, Rheumatoid; Decision Support Techn | 2013 |
Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.
Topics: Adult; Alcohol Drinking; Antitubercular Agents; Canada; Female; Humans; Isoniazid; Latent Tuberculos | 2013 |
Understanding of latent tuberculosis, its treatment and treatment side effects in immigrant and refugee patients.
Topics: Adolescent; Adult; Antitubercular Agents; Australia; Communication Barriers; Emigrants and Immigrant | 2013 |
High rate of completion of preventive therapy for latent tuberculosis infection among asylum seekers in a Swiss Canton.
Topics: Adult; Africa; Antitubercular Agents; Asia; Balkan Peninsula; Chemoprevention; Cohort Studies; Femal | 2013 |
Isolated ocular Jarisch-Herxheimer reaction after initiating tuberculostatic therapy in a child.
Topics: Antitubercular Agents; Child; Female; Humans; Isoniazid; Latent Tuberculosis; Macular Edema | 2014 |
Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.
Topics: Antipsychotic Agents; Antitubercular Agents; Colony Count, Microbial; Computer Simulation; Drug Admi | 2013 |
[Papilledema secondary to tuberculous meningitis in a patient with type 1 diabetes mellitus].
Topics: Adult; Antitubercular Agents; Atrophy; Cerebrospinal Fluid; Developing Countries; Diabetes Mellitus, | 2013 |
Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Chemoprevention; Drug-Related | 2013 |
House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study.
Topics: Adolescent; Adult; Antitubercular Agents; California; Child; Community Health Workers; Drug Administ | 2013 |
Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Directly Observed Therap | 2014 |
Cost-effectiveness of treating latent tuberculous infection: a step towards elimination?
Topics: Antitubercular Agents; Drug Costs; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2013 |
Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
Topics: Antitubercular Agents; Computer Simulation; Cost-Benefit Analysis; Directly Observed Therapy; Drug A | 2013 |
Risk for tuberculosis in child contacts. Development and validation of a predictive score.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Child; Child, Preschool; Contact Tracing; Early Diagn | 2014 |
Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing.
Topics: Adaptive Immunity; Animals; Disease Progression; Granuloma; Isoniazid; Latent Tuberculosis; Lung; Ma | 2014 |
Successful rifampin desensitization in a pediatric patient with latent tuberculosis.
Topics: Child; Clinical Protocols; Contraindications; Desensitization, Immunologic; Diphenhydramine; Drug Do | 2014 |
Multi-functional flow cytometry analysis of CD4+ T cells as an immune biomarker for latent tuberculosis status in patients treated with tumour necrosis factor (TNF) antagonists.
Topics: Adult; Aged; Antigens, Bacterial; Antitubercular Agents; Biomarkers; CD4-Positive T-Lymphocytes; Cyt | 2014 |
Risk factors for treatment default in close contacts with latent tuberculous infection.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Canada; Chi-Square Distribution; Contact Tracing; Fe | 2014 |
Tuberculin skin test reversion following isoniazid preventive therapy reflects diversity of immune response to primary Mycobacterium tuberculosis infection.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Immune System; In | 2014 |
A 52-year-old woman with a positive tuberculin skin test.
Topics: Antitubercular Agents; Canada; Emigrants and Immigrants; Female; Humans; Isoniazid; Latent Tuberculo | 2014 |
Successful management of latent tuberculosis infection in an underserved community by a student-run free clinic.
Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Medication Adher | 2014 |
Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Biolog | 2014 |
Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices.
Topics: Antitubercular Agents; Drug Costs; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2014 |
Comparison of QuantiFERON-TB gold in-tube test with tuberculin skin test in children who had no contact with active tuberculosis case.
Topics: Adolescent; Antitubercular Agents; BCG Vaccine; Child; Child, Preschool; False Positive Reactions; F | 2014 |
Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Administration Schedule; Fem | 2014 |
Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Autoimmune Diseases; Female; Humans; Inte | 2014 |
LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area.
Topics: Adult; Antitubercular Agents; Arthritis, Rheumatoid; Female; Follow-Up Studies; Humans; Immunologic | 2014 |
Isoniazid induces apoptosis of activated CD4+ T cells: implications for post-therapy tuberculosis reactivation and reinfection.
Topics: Animals; Antitubercular Agents; Apoptosis; CD4-Positive T-Lymphocytes; Cell Proliferation; Cytokines | 2014 |
PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Isoniazid; Latent Tuberculosis; Lung | 2014 |
Cost-effectiveness of 12-dose LTBI regimen improved following advocacy to lower the price of rifapentine.
Topics: Antitubercular Agents; Drug Costs; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2014 |
Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relat | 2014 |
Isoniazid preventive therapy in medium-incidence settings: the price is right.
Topics: Antitubercular Agents; Coinfection; Drug Costs; HIV Infections; Humans; Isoniazid; Latent Tuberculos | 2014 |
Evaluating the role of primary care physicians in the treatment of latent tuberculosis: a population study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chi-Square Distribution; Child; C | 2014 |
Latent tuberculous infection in the United States and Canada: who completes treatment and why?
Topics: Adolescent; Adult; Canada; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; | 2015 |
Tuberculosis: which drug regimen and when.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Directly Observed Therapy; Drug Thera | 2015 |
Twelve-dose drug regimen now also an option for preventing tuberculosis in children and adolescents.
Topics: Antitubercular Agents; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Rifampin | 2015 |
Comparison of LTBI treatment regimens for patients receiving anti-tumour necrosis factor therapy.
Topics: Adult; Antibiotics, Antitubercular; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Is | 2015 |
[A positive test QuantiFERON-TB Gold In-Tube in a patient treated with continuous ambulatory peritoneal dialysis].
Topics: Aged; Antitubercular Agents; Drug Administration Schedule; Female; Humans; Isoniazid; Kidney Failure | 2014 |
[Development of eosinophilic pneumonia in a patient with latent tuberculosis infection resulting from isoniazid].
Topics: Adult; Antitubercular Agents; Biopsy; Humans; Isoniazid; Latent Tuberculosis; Male; Pulmonary Eosino | 2014 |
Follow-up results of isoniazid chemoprophylaxis during biological therapy in Colombia.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Autoimmune Diseases; Biological Products; Chemopreve | 2015 |
Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Hospitalization; Humans; Isoniazid; L | 2015 |
Cost of nurse-managed latent tuberculous infection treatment among hard-to-reach immigrants in Israel.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Antitubercular Agents; Child; Child, Preschool; Commu | 2015 |
Intermittent Short Course Rifapentine-Isoniazid Combination for Preventing Tuberculosis in Children: Evidence based Medicine Viewpoint.
Topics: Antitubercular Agents; Female; Humans; Isoniazid; Latent Tuberculosis; Male; Rifampin | 2015 |
Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclon | 2015 |
Treatment of latent tuberculosis infection induces changes in multifunctional Mycobacterium tuberculosis-specific CD4+ T cells.
Topics: Adult; Aged; Antitubercular Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokine | 2016 |
Tuberculosis preventive chemotherapy: the times they are a-changin'.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Latent Tub | 2015 |
Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Female; HIV Infecti | 2015 |
Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Directly Observed Therapy; Female; Humans; | 2016 |
Latent Mycobacterium tuberculosis Infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis | 2015 |
Latent Mycobacterium tuberculosis Infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis | 2015 |
Latent Mycobacterium tuberculosis Infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis | 2015 |
Latent Mycobacterium tuberculosis Infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis | 2015 |
Latent Mycobacterium tuberculosis Infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis | 2015 |
Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.
Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 2021 |
Benefit of treatment of latent tuberculosis infection in individual patients.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Femal | 2015 |
Outbreak of isoniazid-resistant tuberculosis in an immigrant community in Spain.
Topics: Adult; Antitubercular Agents; BCG Vaccine; Bolivia; Contact Tracing; Disease Outbreaks; Emigrants an | 2016 |
Policy recommendation: latent tuberculosis infection screening and treatment in children in immigration detention.
Topics: Adolescent; Antitubercular Agents; Australia; Biological Assay; Child; Child, Preschool; Epidemiolog | 2015 |
Latent Tuberculosis Infection and the Risk of Subsequent Cancer.
Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Female; Humans; Isoniazid; Latent Tubercul | 2016 |
Tolerability and Healthcare Utilization in Maintenance Hemodialysis Patients Undergoing Treatment for Tuberculosis-Related Conditions.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Cohort Studies; Emergency Medical Services; F | 2016 |
Factors associated with treatment for latent tuberculosis in persons living with HIV/AIDS.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; | 2015 |
Monitoring latent tuberculosis infection diagnosis and management in the Netherlands.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Communicable Disease Contro | 2016 |
Editorial Commentary: Do We Have Strategies to Improve the Preventive Treatment of Latent Tuberculosis Infection?
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Tuberculosis | 2016 |
Non-completion of latent tuberculous infection treatment among children in Rio de Janeiro State, Brazil.
Topics: Antitubercular Agents; Brazil; Child; Disease Progression; Female; Follow-Up Studies; Humans; Incide | 2016 |
Undocumented Immigrants Face a Unique Set of Risks from Tuberculosis Treatment: Is This Just?
Topics: Antitubercular Agents; Ethical Analysis; Health Services Accessibility; Humans; Isoniazid; Latent Tu | 2016 |
Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia.
Topics: Adult; Aged; Antitubercular Agents; Colombia; Female; Humans; Immunosuppressive Agents; Isoniazid; L | 2016 |
Benefit of treatment of latent tuberculosis infection in individual patients.
Topics: Humans; Isoniazid; Latent Tuberculosis; Tuberculosis | 2016 |
Abandonment of Treatment for Latent Tuberculosis Infection and Socioeconomic Factors in Children and Adolescents: Rio De Janeiro, Brazil.
Topics: Adolescent; Antitubercular Agents; Brazil; Child; Child, Preschool; Female; Humans; Infant; Isoniazi | 2016 |
Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Gas Chromatography-Mass Spectrometry; Hair; | 2016 |
Adalimumab-Receiving Ulcerative Colitis Patient Suffered Latent Tuberculosis Reactivation Despite Correct Chemoprophylaxis and was Successfully Treated while on Anti-Tumour Necrosis Factor Therapy.
Topics: Adalimumab; Anti-Inflammatory Agents; Antitubercular Agents; Colitis, Ulcerative; Humans; Isoniazid; | 2016 |
A Step toward Tuberculosis Elimination in a Low-Incidence Country: Successful Diagnosis and Treatment of Latent Tuberculosis Infection in a Refugee Clinic.
Topics: Adolescent; Adult; Alberta; Ambulatory Care; Antitubercular Agents; Canada; Child; Disease Eradicati | 2016 |
Donor-derived tuberculosis (TB): isoniazid-resistant TB transmitted from a lung transplant donor with inadequately treated latent infection.
Topics: Adult; Allografts; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antitubercular Agents; Bacteremia; | 2016 |
Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
Topics: Adult; Aged; Antitubercular Agents; Biomarkers; Chemical and Drug Induced Liver Injury; Choice Behav | 2017 |
Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cost-Benefit Analysis; Directly Observed Therapy; Dr | 2016 |
From the Cover: Characterization of Isoniazid-Specific T-Cell Clones in Patients with anti-Tuberculosis Drug-Related Liver and Skin Injury.
Topics: Adolescent; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clone Cells; Female | 2017 |
Resistance to First-Line Antituberculosis Drugs in Washington State by Region of Birth and Implications for Latent Tuberculosis Treatment Among Foreign-Born Individuals.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Child, Preschool; Drug Res | 2017 |
Tuberculosis clinical units improve contact tracing.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Contact Tracing; Female; Fo | 2016 |
Screening and Treatment of Latent Tuberculosis Among Patients Receiving Biologic Agents: A National and International Survey of Rheumatologists.
Topics: Antitubercular Agents; Attitude of Health Personnel; Biological Products; Female; Humans; Interferon | 2017 |
Efficacy and safety of short-term treatment with isoniazid and rifampicin for latent tuberculosis infection in lung transplant candidates.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Female; Follow-Up Studies; Humans; Isoniazid; La | 2017 |
Severe hypertension after initiation of rifapentine/isoniazid for latent tuberculosis in renal transplant candidates.
Topics: Adult; Aged; Antitubercular Agents; Blood Pressure; Cohort Studies; Drug Therapy, Combination; Human | 2017 |
Takayasu's Arteritis with Isolated Pulmonary Artery Involvement in a Middle-Aged Asian Woman with Hepatitis B and Latent Tuberculosis Infection.
Topics: Angiography, Digital Subtraction; Antitubercular Agents; Antiviral Agents; Azathioprine; Female; Flu | 2017 |
Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
Topics: Adult; Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Directly Observed Th | 2017 |
The tuberculosis taboo.
Topics: Antitubercular Agents; Contact Tracing; Drug Therapy, Combination; Global Health; Humans; Isoniazid; | 2017 |
Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
Topics: Adult; Aged; Antibiotics, Antitubercular; Directly Observed Therapy; Drug Therapy, Combination; Fema | 2017 |
Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy.
Topics: Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Female; Humans; Iso | 2018 |
Adherence to treatment of latent tuberculosis infection in a clinical population in New York City.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Female; Humans; Isoniazid; Latent Tubercul | 2010 |
Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Epidemiologic Methods; Germany; Humans; Isoniazid; Lat | 2009 |
Active tuberculosis and Mycobacterium tuberculosis latent infection in patients with HIV/AIDS.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; B | 2009 |
Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity.
Topics: Adult; Aged; Carboxylesterase; Carboxylic Ester Hydrolases; Case-Control Studies; Chemical and Drug | 2010 |
Risk factors for isoniazid hepatotoxicity in children with latent TB and TB: difference from adults.
Topics: Adult; Age Distribution; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Human | 2010 |
Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antitubercular Agents; Centers for Disea | 2010 |
Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Animals; Antitubercular Agents; Child; Clinical Laboratory | 2010 |
The reliability and practicality of the Arkansas method assay of isoniazid adherence.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Monitoring; Female; Freezing; Humans; Isoniazid | 2010 |
Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children.
Topics: Adolescent; Antitubercular Agents; Child; Drug Administration Schedule; Drug Therapy, Combination; E | 2010 |
High incidence of intolerance to tuberculosis chemoprophylaxis.
Topics: Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ch | 2012 |
Evaluation of a school-based program for diagnosis and treatment of latent tuberculosis infection in immigrant children.
Topics: Age Factors; Antitubercular Agents; Canada; Child; Emigration and Immigration; Family Health; Female | 2010 |
[Three-month course of rifampicin and isoniazid for the treatment of latent tuberculous infection].
Topics: Adolescent; Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Late | 2010 |
Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience.
Topics: Adult; Alcohol Drinking; Antitubercular Agents; Emigrants and Immigrants; Female; Health Knowledge, | 2010 |
Acceptability of treatment of latent tuberculosis infection in newly HIV-infected young women in Uganda.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Female; HIV Infections; Humans; Isoniazid; | 2010 |
Concordance of a positive tuberculin skin test and an interferon gamma release assay in bacille Calmette-Guérin vaccinated persons.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; BCG Vaccine; Emigration and Immig | 2011 |
Adverse events associated with treatment of latent tuberculosis in the general population.
Topics: Adult; Age Distribution; Aged; Antitubercular Agents; Case-Control Studies; Chemical and Drug Induce | 2011 |
Minimal-change nephrotic syndrome associated with isoniazid in anti-tuberculosis chemoprophylaxis for a patient with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Chemoprevention; Comorbidi | 2011 |
Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection.
Topics: Antitubercular Agents; Evidence-Based Medicine; Global Health; Host-Pathogen Interactions; Humans; I | 2011 |
Detection and management of latent tuberculosis in liver transplant patients.
Topics: Antitubercular Agents; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interferon-gamma; Isoniazi | 2011 |
[Liver dysfunction during treatment of latent tuberculosis infection].
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Latent Tubercu | 2011 |
[Contact tracing and prophylaxis of tuberculosis].
Topics: Antitubercular Agents; Contact Tracing; Humans; Interferon-gamma; Isoniazid; Latent Tuberculosis; Ma | 2011 |
Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection.
Topics: Animals; Antitubercular Agents; Base Sequence; Disease Models, Animal; DNA, Bacterial; Drug Resistan | 2011 |
Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monocl | 2011 |
Treatment of latent TB: first do no harm.
Topics: Age Factors; Asymptomatic Infections; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tubercul | 2011 |
Assessment and management of latent tuberculosis infection in a refugee population in the Northern Territory.
Topics: Adolescent; Adult; Age Factors; Ambulatory Care Facilities; Antitubercular Agents; Australia; Child; | 2011 |
Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Drug Administration Schedule; Humans; Isoniazid; Laten | 2011 |
Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Antitubercular Agents; Arthritis, Psoriatic; Ar | 2012 |
Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
Topics: Adult; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Chemical and Drug I | 2011 |
Feasibility and efficacy of isoniazid prophylaxis for latent tuberculosis in HIV-infected clients patients in Thailand.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Feasibili | 2012 |
Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis.
Topics: Adult; Amyloidosis; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Biopsy; Colon; Humans; | 2011 |
Tolerability of rifampin monotherapy for latent tuberculosis infection in children.
Topics: Adolescent; Antitubercular Agents; Child; Drug Administration Schedule; Drug Dosage Calculations; Hu | 2011 |
Tuberculous hilar lymphadenopathy progressing after isoniazid administration.
Topics: Antitubercular Agents; Humans; Immunocompetence; Interferon-gamma Release Tests; Isoniazid; Latent T | 2012 |
Isoniazid (INH)-induced eosinophilic exudative pleural effusion and lupus erythematosus. A clinical reminder of drug side effects.
Topics: Aged; Antibodies, Antinuclear; Antitubercular Agents; DNA; Drug Substitution; Eosinophilia; Exudates | 2011 |
A case of multicentric reticulohistiocytosis responsive to azathioprine in a patient with no underlying malignancy.
Topics: Antitubercular Agents; Azathioprine; Histiocytosis, Non-Langerhans-Cell; Humans; Immunosuppressive A | 2011 |
Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
Topics: Adult; Antitubercular Agents; Child; Child, Preschool; Contraindications; Directly Observed Therapy; | 2011 |
[Development of cervical tuberculous lymphadenitis in a patient with Crohn's disease receiving infliximab despite of chemoprophylaxis with isoniazid].
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antitubercular Agents; Crohn Disease; Femal | 2011 |
[Neonatal exposure to active pulmonary tuberculosis in a maternity ward: screening and clinical course of a cohort of exposed infants].
Topics: Antitubercular Agents; Cohort Studies; Cross Infection; Female; Follow-Up Studies; Humans; Infant; I | 2012 |
Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool | 2012 |
Is isoniazid for 6 months more cost-effective than isoniazid for 9 months?
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Cost-Benefit Analysis; Drug | 2012 |
Successful treatment of pediatric latent tuberculosis infection in a community health center clinic.
Topics: Adolescent; Antitubercular Agents; Chi-Square Distribution; Child; Child, Preschool; Community Healt | 2012 |
Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control.
Topics: Adult; Antiretroviral Therapy, Highly Active; Bacteriological Techniques; Biopsy, Fine-Needle; Chemo | 2012 |
Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female | 2012 |
Chemoprophylaxis with isoniazid in liver transplant recipients.
Topics: Adult; Aged; Antitubercular Agents; Chi-Square Distribution; Drug Administration Schedule; Drug Ther | 2012 |
A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Dermatologic Agents; Humans; Isoniaz | 2013 |
Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques.
Topics: Animals; Antiprotozoal Agents; Antitubercular Agents; Disease Models, Animal; Dose-Response Relation | 2012 |
Tuberculous pleurisy diagnosed by medical thoracoscopy in an adalimumab-treated rheumatoid arthritis patient after treatment of latent tuberculosis infection.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antitubercular Agents; A | 2013 |
Is isoniazid safe for liver transplant candidates with latent tuberculosis?
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antitubercular Agents; Biomarkers; Brazil; Drug Admin | 2012 |
Point-of-care urine tests for smoking status and isoniazid treatment monitoring in adult patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Cotinine; Female; Humans; Isoniaz | 2012 |
Latent infection treatment to prevent TB transmission in school settings.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Schools; Taiwan; Tuberculin Test; Tub | 2012 |
'Is it safe?' Safety is a process, not a question.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Female; Humans; Is | 2012 |
Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Australia; Cohort Studies; Female; Humans; | 2012 |
Does an interferon-gamma release assay change practice in possible latent tuberculosis?
Topics: Adult; Antitubercular Agents; Disease Progression; Drug Therapy, Combination; Female; Humans; Interf | 2013 |
Evaluation of tuberculosis underreporting in Greece through comparison with anti-tuberculosis drug consumption.
Topics: Antitubercular Agents; Epidemiological Monitoring; Ethambutol; Greece; Humans; Isoniazid; Latent Tub | 2012 |
Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection.
Topics: Adult; Antitubercular Agents; Contact Tracing; Cost-Benefit Analysis; Female; Humans; Isoniazid; Lat | 2013 |